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Abstract 
 
Cytochromes P450 (CYPs) constitute a wide group of NAD(P)H-dependent 
monooxygenases, found throughout all kingdoms of life. Among the most important 
functions of CYPs are the synthesis of bioactive compounds and the conversion of 
xenobiotics. These functions can be translated into biotechnological applications, 
such as the production of highly regio- and stereo-specific drug metabolites for the 
pharmaceutical industry, or to confer activity towards toxic compounds for 
agronomics and bioremediation purposes. 
Plants possess a large number of CYP sequences, but most still remain 
uncharacterised, due to the difficulty in the isolation of the membrane-bound 
enzyme and in the reconstitution of an active and efficient redox system. 
In this project, a fusion construct for the co-expression of the CYP with a suitable 
reductase was created. The construct consisted of a C-terminal Arabidopsis ATR2 
reductase (codon-optimised for expression in E. coli and truncated of the N-terminal 
membrane anchor) connected through a poly-GlySer linker to the heme domain. An 
N-terminal Im9 peptide replaced the natural membrane-binding domain of the CYP. 
When CYP73A5 from Arabidopsis was cloned into the construct, it was able to convert 
almost 60 % of the substrate cinnamic acid to the hydroxylated derivative, in whole 
cell assays. This result demonstrated that this expression platform enables the 
expression of active redox self-sufficient P450 catalysts and it can be further utilised 
for the characterisation of orphan CYPs. 
Following from gene expression studies and reports on the existence of oxidative 
derivatives of TNT, the potential involvement of CYP81D11 in the detoxification of 
TNT was explored with different in planta assays, employing transgenic Arabidopsis 
lines and tobacco leaf discs. The results obtained were contrasting and did not 
provide a clear picture on the role of CYP81D11. Further studies have to be carried 
out in the future, using CYP81D11-knockout lines, as well as the purified enzyme. 
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Chapter 1: Introduction 
 
1.1 History of cytochrome P450 enzymes: the discovery 
Cytochrome P450 (CYP) enzymes form a superfamily of heme-thiolate 
monooxygenases distributed ubiquitously across all kingdoms of life, with few 
exceptions. According to the latest count, published by Prof. David Nelson, University 
of Tennessee, in April 2016 (http://drnelson.uthsc.edu/P450.statsfile.html), more 
than 35,000 P450 sequences have been annotated, with the largest group presented 
by plants (> 13,000), followed by mammals (>10,000) and fungi (>7,800), as reported 
in table 1.1. 
 
Table 1.1: Number of CYP sequences annotated as of April 2016, according to Prof. Nelson’s latest 
updated count (http://drnelson.uthsc.edu/P450.statsfile.html, 09/09/2016), on the Cytochrome P450 
homepage. 
 
Organism Number of P450 sequences 
Plants 13,978 
Mammalian 10,477 
Fungi 7,873 
Bacteria 2,156 
Protozoa 602 
Archaea 52 
Viruses 28 
TOTAL 35,166 
 
The fifty-year old history of cytochrome P450 enzymes stemmed from the 
identification and characterisation studies on mammalian microsomal cytochrome 
b5 (cytb5) (1-3). Klingenberg, from the University of Pennsylvania, confirmed, a few 
years later, the preliminary observations made by Dr. G. R. Williams on rat liver 
microsomes. A microsomal compound, upon reduction with NADPH or dithionite and 
subsequent addition of carbon monoxide (CO), displayed a peculiar absorbance peak 
at 450 nm, different from what observed for cytb5 (4). In the same period, Garfinkel 
(a colleague of Klingenberg) conducted studies on liver microsomes from pigs, 
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instead, with a focus on electron transport chains. In the samples examined, a 
pigment could be separated using centrifugation from the well-known cytb5. This 
pigment could be reduced with dithionite and, by binding CO, it gave a characteristic 
absorbance peak at 450 nm (5). In 1962, Omura and Sato, from Osaka University, 
published the first paper focused on this CO-binding pigment. In this work, rabbit liver 
microsomal suspensions were employed, unveiling new characteristics of the 
compound, which was named ‘P-450’. The dithionite-reduced P-450 could react not 
only with CO, but also with ethylisocyanide and nitric oxide; these reactions had been 
already previously described for other hemoproteins. These observations, in addition 
to the overabundance of recorded total heme (as compared to the amount of 
recorded cytb5) in the microsomal sample, led to the speculation that the P-450 
compound was in fact a hemoprotein. Omura and Sato reported also that the P-450 
behaved in different ways in the presence or absence of oxygen. In anaerobic 
conditions, the compound could be reduced by NAD(P)H to the same extent as with 
dithionite. However, when oxygen was present, the P-450 pigment could be reduced 
effectively only with dithionite and was highly unstable thereafter, due to the 
peroxidation of the microsomal lipids and, subsequently, the degradation of the 
heme. In contrast to cytb5, cysteine and ascorbate did not reduce the P-450. Another 
peculiar property was observed when the microsomes were solubilised with snake 
venom (which contained phospholipase A) or deoxycholate, in anaerobic conditions. 
The release of the compound from the microsomal phospholipids induced a 
hypsochromic shift in the spectrum, leading to the disappearance of the 450 nm peak 
and the formation of a new absorption maximum, at 420 nm (figure 1.1) (6). The 
newly-formed compound was therefore named ‘P-420’. When a difference spectrum 
of the dithionite-reduced minus the oxidised form of P-420 was recorded, the trace 
resembled that of other hemochromogens, with peaks at 427 nm, 530 nm and 560 
nm, further proving the hemoprotein nature of the compound (7).  
Chapter 1: Introduction 
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Figure 1.1: Original absorption spectra from Omura and Sato’s 1962 publication (6). Top panel: spectra 
of the microsomal suspensions, reduced with sodium dithionite and treated with carbon monoxide for 
20 s (curve A), or treated with 100 M ethylisocyanide (curve B). Bottom panel: spectra of the 
microsomal suspensions, digested with 1 % snake venom and treated with carbon monoxide (curve A) 
or with ethylisocyanide (curve B).  
 
Subsequently, Omura and Sato calculated the molar extinction coefficient of the P-
450 compound (91 mM -1 cm-1) and purified its ‘solubilised’ counterpart (P-420), 
with a yield of 6-7 moles of protoheme/mg of total protein. The multistep 
purification process was preceded by two fractional solubilisation steps: first, the 
microsomes were digested with a lipase (pancreatic steapsin) and then solubilised 
Chapter 1: Introduction 
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either with snake venom or deoxycholate (8). Nevertheless, it was observed that the 
P-420 compound could also form during the enzymatic digestion of the microsomes, 
meaning that the transition P-450 to P-420 was not exclusively due to microsome 
solubilisation (9).  
Shortly thereafter, Cooper et al., examining some earlier studies by Ryan and Engle 
focused on steroid synthesis in bovine adrenocortical microsomal fractions (10), and 
finally assigned a function to the P-450 compound.  In fact, Cooper and co-workers 
demonstrated that the specific hydroxylating microsomal fraction contained a P-450 
compound. Additionally, they showed that the catalysis was inhibited by CO and 
dependent not only on the presence of NADPH, but also of molecular oxygen. This 
observation proved valid also for other types of reactions occurring in rat 
microsomes, such as codeine demethylation and acetanilide hydroxylation, leading 
to the classification of the P-450 pigment from mammalian microsomes as an 
oxygenase. Furthermore, the same authors, observing that the incubation of the 
bovine C21 steroid hydroxylase P-450 with sulfhydryl inhibitors led to an irreversible 
spectral transition to P-420, concluded that the P-420 compound was an inactivated 
version of the P-450 enzyme (11). Gunsalus and co-workers were among the first 
researchers to focus on P450 reactions in bacteria, working with different strains of 
Pseudomonas putida. In this organism the first multi domain P450 system, named 
P450cam, was discovered, and characterised as responsible for the hydroxylation of 
camphor (12, 13). Other pioneering studies in the area of microbial CYP activities 
were carried out by Appleby, who described in 1967 the involvement of P-450 
enzymes in nitrogen reduction by rhizobium bacteria (14). 
Since then, thousands of P450-related papers have been published every year, as 
recorded by the National Center for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/, figure 1.2). 
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Figure 1.2: Number of papers on CYP enzymes published every year in the last 60 years, as recorded 
by the NCBI database. 
 
1.2 Structure, nomenclature and organisation of CYP enzymes 
Structure 
Cytochrome P450 enzymes are highly divergent at the primary sequence level with, 
in some cases, a sequence identity lower than 20 %. Only a few domains, in fact, are 
conserved throughout the species, mainly located around the active site, which is 
characterised by a porphyrinic heme ring, with a central iron atom coordinated with 
four nitrogen atoms, a cysteine (the only residue conserved among all P450s) and a 
water molecule. The most important consensus sequences are Ala/Gly-Gly-X-
Ala/Glu-Thr-Thr/Ser (responsible for oxygen binding and activation) in the core of the 
I helix, which runs   over the distal face of the heme, Phe-XX-Gly-X-Arg-X-Cys-X-Gly 
(the Cys is the heme iron ligand) and Glu-X-X-Arg, both situated at the proximal side 
of the heme. At the N-terminus of plant and animal P450 sequences a proline-rich 
segment, X-Pro-Gly-Pro, can often be found, followed by Pro-X-X-Gly (see alignments 
in figure 1.3) (15-17). 
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Figure 1.3: Alignment of different cytochrome P450 enzymes (continues on the following page) 
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Figure 1.3: Alignment of nine different cytochrome P450 enzymes: human CYP19A1 (aromatase), 
CYP3A4 and CYP2D6; bacterial P450-BM3, XplA, P450cam; plant CYP71AV1, CYP76B1, CYP73A5. 
Highlighted in red is the conserved cysteine ligand, in blue are the conserved sequences mentioned in 
the text. Underlined in green are the conserved eukaryotic N-terminal residues. For P450 BM3, only 
the heme domain has been included. 
 
Like the variation seen at the primary sequence level, the substrate-recognition sites 
and the signal peptides for the targeting/incorporation of these proteins into the 
membrane are also very variable regions in P450 structures. Despite this, an overall 
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tertiary structure is preserved among all P450s, with alpha and beta domains, the 
former containing the catalytic centre, the latter forming the substrate access 
channel, with the substrate recognition site, assembled to form a conical prism 
(figure 1.4).    
 
 
 
 
Figure 1.4: Top-Schematic representation of the general secondary and tertiary structure observed for 
cytochrome P450 enzymes (scheme from Werck-Reichhart and Feyersen (15)). Bottom-Overlapped 
ribbon structures of four CYPs: CYP3A5, CYP2B4, CYP2C5, CYP2C9 (figure from Bak et al. (17)), 
demonstrating how the overall tertiary conical structure is conserved across different CYPs. Depicted 
in pink is the heme in the catalytic site, in orange is the heme-binding loop. 
 
In 1987, Poulos et al. solved the first P450 structure, that of a camphor hydroxylase, 
P450cam, from P. putida (PDB ID: 2CPP) (18). According to the CYPED Cytochrome 
P450 Engineering Database (https://biocatnet.de/, (19)), a platform created by Prof. 
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Pleiss’ group at the University of Stuttgart, 595 pdb entries, corresponding to 595 
different CYP protein structures, have been deposited so far. In some cases, such as 
for CYP2B4, CYP3A4, CYP55A1, CYP101A1, multiple isoforms are present for each 
CYP, due to mutated residues or for the presence of a substrate or an inhibitor in the 
catalytic site. 
Nomenclature   
The nomenclature of P450 enzymes is based on a triple alphanumeric code, where 
the abbreviation ‘CYP’ is followed by the family number, which groups all the P450s 
with > 40 % sequence identity; a letter, which identifies the subfamily of CYPs with > 
55 % sequence identity, and the gene number, e.g. CYP73A5. There are a few 
exceptions to the rule, such as for example Bacillus megaterium CYP102A1 and P. 
putida CYP101, more commonly mentioned in studies and reports as P450 BM-3 and 
P450cam, respectively. The family and subfamily numbering system depends on the 
chronological order of gene discovery. Animals, lower eukaryotes and plants were 
allocated the first 100 families, with CYP1-49 corresponding to animals, CYP51-69 to 
fungi and CYP71-99 to plants. Bacterial CYPs span from CYP101 onward. Soon, in 
many cases, the family range was exceeded, therefore additional 200 ‘blank spaces’ 
were added for each group of organisms, for the classification of newly-found 
families: in this way bacterial sequences spanned from CYP101 to CYP299, animal 
CYPs from CYP301 to CYP499, lower eukaryotes from CYP501 to CYP699 and plants 
from CYP701 to CYP999. In the case of lower eukaryotes, all the digits were again 
filled, and for this reason new allocations for each group were defined, similarly as 
before, with numbers up to CYP9999 (16). A more in-depth phylogenetic analysis of 
the CYP sequences, encouraged by widening access to genomic data (for example, 
the complete Arabidopsis thaliana genome sequence, published by the Arabidopsis 
Genome Initiative in 2000 (20)), led to the addition of a further classification layer, 
where CYP families are subdivided into clans. By comparing the genomic data 
available for rice (Oryza sativa) and Arabidopsis, with a total of 727 CYP gene 
sequences, Nelson et al., defined ten different plant clans, some consisting of 
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numerous families, such as CYP71, CYP72, CYP85 and CYP86, named after the lower 
family number present in the grouping (21).  
Organisation 
While all known prokaryotic P450 enzymes are cytosolic, eukaryotic CYPs are mainly 
bound to membranes, either on the outer side of the endoplasmic reticulum (ER), as 
in the case of the majority of plant P450s, or associated with the inner mitochondrial 
membranes.  
The activity of CYP enzymes requires the presence of redox partners, which allow the 
creation of a redox potential gradient for the efficient shuttling of electrons from the 
donor, in most cases NADH or NADPH, to the heme. For this reason, a cytochrome 
P450 reductase, with bound flavin adenine di/mononucleotides or FeS clusters, is 
usually co-localised and co-expressed with the CYP (a more detailed overview of the 
redox partners can be found in the next section). The redox chain may be laid out as 
two/three independent soluble modules (class I and III bacterial systems) or 
associated via N-terminal anchors to the membranes (microsomal systems) or 
completely fused as a single protein (see P450-reductase arrangements in figure 1.5). 
Examples of the latter are the BmP450 BM-3 and P450-PFOR systems from 
Rhodococcus and Burkholderia (22). Another example is XplA (CYP177A1) from 
Rhodococcus rhodochrous, where the heme domain is fused to a flavodoxin domain. 
XplA is encoded in the same gene cluster as the FAD-bound reductase XplB (23).  
Exceptions are given by some independent P450s which do not require a reductase 
for the catalytic activity. Examples of the latter case are CYPs that exploit the 
reversed-peroxide shunt (see section 1.3), using H2O2 as a ‘trigger’ for the direct 
formation of one of the final reactive intermediates of the catalytic cycle, skipping 
the general sequence of reductions and oxidations (24). Other examples of 
autonomous P450 enzymes are the fungal P450nor (J in figure 1.5) and human 
P450TXAS (K in figure 1.5) which perform the denitrification of nitric oxide and the 
conversion of prostaglandins to thromboxanes, respectively.       
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Figure 1.5: Representation of the different P450-redox partner configurations. (A) bacterial system 
(class I), (B) mitochondrial system (class I), (C) microsomal system (class II), (D) bacterial system (class 
III), (E) bacterial thermophilic system (class IV), (F) bacterial fusion system (class V), (G) class VI, 
bacterial fusion system (class VI), (H) bacterial fusion system (class VII), (I) bacterial fusion system (class 
VIII), (J) eukaryotic P450nor (class IX), (K) P450TxA, an independent eukaryotic system (figure from 
Hannemann et al. (22)). 
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The activity of P450 enzymes can also be affected, in a positive or negative way (no 
general rule is applicable) by the presence of microsomal cytb5, which can act as a 
mediator of the electron transport between the P450 and the reductase domain. 
Zhang and colleagues investigated the effect of cytb5 on CYP2B4 catalysis, in the 
presence or absence of the natural reductase partner. This study revealed an 
increased product formation when cytb5 was present in a 1:1 ratio with the CYP, when 
compared to the CYP-reductase conventional pairing. In addition, the same research 
group discovered a competition between cytb5 and the reductase for the binding to 
a specific site on the CYP when both the electron donors are present (25).      
Cytochrome P450 redox partners 
The electron-shuttling in cytochrome P450 catalysis relies on the presence of a redox 
chain, constituted, in the case of microsomal CYPs, by a cytochrome P450 reductase 
(abbreviated to CPR or POR or CYPOR). This reductase partner, co-localised in the ER-
membrane, is a diflavin enzyme, presenting three binding sites: two for the flavin 
cofactors (flavin mononucleotide, FMN, and flavin adenine dinucleotide, FAD) and 
one for the reduced nicotinamide adenine dinucleotide phosphate (NADPH). 
Vermilion and Coon characterised the purified CPR through photochemical 
reduction. Comparisons between the native reductase and an FMN-depleted 
reductase were carried out in order to evaluate the respective contributions of the 
two flavin cofactors in the redox chain. It was concluded that FAD is the initial 
acceptor of reducing equivalents from NADPH, which are then passed on to the FMN. 
Subsequently, FMN fulfills the stepwise one-electron transfer to the final acceptor, 
the P450 heme (26).  
The elucidation of the 3D structure of a rat microsomal CPR by Wang et al., allowed 
further understanding of the spatial arrangement of the domains constituting the 
redox chain. The authors identified an N-terminal hydrophobic domain, constituting 
the anchor to the ER membrane, followed by the FMN-binding domain and a linker 
region of approximately 150 amino acids. This region, consisting mainly of -helices 
was assigned the role of ensuring the optimal orientation and distance between the 
flavin domains, which, upon electron acceptance and transfer, change spatial 
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configuration. The FAD- and NADPH-binding domains were localised at the C-
terminus of the peptide chain (27) (figure 1.6). 
 
Figure 1.6: Ribbon representation of the crystal structure of rat cytochrome P450 reductase (PDB ID: 
1AMO). From N-terminus to C-terminus: the FMN-binding domain is coloured in dark blue (bound FMN 
in light blue), linker region in fuchsia, FAD and NADPH-binding domains in light blue (bound FAD and 
NADPH in yellow and red, respectively) (figure from Wang et al. (27)). At the bottom, a linear 
representation shows the arrangement of the FMN/FAD/NADPH-binding domains, with the same 
colour code as for the above ribbon representation. 
 
Figure 1.7 represents the proposed arrangement and interaction among subunits: the 
N-terminal domain of the CPR, with the bound FMN, is inserted in ER membrane. In 
the final stage, when the FMN domain has to transfer the reducing equivalents to the 
P450 heme, the protein configuration changes, thanks to the flexible central linker, 
from a ‘close’ to an ‘open’ setting (28). 
 
 
 
N C 
         FMN               FAD     linker            FAD            NADPH 
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Figure 1.7: Interaction between the domains (N-terminal FMN and C-terminal FAD, then FMN with 
P450 heme) involved in the electron flux, from the donor (NADPH) to the final acceptor (CYP). CYPOR 
= CPR (figure from Iyanagi et al. (29)). 
 
Sequence alignments between the characterised rat CPR and other flavoenzymes, 
such as rat neuronal nitric-oxide synthase, bacterial B. megaterium P450 BM-3, 
Escherichia coli sulfite reductase, Desulfovibrio vulgaris flavodoxin and the plant 
Spinacia oleracea ferredoxin-NADP+ reductase, demonstrated a high level of 
sequence conservation (up to 58 %), especially at the cofactor-binding regions and 
for most of the secondary structure elements (27). This reflects the promiscuity of 
the CPR, which, in mammals as well as in other systems, interacts with a multitude of 
highly diversified CYPs. Radioimmunoassays performed on purified CYPs and CPRs 
from rats, collected from samples treated with phenobarbital and -naphthoflavone 
(NF), revealed a ratio of CYP to CPR of 15:1 for the untreated controls and of up to 
21:1 for the NF-treated samples (30). 
Humans possess a single CYP reductase gene, which displays a > 90 % sequence 
identity with the rat CPR. Therefore, the information gathered by Wang et al. was an 
excellent basis to build on for the structural characterisation of the human CPR. As 
expected, Xia and colleagues discovered a high degree of similarity between the 
conformation of the two proteins, in terms of secondary structures and cofactor 
binding domains. The resulting human CPR structure, solved at a higher resolution 
than for the rat CPR (at 1.75 Å versus 2.6 Å, respectively), is reported in figure 1.8. 
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Figure 1.8: Ribbon representation of human cytochrome P450 reductase. From N- to C- terminus, the 
FMN-binding domain is represented in blue (same colour for the bound FMN), the linker region is in 
grey, whereas the FAD- and NADPH-binding domains are in yellow (bound FAD in orange and bound 
NADPH in red). The highlighted amino acids are mutation sites, which affect the stability of the FAD-
binding domain. H621, in brackets, is a residue present in the rat CPR but not in the human CPR (figure 
from Xia et al. (31)). 
 
Multiple studies reported that cytochrome P450 enzymes are not the only partners 
for CPR. In fact, since the first reports published in the late ‘60s about the CYP/CPR 
complex (32), it has been discovered that CPR can also support the activities of heme 
oxygenase and squalene epoxidase (33). 
In the case of bacterial and mitochondrial eukaryotic CYPs (class I P450s), the redox 
partner system may consist of an FAD-containing reductase domain, which receives 
reducing equivalents from either NADH or NADPH, shuttles them to a partner 
ferredoxin (which contains FeS clusters) or to an FMN-binding flavodoxin and, finally, 
to the heme partner. In bacteria all the modules of the electron chain are soluble, 
whereas in mitochondrial systems the first electron recipient is membrane-bound, as 
is the CYP partner, and the ferredoxin intermediate partner is soluble. The most well-
described case of a class I cytochrome P450 is P450cam (CYP101) from P. putida, a 
camphor hydroxylase discovered in 1968 (12). In P450cam, the electrons from NADH 
are shuttled through an FAD-binding putidaredoxin reductase, then to an FMN-
containing putidaredoxin and finally to the P450 heme (34) (figure 1.9). 
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Figure 1.9: Representation of the electron transport chain in the P450cam from P. putida. Electrons 
from NADPH are shuttled through the redox partner (first the reductase then the redoxin domain) and, 
ultimately, to the P450 heme. 
 
In mammals, adrenodoxin (AdX) is the main redoxin partner. The structure of AdX 
was firstly solved by Pikuleva et al. (35), and several studies have since offered 
suggestions for the exact mechanism of electron transport from NADPH to the heme. 
As proposed by Beilke et al. (36), the reduction of the P450 substrate depends on a 
four-step process, which is initiated by the binding of NADPH to adrenodoxin 
reductase (AdR), followed by the coupling with a dimer formed by two molecules of 
AdX. Once reduced, the Adx monomers detach from the tetramer one by one and 
become re-oxidised after the interaction with the CYP. Finally, the two oxidised AdX 
dimerise again for a new cycle of P450 reaction (figure 1.10). 
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Figure 1.10: Electron transport chain in the mammalian AdR/AdX-CYP system (figure modified from 
Ewen et al. (37)). The multistep process starts with the binding of NADPH to Adrenodoxin Reductase 
(AdR) (step 1); two electrons are donated from NADPH first to AdR (step 2) and then, in a stepwise 
manner, to each of the Adrenodoxin (Adx) molecules present in the system (steps 3-4c). Each reduced 
Adx donates an electron to the CYP (inner square). The free, re-oxidised AdR and Adx molecules (5-6) 
are now ready for a new cycle.  
 
Schiffler and Bernhardt carried out a comparative study between P. putida P450cam 
and human CYP11A1, CYP11B1, CYP11B2 redox chains. Through amino acid sequence 
alignments, EPR studies and topology examination, the authors demonstrated a high 
degree of similarity between the redoxin partners in the two systems (putidaredoxin 
for P450cam and adrenodoxin for the human CYP11s) (38).  
With the aim of enhancing CYP activities or assigning new substrate/product 
specificities many researchers have manipulated the CYP/CPR system in different 
ways. As an example, Neunzig and colleagues heterologously expressed a set of 
human P450 enzymes in yeast and co-expressed yeast or plant redox partners. A 
comparison of these mixed systems with the human CYP/CPR system showed that 
CYP2D6 activity was best supported by non-human partners (39). Also mutagenesis 
of the redox partner can help increase the efficiency of the electron transport to the 
CYP, as demonstrated by Schiffler et al. In this study, the group succeeded in the 
significant improvement of the interaction between a bovine adrenodoxin and 
different CYP11 enzymes involved in the synthesis of hormones (40). 
2
3
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4b4c
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6
5b
1 
Chapter 1: Introduction 
31 
 
1.3 Catalytic cycle of cytochromes P450 
Cytochrome P450 enzymes are generally described as monooxygenases, as they 
cleave molecular oxygen while reducing equivalents, in a stepwise manner, are 
shuttled to the active site through the associated redox chain (as described in the 
previous section), leading to the final, concomitant release of the oxygenated 
product and water.  
General P450 reaction: RH + O2 + NAD(P)H + H+  ROH + H20 + NAD(P)+ 
The P450 catalytic cycle has been described extensively over the years. Generally, it 
starts with the access of the substrate in the active site, causing the displacement of 
the water ligand and a structural rearrangement (step 1 in figure 1.11). A first 
electron is donated by NAD(P)H through the reductase partner and the heme shifts 
from the low to the high spin state (step 2). An oxidative step with dioxygen then 
occurs (step 3), followed by the second electron donation (step 4). Two consecutive 
protonation steps yield first a ferric hydroperoxo-complex (step 5) then the highly 
reactive ‘Compound I’ (step 6), which induces the rearrangement of the substrate, 
leading to the release of the final product (steps 7 and 8). The dissociation of the 
oxygenated compound allows the system to return to the initial oxidated stage, with 
bound water, ready to catalyse a new reaction (41-44). 
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Figure 1.11: General P450 catalytic cycle. (1)-The presence of the substrate in the catalytic site causes 
the displacement of the water ligand. (2-4)-Two electrons are donated in a stepwise manner by 
NAD(P)H to the system through the redox partner, with an intermediate step of oxygenation. (5, 6)-
After two protonation steps, with formation of the reactive compound I, the cycle ends with the release 
of the final product and binding of water to the active site. The system is now ready to perform another 
cycle of catalysis. The internal dashed arrows  indicate the undesired uncoupling reactions that may 
take place within the P450 cycle, leading to the formation of reactive oxygen species in place of the 
desired product.       
 
During the catalytic cycle three undesired abortive reactions may occur, with 
formation of reactive oxygen species such as anion superoxide and hydrogen 
peroxide as well as water, instead of the desired product, decreasing the effective 
catalytic efficiency of the P450 enzymes. These uncoupling reactions, where the 
double electron transport is not coupled to the oxygenation of the substrate, are 
reported in figure 1.11 (internal dashed arrows). Grinkova and colleagues studied the 
uncoupling phenomenon in human CYP3A4 activity, by measuring the oxidation of 
NADPH and oxygen consumption compared to the residual substrate concentration: 
FeIII 
FeIII 
FeIII  
FeII 
FeIII 
FeIII 
FeIII 
FeIV Compound I 
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they observed that more than 90 % of the oxygen consumption of the system, when 
CYP3A4 was incubated with testosterone, was associated with uncoupling reactions 
(mainly to the oxidase shunt, with release of water from Compound I) (43).  
Cytochromes P450 are able to catalyse a vast array of reactions, from 
monooxygenations to hydroxylations, epoxidations, N-/S-/O- dealkylations to N- 
demethylations, isomerisations, dimerisations, reductions, dehalogenations and 
deaminations (41, 42). For this reason, CYP enzymes are very interesting targets for 
the production of high-value chemicals for the food, pharma and cosmetic sectors. 
Additionally, CYPs can be exploited for pharmacological ADME/Tox studies due to 
their involvement in drug metabolism (mainly CYP3A4 and CYP2D6 in human), as also 
for agronomical and bioremediation purposes.   
 
1.4 Human Cytochromes P450 
As confirmed by the outcomes from the Human Genome Project almost 15 years ago 
(45), the human genome contains 57 genes encoding cytochromes P450, subdivided 
into 18 families (46): many are expressed in the liver, where they are involved in the 
metabolism of xenobiotics, leading to either the detoxification or the bio-activation 
of target compounds. P450 enzymes are also located in the intestines (mainly CYP3A, 
CYP2C (47)), in the lungs (CYP1A1, CYP1B1, CYP2F1, CYP2S2, CYP4B1), kidneys and in 
the brain (CYP2E1, CYP2D6, CYP2B6 (48)). In most cases, human CYPs are microsomal, 
with the exception of seven CYPs, located in the mitochondria. Moreover, human 
CYPs display broad substrate specificity and can catalyse multiple reactions, such as 
the catabolism/activation of xenobiotics and the synthesis of endobiotics (steroid 
hormones, fatty acids, eicosanoids and vitamins (table 1.2)). An important example 
is CYP19A1, also named aromatase, responsible for the synthesis of estrogens (49). 
Mutations, deficiency or excess of CYP19A1 can lead to hormonal imbalance, 
ultimately causing endometrial cancer, metastatic breast cancer, virilisation (50-52). 
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Table 1.2: Subdivision of the human CYPs based on major substrate specificity. N.A.= not available, 
referred to orphan CYPs (classification from Guengerich (53)). 
 
Sterols Xenobiotics Fatty Acids Eicosanoids Vitamins N.A. 
CYP1B1 CYP1A1 CYP2J2 CYP4F2 CYP2R1 CYP2A7 
CYP7A1 CYP1A2 CYP2U1 CYP4F3 CYP24A1 CYP2S1 
CYP7B1 CYP2A6 CYP4A11 CYP4F8 CYP26A1 CYP2W1 
CYP8B1 CYP2A13 CYP4B1 CYP5A1 CYP26B1 CYP4A22 
CYP11A1 CYP2B6 CYP4F11 CYP8A1 CYP26C1 CYP4X1 
CYP11B1 CYP2C8 CYP4F12 
 
CYP27B1 CYP4Z1 
CYP11B2 CYP2C9 CYP4F22 
 
CYP27C1 CYP20A1 
CYP17A1 CYP2C18 CYP4V2 
   
CYP19A1 CYP2C19 
    
CYP21A2 CYP2D6 
    
CYP27A1 CYP2E1 
    
CYP39A1 CYP2F1 
    
CYP46A1 CYP3A4 
    
CYP51A1 CYP3A5 
    
 
CYP3A7 
    
 
CYP3A43 
    
 
 
As reported by Williams et al., more than 75 % of the administered drugs are 
metabolised by P450 enzymes, followed by UDP-glucuronosyltransferases and 
esterases (54). Among the CYPs highlighted in this study, CYP3A4 was the biggest 
contributor to the bioconversion of drugs (figure 1.12). 
 
Figure 1.12: Group of P450 enzymes with relative contribution to drug metabolism. CYP3A4 was 
identified as the biggest contributor, followed by CYP2C9, CYP2D6 and CYP2C19 (figure from Williams 
et al. (54)). 
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In addition to its activity towards pharmaceuticals, such as the antineoplastic 
ellipticine (55) and the anticancer prodrugs cyclophosphamide and ifosfamide (56), 
CYP3A4 has been reported as active towards natural toxins, such as the aflatoxin B1 
from Aspergillus (57); and carcinogens, such as the polycyclic hydrocarbon benzo--
pyrene (58).  
Human CYPs have also been tested towards environmental pollutants, such as 
insecticides, herbicides and volatile organics. Afterwards, plant systems such as rice, 
tobacco and Arabidopsis have been engineered to express these reactive human CYPs 
(mainly CYP2E1 and CYP1A1, CYP2B6, and CYP2C19) to introduce resistance to the 
toxic compounds (59-62). 
Human cytochrome P450 enzymes can also be active towards endogenous 
substrates. The already-mentioned hepatic and intestinal CYP3A4 displays a very 
broad activity (63), as it is also able to hydroxylate cholesterol (64) and a range of 
endogenous steroid hormones, such as progesterone and androstenedione (65-67). 
It has been observed that the expression of human CYP4A2 in rat led to an increased 
amount of renal 20-hydroxyeicosatetraenoic acid (20-HETE). This arachidonic acid 
regulates the contractions of smooth muscles, affecting the vascular flow, and 
resulting ultimately in higher blood pressure and hypertension. When N-hydroxy-N’-
(4-butyl-2-methylphenyl)-formamidine (HET0016, a known inhibitor of 20-HETE 
synthesis), was supplied, the effect was reversed (68). Similar results were obtained 
also with CYP4A11 and CYP4A12, the expression of which were observed as strictly 
correlated to the overproduction of 20-HETE (69, 70). 
Genetic variations of the human P450 enzymes can result in deleterious phenotypes 
such as abnormalities in the rate of absorption, delivery or excretion of drugs and/or 
diseases. As highlighted on the CypAllele website (curated by Sim and Ingelman-
Sundberg from the Karolinska Institutet (71)), a particular case is that of CYP2D6. This 
P450 enzyme has been found in numerous (more than 90) variants, with varying 
frequencies across the different ethnicities (72). As an example, CYP2D6*17, a 
common variant found in Black African individuals, leads to a decreased CYP2D6 
activity. CYP2D6 expressed in the brain has a documented neuroprotective activity 
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against toxins (73). Individuals displaying decreased or deleted CYP2D6 activity, lack 
this protection and therefore are more prone to neurodegenerative diseases. This 
was demonstrated in a genetic study where the levels of CYP2D6 were compared 
between Parkinson’s patients and healthy controls (74, 75). On the opposite side, 
individuals expressing multiple copies of CYP2D6, exhibit an excessively fast drug 
metabolism, with resulting toxicity, as demonstrated in the case of codeine. Two 
specific variants of the CYP2C19 gene, CYP2C19*2 and CYP2C19*3, cause the 
complete inactivation of the catalyst. For this reason, the subjects, presenting a ‘poor’ 
metabolism towards the substrates of CYP2C19, such as drugs, have to undertake 
alternative therapeutic treatments (either in terms of active compound or in dosage) 
as compared to ‘normal’ metabolisers (76). Another important aspect to take into 
account is the effect of the inhibition of drug-metabolising P450s: by blocking these 
detoxifying activities, the drug compound, which remains unaltered, accumulates, 
with resulting toxicity. This can occur especially when multiple therapies are 
administered at once. As an example, numerous reports showed that selective 
serotonin reuptake inhibitors (SSRI) antidepressants compete with a range of 
therapeutic substrates, such as the antidepressant imipramine and the anxiolytic 
alprazolam, for the binding to the CYP2D6 active site, therefore blocking the related 
activity and decreasing the final clearance of the compounds (77-79). SSRIs can also 
inhibit CYP3A4 catalysis. A well-documented CYP3A4 inhibitor is the antifungal 
ketoconazole, which, leads, as reported by Gomez et al., to the overaccumulation of 
the antisuppressant cyclosporine (80). As reported by Koudriakova and co-workers, 
also the HIV protease inhibitor ritonavir competes with the CYP3A4 substrate. The 
co-administration of ritonavir, and resulting inhibition of CYP3A4-mediated activity, 
was seen by Kempf et al.  as an option to induce the bioaccumulation of 
concomitantly used anti-HIV medications and potentiate their pharmacological effect 
(81). From the pharmaceutical point of view, considering the involvement in the 
activation or detoxification of drugs, human cytochrome P450 enzymes constitute a 
precious source of information for pharmaceutical companies, in toxicological studies 
as well as in the design of novel therapeutics with diversified structures or modified 
mode of action. Furthermore, screening assays for the determination of allelic 
variants of P450 drug metabolising enzymes (CYP3A4, CYP2D6, CYP2C9, etc.) should 
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be of particular help in the design of personalised therapies, whereby dysfunctional 
catalysts are identified. 
 
1.5 Bacterial Cytochromes P450 
Bacterial CYPs are soluble enzymes and for this reason the characterisation of these 
systems has been easier to complete, when compared to the membrane-bound 
eukaryotic enzymes. Bacterial cytochrome P450s catalyse a wide array of reactions, 
such as the synthesis of pharmacologically active compounds (as secondary 
metabolites), the breakdown of xenobiotics and the metabolism of fatty acids. The 
two best characterised bacterial P450 systems, which have been mentioned many 
times throughout the previous sections, are B. megaterium P450 BM-3 (CYP102A1) 
and P. putida P450cam (CYP101). Characterised bacterial CYP activities are listed in 
table 1.3. 
Table 1.3: Examples of known bacterial P450-mediated activities (information from Kelly and Kelly 
(82)). 
 
Organism CYP Function 
Pseudomas putida CYP101A1 (P450cam) catabolism of camphor  
Bacillus megaterium CYP102A1 (P450-BM3) fatty acid catabolism 
Streptomyces 
avermitilis 
CYP105P1, CYP105D6 filipin biosynthesis/antifungal 
Saccharopolyspora 
erythrea 
CYP107A1 erythromycin biosynthesis/antibacterial 
Streptomyces 
lavendulae 
CYP107N1, CYP160A1, 
CYP105F1 
mitomycin c biosynthesis/antitumour 
Streptomyces 
hygroscopicus 
CYP122A2 rapamycin 
biosynthesis/immunosuppressant/anti-
ageing? 
Mycobacterium 
tuberculosis 
CYP125A1 catabolism of cholesterol 
Jeotgalicoccus sp. 
ATCC 8456 
CYP152A3 decarboxylation of fatty acid 
Streptomyces fradiae CYP105L, CYP113B1, 
CYP154B1 
tylosin biosynthesis/veterinary 
antibacterial 
Streptomyces noursei CYP105H1, CYP161A1 nystatin biosynthesis/antifungal 
Streptomyces 
spheroides 
CYP163A1 novobiocin biosynthesis/antibacterial 
Sorangium cellulosum CYP167A1 epothilone biosynthesis/antitumour 
Streptomyces 
avermitilis 
CYP171A1 avermectin biosynthesis/anthelmintic and 
insecticide 
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The P450 BM-3 fusion was first described in 1986 by Narhi and Fulco, who were 
studying the hydroxylation of fatty acids in B. megaterium ATCC 14581. On the basis 
of previous reports demonstrating that the hydroxylating activity and the expression 
of the responsible enzyme are highly induced by barbiturates, the two researchers 
used phenobarbital to induce the overexpression of the enzyme for purification and 
biochemical characterisation. Upon SDS-PAGE analysis, the isolated enzyme 
corresponded, on the gel, to a single 119,000 KDa band, which was double the size of 
previously-described CYPs. Trypsin digestion revealed an N-terminal 54 KDa heme 
domain and a 65 kDa C-terminal reductase domain. Differently from other bacterial 
system, the redox partner had the features of eukaryotic CPRs, as it presented bound 
FAD and FMN, as verified using spectrophotometrical observations (83, 84). This 
soluble fusion system was active towards long-chain fatty acids, using preferentially 
NADPH (rather than NADH) as an electron donor and, displaying the highest catalytic 
activity in the P450 world, with a turnover number of 280 s-1 (85). The structure of 
the P450 BM-3 heme domain and FMN-binding domain was elucidated a few years 
later, by Sevriouvkova et al. (figure 1.13). 
 
Figure 1.13: Structure of B. megaterium P450 BM-3 (lacking the FAD-binding domain), as elucidated 
by Sevrioukova et al. (86). From N-terminus to C-terminus: the P450 heme domain is represented in 
blue, the heme in red, the FMN-binding domain in green (bound FMN in yellow). 
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Two other interesting bacterial P450 systems are XplA (CYP177A1) and P450RhF 
(CYP116B2), both from Rhodococcus. The XplA enzyme, which has only been found 
at military sites or manufacturing areas contaminated with explosives, is a successful 
example of the application of microbial CYPs for biotechnological purposes. This 
enzyme, with a fused flavodoxin domain, is key for the survival of the microbes in 
soils heavily contaminated with the toxic explosive hexahydro-1,3,5-trinitro-1,3,5-
triazine (RDX). In fact, XplA catalyses the denitration and cleavage of the aromatic 
ring of the RDX molecule, enabling the bacteria to use it as a source of nitrogen for 
growth (87). Transgenic plants expressing XplA were able to biotransform and retain 
the RDX taken up from the soil. This novel technology for bioremediation, currently 
under field trials in the United States, constitutes a promising sustainable tool to 
clean up explosive-contaminated lands (23, 88).  
Roberts and colleagues isolated P450Rhf from Rhodococcus sp. strain NCIMB 9784. 
This enzyme was another example of a fused P450 system, presenting an N-terminal 
heme domain connected through a 16 amino acid-linker to a C-terminal redox 
partner, composed of an FMN-binding domain, followed by an NADPH-binding 
domain and a 2Fe-2S cluster. Activity screenings demonstrated that this CYP is able 
to catalyse the formation of 7-hydroxycoumarin by dealkylating 7-ethoxycoumarin 
(89). Since its discovery, this system has been exploited widely for the creation of 
chimeras, whereby P450 heme domains are connected to the Rhf-reductase domain 
(RhfRed = C-terminal section of P450Rhf). This is the case, for example, with the 
LICRED platform (figure 1.14, 90) developed by Dr. Sabbadin in our laboratory, which 
has been validated with P450cam and XplA and subsequently tested also with 
Nocardia farcinica and human CYPs (91).  
Chapter 1: Introduction 
40 
 
 
 
Figure 1.14: Illustration of the LICRED drop-in platform developed by Dr. Sabbadin. The construct 
consists of a C-terminal RhfRed domain (from P450Rhf). The P450 heme targets can be cloned at the 
N-terminus by means of LIC-cloning (figure from Sabbadin et al. (90)). 
 
Zhang and co-workers created three fusions of Micromonospora griseorubida 
P450MycG with RhfRed, with the spinach Fdx/FdxR redox system as well as with the 
whole P450Rhf. Interestingly, the three fusions yielded final products that were 
different from the expected native products, mycinamicin antibiotics (92). Another 
recent example is that of Makino and co-workers, who engineered CYP-RhFRed 
fusion constructs in order to characterise the function of different CYP110 enzymes 
from cyanobacteria, identifying a particularly broad substrate specificity for Nostoc 
CYP110E1 (93). 
The model bacterial system Escherichia coli does not have any cytochromes P450 and 
it has been routinely employed over the years for the heterologous expression of 
cytochrome P450 enzymes, in alternative to other bacteria (B. megaterium, P. 
putida), yeasts (Pichia pastoris, Schizosaccharomyces pombe, Saccharomyces 
cerevisiae) and tobacco plants. 
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Numerous studies carried out by members of the Bernhardt group exploited the 
great potential of microbes as factories for the production of high-value chemicals. 
Among the reported successful processes are the introduction into E. coli of 
CYP106A2 from B. megaterium ATCC 13368, coupled with a bovine redox partner and 
an electron recycling system, for the regioselective hydroxylation of 3-oxysteroids 
(94). Further substrate screens with the same CYP complex, revealed novel 
hydroxylating activities towards diterpenes and triterpenes and 3-hydroxysteroids, 
such as pregnenolone and dehydroepiandrosterone (DHEA), in B. megaterium whole 
cell incubations. These results were particularly important from the pharmaceutical 
point of view, as hydroxylated steroids in the human organism display multiple 
effects, such as antiinflammatory, neuroprotective  and immunoregulatory effects, 
as in the case of the obtained 7-hydroxy-DHEA (95). It has been demonstrated that 
CYP106A2, as well as CYP106A1, in B. megaterium (strains MS941 and DSM319) 
whole cell assays, are also able to hydroxylate diterpenes and triterpenes (96, 97). 
More recently, the plethora of substrates for these two CYP106A has been further 
expanded, with the discovery, beyond the already characterised hydroxylations at 
the 6β, 7β, 9α, and 15β-positions, of a novel 11-oxidase activity (98). On the same 
line, Bracco and colleagues generated mixed systems consisting of a N. farcinica 
CYP154C5, P. putida redox partners and E. coli for expression and activity assays 
towards a series of steroids. It has been discovered that this CYP was able to catalyse, 
differently from CYP106A1/A2, the 16 hydroxylation of testosterone and all the 
other screened substrates, with higher efficiency than previous reports with P450 
enzymes from Rhodococcus or from Streptomyces (99). The highly selective 
hydroxylations, of which some examples have just been described here, are 
particularly attractive for pharmaceutical companies, as this type of molecular 
functionalisation can directly affect the metabolism and bioavailability of drugs.  
Researchers have created several mutants of known systems in order to direct 
catalysis towards desired products. As an example (among the multitude of similar 
protein engineering studies), Peters et al. successfully created, by means of directed 
evolution and site-directed mutagenesis, a mutant of P450 BM-3, enabling a novel 
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functionality: the stereo- and regio-specific hydroxylation of short and medium 
length alkanes, such as propane, heptane, octane (100).  
 
1.6 Plant Cytochromes P450 
The most numerous group of P450 genes can be found in plants, with, as reported in 
section 1.1, more than 13,000 sequences annotated so far. Not counting the 
pseudogenes, Arabidopsis alone contains 244 cytochrome P450s, whereas rice (O. 
sativa) presents 350 CYP genes. These very high numbers, when compared to other 
living systems, reflect the importance of this group of enzymes, which, according to 
evolution and adaptation, have duplicated and mutated, generating different 
isoforms among the same gene family with amplified or diversified activities (101). 
Examples of this case are the numerous genes, 54, grouped in the CYP71 family, the 
largest among all plant P450 families, of which only a few have been identified as 
participants at different steps in the camalexin-based plant defence mechanism (17).  
The activity of CYPs in plants spans numerous biosynthetic processes and metabolic 
pathways, leading to fundamental compounds for plant life. Among these are 
signalling and defence molecules (e.g. oxylipins, phytoalexins, glucosinolates, 
alkaloids, cyanogenic glucosides), developmental hormones (gibberellins, 
brassinosteroids, abscisic acid, cytokinins) or structural components (lignins, cutins, 
suberin). These specialised metabolites, deriving from secondary processes, can be 
used as flavours, aromas, nutraceuticals and drugs. 
One of the first biochemical characterisation studies on plant P450s was conducted 
on avocado (Persea americana) fruits in 1989 by O’Keefe and Leto. Active P450 
enzymes, named ARP1 and ARP2, belonging to the CYP71 family, were successfully 
obtained, through solubilisation of the microsomal fractions extracted from ripened 
avocado tissues (102). 
The 2015 Nobel Prize in Physiology or Medicine was awarded to scientist Tu YouYou 
for her discovery, in the early ‘70s, of the antimalarial properties of artemisinin, a 
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compound naturally produced in Artemisia plants (Artemisia annua) (103). The World 
Health Organization recognised this compound “as the first-line treatment for 
uncomplicated Plasmodium falciparum malaria”, in combined therapies. The very 
low amounts of artemisinin or precursors extractable from plants, alongside the 
economical unfeasibility of chemical synthesis, led to the long quest of researchers 
around the world towards the discovery of alternatives for the efficient production 
of the compound. Among the approaches used, are breeding programmes to obtain 
high-yielding hybrid plants and metabolic pathway engineering into different hosts 
for enhanced production. An example for the first type of approach is that developed 
by Prof. Graham’s group at the Centre for Novel Agricultural Products (CNAP), with 
the Artemisia Project, funded by the Bill & Melinda Gates Foundation (104). Genetic 
analyses and field trials led to the identification of key traits affecting the yields in 
artemisinic acid (which can be subsequently chemically converted to artemisinin); 
two hybrid Artemisia varieties have been produced and are now available on the 
market (105). On the other side, Paddon et al. manipulated and optimised the 
pathway leading to artemisinic acid (106, 107), by creating a synthetic yeast strain 
able to express, in parallel, enzymes that are directly involved in the pathway, as well 
as secondary factors, required to enhance the efficiency of the process. In particular, 
the authors, engineered the co-expression, with the CYP, of the partner reductase, 
two hydrogenases and cytb5. Competing enzymes were also inhibited. In this way, the 
authors succeeded in the production of up to 25 mg of artemisinic acid per liter of 
culture (107).  This work was based on Ro and co-workers’ discovery that a P450 
enzyme was a key player in the biosynthesis of artemisinic acid in Artemisia plants: 
CYP71AV1 is, in fact, responsible of three oxidation steps of the precursor 
amorphadiene to artemisinic acid (108, 109) (figure 1.15). 
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Figure 1.15: Reaction scheme illustrating the multiple steps catalysed by CYP71AV1, supported by CPR 
and cytb5, in the synthesis of artemisinin. (I): Amorpha-4,11-diene is hydroxylated by CYP71AV1 to 
artemisinic alcohol; (II): Artemisinic alcohol is oxidised by CYP71AV1 and artemisinic alcohol 
dehydrogenase 1 to artemisinic aldehyde; (III): Artemisinic aldehyde is converted by CYP71AV1 and 
artemisinic aldehyde dehydrogenase 1 to artemisinic acid, precursor of artemisinin. 
 
Another plant metabolite with great pharmaceutical value is taxol, produced by yew 
trees (Taxus species) which is the active compound of Paclitaxel, a chemotherapeutic 
listed in the World Health Organisation “Model lists of essential medicines” (110). 
Schoendorf et al., through differential display real-time PCR (DD-RT-PCR), identified 
a set of transcripts related to taxol biosynthesis. Within the set, were 13 P450 
sequences, which showed a high sequence identity (between 52 and 83 %) with three 
families of CYPs (CYP83, CYP88, CYP90), some members of which have been already 
confirmed as active towards the synthesis of terpenoids (111). Schoendorf’s study 
demonstrated that one of the CYPs, taxane 10β-hydroxylase (CYP725A1), expressed 
in yeasts fed with taxol precursors, was able to catalyse the conversion of taxadien-
5α-yl acetate to taxadien-5α-acetoxy-10β-ol (figure 1.16) (112). 
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Figure 1.16: Abbreviated scheme of the taxol biosynthetic pathway from the geranylgeranyl 
diphosphate precursor. Highlighted in blue is the reaction catalysed by CYP725A1. The dashed arrows 
indicate missing intermediates not reported in the figure. 
 
Later studies confirmed that of the 19 reactions leading from the 
geranylgeranyldiphosphate (GPP) precursor to taxol, half of the reactions are 
catalysed by P450 hydroxylases (113-115).  
In an interesting proof-of-concept work, Lassen et al. demonstrated that 
photoautotrophic cyanobacteria can be employed as viable alternatives to the 
conventionally-used E. coli for gene expression. Additionally, PsaM, a section of 
photosystem I (PSI) in cyanobacteria, was exploited as a tag, in order to co-localise 
the target protein with the host’s PSI in the thylakoids. The aim of this approach was 
to implement the electron flux required for P450 catalysis, by exploiting the 
photosynthetic system of the host cyanobacterium, complemented with ferredoxin, 
as also shown (and proven effective) in a previous study by Jensen et al. (116). In 
particular, Lassen and co-workers transformed the fusion of CYP79A1, one of the 
enzymes involved in the synthesis of cyanogenic glucosides in great millet (Sorghum 
bicolor), with PsaM into Synechococcus sp. PCC 7002. The CYP79A1-PsaM fusion was 
successfully expressed in the thylakoids; both in vitro and in vivo assays 
demonstrated that the complex was able to convert the substrate of CYP79A1, 
CYP725A1 
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tyrosine, into the expected oxime, exploiting energy from light (117). Subsequently, 
the whole dhurrin metabolon from S. bicolor (constituted by two CYPs, CYP79A1, 
CYP71E1 and a glucosyl transferase, UGT85B1 (118-120), see figure 1.17), was 
engineered into cyanobacteria (Synechocystis sp. PCC 6803).  
 
Figure 1.17: Scheme representing the series of reactions carried out by the ‘dhurrin metabolon’, the 
dhurrin biosynthetic pathway in S. bicolor. CYP79A1 in three consecutive steps converts tyrosine into 
p-hydroxyphenylacetaldoxime. Subsequently, CYP71E1 catalyses the formation of p-
hydroxymandelonitrile, which can degrade with release of cyanide. Alternatively, UGT85B1 can 
conjugate p-hydroxymandelonitrile with sugar, leading to dhurrin.  
 
This synthetic engineering approach enabled the expression of the two CYPs as part 
of the cyanobacterial membrane, the expression of the soluble UGT, as well as the 
light-driven production of the expected final product, the cyanogenic glucoside 
dhurrin. This was achieved independently from the prohibitively-expensive NADPH 
and from the P450-reductase partner, which was efficiently replaced by the host’s 
photosynthetic system and by the supplied ferredoxin as the intermediate electron 
carrier (121). As demonstrated in these studies, cyanobacteria can be valuable hosts 
for expression, with the advantage of working as powerhouses to feed light-derived 
CYP79A1 CYP79A1 CYP79A1 
CYP71E1 
CYP71E1 CYP71E1 
UGT85B1 
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energy to P450-mediated activities. This approach could be particularly promising for 
the synthesis of high-value chemicals.  
The knowledge acquired on plant CYP enzymes can be turned into further societal 
benefit by exploiting those enzymes involved in the synthesis of defence compounds 
(cyanogenic glucosides) or in the breakdown of xenobiotics (herbicides, pesticides, or 
pollutants) for the development of resistant crops or for the improvement of the 
nutritional value of staple crops. 
A transgenic Arabidopsis line was produced, which, by expressing the above-
mentioned dhurrin metabolon (with the two CYPs and the UGT), displayed resistance 
against target herbivores (122). From another point of view, these studies can be the 
basis to solve another problem: food security. According to the US Department of 
Agriculture, cassava (Manihot esculenta) is a very important staple crop, ranking 
fourth after rice, maize and wheat (123). This plant is characterised by the ability to 
grow well in poor soils, it presents a very high tolerance to drought and the tubers 
can be left unharvested for a long time. This plant is mainly produced in developing 
countries, such as West Africa, tropical South America and South-East Asia, where it 
is used for its leaves (rich in vitamin A and B) and tuberous roots, as sources of 
carbohydrates. In addition, cassava, like great millet, produces high levels of 
poisonous hydrogen cyanide, released from cyanogenic glucosides (up to 1.5 g / kg), 
that are synthesised when the plant tissues are damaged by herbivores, but also 
during food preparation. All the parts of the cassava tuber have to be appropriately 
treated, to avoid poisoning, and, as a result, most of the nutrients are lost in the 
process. This factor is particularly negative in areas hit by food scarcity. Through 
sequence homology searches with the dhurrin pathway enzymes, it has been 
discovered that three CYPs, namely CYP71E7, CYP79D1 and CYP79D2, are involved in 
the synthesis of the two cyanogenic glucosides in cassava, linamarin and lotaustralin, 
from L-valine and L-isoleucine, respectively (124, 125). The identification of these 
enzymatic actors in the synthesis of cyanogenic glucosides constitutes an important 
starting point for the development of transgenic acyanogenic cassava plants, with 
decreased toxicity and higher nutritional value.  
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Exactly in the same way as in the human liver, cytochromes P450 in plants and 
bacteria are also able to metabolise xenobiotic compounds, such as pollutants and 
herbicides. These functions can be of high biotechnological relevance, as they can 
guide us towards new bioremediation strategies.  An overview on this particular 
application of plant CYPs can be found in chapter 5. 
 
1.7 Fungal Cytochromes P450 
Fungal cytochrome P450 enzymes are involved in the biosynthesis of primary and 
secondary metabolites, with interesting biotechnological applications, and also in the 
degradation of xenobiotics. Considering that there are more than 2,500 fungal 
species, and also taking into consideration the high sequence variation generally 
displayed by CYPs across all domains of life, as well as Prof. Nelson’s classification 
system (16), it is of no surprise that the overall number of fungal CYP families is high, 
with more than 330 annotated so far (126).  
Fungal CYPs generally display a class II arrangement (see figure 1.5), with a FAD/FMN-
binding CPR, transferring electrons to the heme from NADPH. Ichinose and Wariishi 
reported the unusual case of CYP5150A2 from Phanerochaete chrysosporium, which 
is able to catalyse the hydroxylation of diclofenac by receiving electrons from CPR. It 
was observed that the catalytic reaction was more efficient when cytb5 was added to 
the reaction mix, as well as when  an alternative cytb5 reductase/cytb5 redox system 
was present, in place of the CPR (127). In addition, two peculiar CYP constructs have 
been found in fungi: P450nor (CYP55A4) and P450foxy (CYP505), from Fusarium 
oxysporum, both self-sufficient enzymes. In particular, P450nor is a single unit CYP, 
which catalyses the degradation of nitric oxide, conferring the denitrification 
capability to the organism. This activity does not require the presence of a redox 
partner, as the electrons are transferred directly from NAD(P)H to the heme, due to 
the composition and the conformation of the heme pocket. In the case of P450foxy, 
the P450 heme is directly fused to the redox partner. This membrane-bound fusion 
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enzyme shows a high degree of similarity, in terms of sequence and activity, with 
P450 BM-3 and functions as a fatty acid hydroxylase (128).  
Additional characterised activities for fungal CYPs inclosed those involved in the 
biosynthesis of sterols, mycotoxins and gibberellins and the catabolism of pollutants 
and antifungal compounds (126, 129, 130). 
 
1.8 Challenges of using CYPs for biotechnological applications 
Since the first description in the early ‘60s, an astonishing amount of literature has 
been published so far on the cytochromes P450. A plethora of characterisation 
studies on P450s from different organisms have underlined the importance of CYPs, 
in the synthesis, metabolism or catabolism of a wide array of substrates, many of 
which have been discovered having valuable biotechnological applications. However, 
due to the complexity of the multicomponent P450 system, as well as the high 
occurrence of unproductive uncoupling reactions, the difficulty of producing 
recombinant stable activities and the generally poor product yields, the exploitation 
of this class of enzymes has been constrained. Besides the optimisation of the 
expression, purification, activity assay conditions and the manipulation of the P450 
heme sequence, engineering need to be directed towards the enhancement of the 
electron transport system, through modifications at the redox partner level. In 
addition, optimal heterologous systems should be created, with “mix & match” 
combinations of P450 heme, redox partner and host. Furthermore, a significant 
amount of work has also to be carried out for the optimisation of the catalysis at both 
the biochemical and engineering levels (131). 
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Aim of the project 
This project aims to develop genetic constructs that would enable the stable and 
soluble expression of cytochromes P450 from plants. It is envisaged that these 
constructs could be utilised as drop-in vectors for the study of plant P450s with 
unknown function. Using the well-known CYP73A5 from Arabidopsis as a reference 
for validation, a particular focus is given to uncharacterised enzymes that could be 
potentially involved in the metabolism of xenobiotics. The constructs will include a 
plant reductase partner, which will be fused to the CYP domain, in order to obtain a 
redox self-sufficient fusion protein. Bacteria (Escherichia coli) will be the expression 
hosts of choice, due to their relative simplicity. In addition, yeasts (Saccharomyces 
cerevisiae) will also be employed, for comparative purposes. Finally, the obtained 
construct will be validated, by testing the activity of the inserted CYP73A5. 
A section of the work is dedicated to the characterisation of the potential role of 
CYP81D11 in the detoxification of the explosive 2,4,6-Trinitrotoluene (TNT). Previous 
gene expression studies on plant tissues after exposure to TNT revealed that 
CYP81D11 was the most upregulated CYP, making it an interesting target for further 
study. Transgenic Arabidopsis plants and tobacco leaf discs will be employed for 
different types of assays. In particular, Arabidopsis thaliana plants overexpressing 
CYP81D11 will be incubated on liquid and agar media containing TNT to observe the 
presence of any activity, enhanced uptake or increased tolerance towards this 
compound, in comparison to wildtype and knockdown Arabidopsis plants. 
Furthermore, leaf discs from Nicotiana benthamiana leaves will be incubated with 
TNT to verify possible differences in the TNT metabolic pattern within the plant 
tissues, in comparison with controls.
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Chapter 2: General Materials and Methods 
2.1 Chemical reagents 
Reagents and consumables were purchased from: VWR (USA), Sigma-Aldrich (Poole, 
UK), Fisher Scientific (Loughborough, UK), Melford (Ipswich, UK), Formedium 
(Norfolk, UK), Duchefa Biochemie (Netherlands), New England Biolabs (USA), GE 
Healthcare (London, UK), Promega (Southampton, UK), Qiagen (West Sussex, UK), 
Expedeon (Swavesey, UK), Clontech Laboratories (USA), Invitrogen (Paisley, UK).  
Pure water for the preparation of the media, the solutions and the assays was 
obtained with an Elga PureLab Ultra water polisher, from Elga Labwater (High 
Wycombe, UK). 
 
2.2 Organisms 
Bacterial strains: Escherichia coli strains DH5, Rosetta 2 (both from the Bruce group 
stocks), XL1-Blue, BL21(DE3) and Arctic express (from Agilent Technologies) were 
used for cloning steps and protein expression (table 2.1). Agrobacterium tumefaciens 
strain GV3101, obtained from the Bruce group stocks, was used for tobacco tissues 
infiltrations.   
Yeast strain: Saccharomyces cerevisiae WAT11-modified (166), from the Bruce group 
stocks, was used for endogenous co-expression of ATR1 reductase. 
Plants: Arabidopsis thaliana ecotype Columbia 0 (Col0) CYP81D11-modified lines 
(overexpressing and knock-down) for activity/phenotyping assays were obtained 
from Prof. J. Napier, Rothamsted Research; Nicotiana benthamiana was used for 
transient expression and activity assays, seeds were received from Luisa (Simon 
McQueen-Mason’s group, York).  
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Table 2.1: Specifications of the bacterial strains used in the present work 
 
 
2.3 Media 
Media for bacterial growth 
Cultures of E. coli were firstly grown in nutrient media, such as Lysogeny broth (LB) 
or Super Optimal broth with Catabolic repressor (SOC) or Y medium and later sub-
cultured in Auto Induction (AI) medium or M9 minimal medium for gene expression. 
Name Genotype Application Endogenous 
Resistance and 
features 
DH5 
(InvitrogenTM) 
F– Φ80lacZΔM15 
Δ(lacZYA-argF) 
U169 recA1 endA1 
hsdR17 (rK–, mK+) 
phoA supE44 λ– thi-
1 gyrA96 relA1 
Cloning None, 
High insert stability, 
high plasmid yield, 
blue/white screening 
of recombinant clones 
XL1-Blue recA1 endA1 
gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F’ 
proAB lacqZM15 
Tn10 (TetR)] 
Cloning  Tetracycline,  
Blue/white color 
screening of 
recombinant clones 
Rosetta2 F- ompT hsdSB(rB-
mB-) gal dcm 
pRARE2 (CamR) 
Protein 
expression 
Chloramphenicol, 
increased expression 
of eukaryotic proteins 
with rare codons 
ArcticExpress(DE3) B F- ompT hsdS(rB-
mB-) dcm+ TetR 
gal(DE3) endA 
The[cpn10 cpn60 
(GentR) 
Protein 
expression 
Gentamycin, 
constitutive 
expression of 
chaperonins 
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Plasmid transformation and competent cell growth were performed in SOC medium. 
All the antibiotics for selection were prepared at a working concentration of 50-100 
g/ml and filter-sterilised prior to use. 
The LB medium consisted of 5 g/l yeast extract, 10 g/l tryptone and 10 g/l sodium 
chloride. 1% w/v of agar was added for the preparation of LB agar plates. 
The SOC medium was obtained by adding 10 ml/l of filter-sterilized 2 M glucose to 
SOB medium, just prior to use. SOB medium composition: 20 g/l tryptone, 5 g/l yeast 
extract, 0.5 g/l sodium chloride. The solution was autoclaved and 10 ml of filter-
sterilised 1 M magnesium chloride and 10 ml of filter-sterilised 1 M magnesium 
sulphate were finally added to obtain the complete SOB medium. 
The Y medium consisted of 5 g/l yeast extract, 20 g/l of tryptone, 5 g/l magnesium 
sulphate, pH 7.6. 
 The AI medium was a complex medium containing 10 g/l tryptone, 5 g/l yeast extract, 
20 ml/l 50X 5052 solution (250 g/l glycerol, 25 g/l glucose, 100 g/l -lactose), 50 ml/l 
NPS solution (1.8 g of sodium sulphate, 8.5 g KH2PO4, 8.85 g Na2HPO4, 6.7 g 
ammonium chloride dissolved in 45 ml of H20), 1 ml/l 1 M magnesium sulphate, 1 ml 
1000x trace metals (0.1 M FeCl3, 1 M CaCl2, 1 M MnCl2, 1 M ZnSO4, 0.2 M CoCl2, 0.1 
M CuCl2, 0.2 M NiCl2, 0.1 M Na2MoO4, 0.1 M Na2SeO3, 0.1 M H3BO3 in water). 
The M9 medium (5X concentrated) was composed of 33.9 g/l of Na2HPO4, 15 g/l 
KH2PO4, 2.5 g/l sodium chloride, 5 g/l ammonium chloride. The medium, diluted 
down to 1X strength with Elga water, was complemented with filter-sterilised 1 M 
glucose (10 ml/l), 1 M CaCl (100 l/l) and 1 M magnesium sulphate (2 ml/l) right prior 
to use.  
Media for plant growth and assays 
Murashige & Skoog (132)(MS, used at ½ strength) was prepared with 2.15 g/l MS 
powder and 20 mM sucrose. The pH value was corrected to 5.7 with sodium 
hydroxide prior to autoclave sterilisation. 
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2.4 Molecular Biology techniques 
2.4.1 Polymerase Chain Reaction (PCR) & colony PCR 
All the oligonucleotides used as primers for the PCR reactions were designed using 
the OligoAnalyzer online tool (https://www.idtdna.com/calc/analyzer), provided by 
Integrated DNA Technologies (IDT) and synthesized by either IDT or Sigma. The chain 
reactions were performed on Bio-Rad DNA Engine thermal cyclers, using Pfu, 
Phusion, Q5 and GoTaq polymerases, following the instructions and protocols 
provided by the manufacturer.  The colony PCR was performed using single bacterial 
colonies (previously transformed with a plasmid and grown on antibiotic-containing 
medium), instead of pure DNA, as templates for the amplification cycles. 
2.4.2 DNA restriction digestion 
The destination vectors were linearised by single or double digestion with 
appropriate endonuclease enzymes: NcoI, XhoI, AvrII, SacI, BamHI, BseRI (from NEB), 
mainly. As indicated by the product’s guidelines, all the restriction reactions, with 1 
U of enzyme / g of DNA in the provided CutSmart buffer, were performed at 37 °C 
for 30 min – 2 h. 
2.4.3 Dephosphorylation of linearised vector  
To avoid the re-annealing of the DNA ends generated by the digestion, the linearised 
vectors were treated with FastAP alkaline phosphatase (ThermoScientific), which 
allowed the removal of the overhanging phosphate groups. As suggested by the 
manufacturer, the dephosphorylation reactions were carried out at 37 °C for 10 min 
and the enzyme was subsequently inactivated by heating at 75 °C for 5 min. 
2.4.4 Agarose gel electrophoresis 
The size of the PCR amplicons and the effective linearisation of the vector were 
analysed via gel electrophoresis. The samples, mixed with the stain, were loaded on 
a 1.2 % w/v agarose gel, prepared with TAE buffer (for 50X strength: 242 g/l of Tris 
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base, 57.1 ml/l of glacial acetic acid, 100 ml/l of 0.5 M EDTA) and supplemented with 
ethidium bromide (2 l/100 ml buffer) to visualise the DNA. A BioRad PowerPac 3000 
was employed to generate the current, generally 100-140 V, for the migration of the 
analytes, charged negatively, towards the cathode. The sizes of the analytes were 
compared to a DNA ladder, generally a 1 kb DNA Ladder (from NEB, catalogue 
number N3232 or Promega, catalogue number G5771, with markers sized 0.5-10 
Kilobases). A gel documentation imaging system, equipped with a UV chamber and a 
camera lens, was used to visualise the DNA and record a picture of the gel. 
2.4.5 DNA isolation 
The PCR amplicons and the digested plasmids were isolated using the Wizard® SV Gel 
and PCR Clean-Up System (Promega), following the provided protocol. Briefly, the 
DNA samples were mixed with the membrane binding solution (1:1 ratio) and loaded 
onto the Minicolumn. After a 1-min incubation, centrifugation at 16,000 g for 1 min 
allowed the separation of the linear DNA present in the sample from the buffer and 
residual chemicals/enzymes from previous steps. The immobilised DNA was 
subsequently washed with an ethanol-based wash buffer and the final, clean, DNA 
was then eluted with nuclease-free water. 
For the isolation of plasmids, a QIAprep Spin Miniprep kit (Qiagen) was employed, 
following the instructions from the manufacturer. The procedure, similar to that used 
for the purification of linear DNA, was preceded by a lysis step, where cells 
transformed with the plasmid were disrupted chemically to allow the release, among 
other cellular contents, of the plasmid of interest.   After a centrifugation step, at 
17,900 g for 1 min, the plasmid was loaded onto a spin column with a selective 
membrane and separated from the cell debris via centrifugation, at 17,900 g for 
another min. Two ethanol-based washing steps followed (at the same centrifugation 
speed and time), with a final elution of the plasmids with pre-heated nuclease-free 
water. 
In both cases the isolated DNA was kept on ice for immediate use or stored at -20 °C. 
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2.4.6 Cloning: ligation, InFusion 
Different procedures were employed to introduce the insert of interest in the 
destination plasmid. The traditional method consisted of ligating the compatible ends 
of the insert with those of a linearised vector using a T4 DNA ligase (NEB), which 
catalyses the formation of phosphodiester bonds. According to the protocol 
provided, the reaction mixtures, with 1 l of enzyme, corresponding to 400 NEB 
Units, and different vector: insert ratios (1:1, 3:1, 1:3), were incubated for up to 2 h 
at room temperature and then the enzyme was inactivated at 65 °C. InFusion cloning 
(Clontech) is an alternative method for cloning inserts into vectors. Using the Infusion 
kit, the desired insert was PCR-amplified for the introduction of 15 basepair-long 3’ 
and 5’-flanking adapters homologous to the ends generated by enzymatic digestion 
of the destination vector. The linearised vector and the “adapted” insert were mixed 
(insert:vector ratio of 2:1) with 2 l of the InFusion enzyme premix and incubated at 
50 °C for 15 min. At the end of both cloning reactions (ligation and InFusion) the 
mixtures were straightaway transformed into competent DH5 or XL1-Blue E. coli 
cells. 
2.4.7 Preparation of competent cells 
A chemical treatment was used for the preparation of competent E. coli cells, in order 
to allow the efficient transformation of exogenous DNA of interest. 
A single colony 5 ml inoculum in Y medium was firstly incubated at 37 °C. After 
allowing a first round of cell replication, the starter culture was seeded into 250 ml 
of SOB medium in a 2 l Erlenmeyer flask, to allow a good overall aeration of the 
culture. The flask was left on the orbital shaker (set at 200 rpm) at 18 °C until the 
optical density of the culture (OD600) reached a value of 0.6. The cells were harvested 
by centrifugation at 5,000 g for 15 min at 4 °C. The cell pellets were firstly treated 
with a medium composed of 30 mM potassium acetate, 100 mM rubidium chloride, 
10 mM calcium chloride, 50 mM manganese chloride, 15 % v/v glycerol, pH 5.8. After 
a 15-min centrifugation at 5,000 g at 4 °C the cells were re-suspended in 10 mM 
MOPS, 75 mM calcium chloride, 10 mM rubidium chloride, 15% v/v glycerol. The 
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resulting cell suspension was aliquoted, snap frozen in liquid nitrogen and stored at 
– 80 °C. 
2.4.8 DNA transformation 
2.4.7.1 Heat shock 
The E. coli competent cells, briefly let to thaw on ice, were mixed with 1 l (approx. 
50 ng) of plasmid DNA. After 10 to 30 min of further incubation on ice, the mix was 
heated for 25 (for Arctic express) or 60 s (for all the other strains) on the water bath, 
set at 42 °C. The mix was then placed back on ice for two min and the cells were 
recovered with pre-warmed nutrient medium (SOC or LB). After a 1- h incubation at 
37 °C on the orbital shaker (set at a speed of 180 rpm), the transformed cells were 
spread onto LB -agar plates. The antibiotic in the medium was matched to the 
presence of the antibiotic resistance gene encoded on the transformed vector, to 
allow the selection of the transformed cells. 
2.4.7.2 Electroporation 
A 50 l aliquot of competent A. tumefaciens (strain GV3101) was first mixed with 1 
l of vector DNA. After a brief incubation on ice, the cells were transferred into a 2 
mm micropulsar cuvette and electroporated using a BioRad Gene Pulser II system. 
Electroporation setting: 2.5 kV, 400  resistance, 25 F capacitance. The cells were 
recovered with 1 ml of LB medium, incubated for 3 h on the orbital shaker (200 rpm) 
at 30 °C and spread onto LB agar plates, with the appropriate antibiotic for resistance 
selection.  
2.4.9. DNA sequencing   
The purified DNA samples at a concentration of 80-100 ng/l were sequenced either 
via the departmental Genomics Technology Facility or through the external GATC 
Biotech AG (Germany) sequencing provider.  
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2.5 Biochemistry techniques 
2.5.1 Protein heterologous expression 
2.5.1.1 In E. coli Rosetta2, Arctic express, BL21(DE3) 
Many different conditions were tested for the soluble expression of the target 
proteins; specific conditions are supplied in the relevant Chapters. In general, 
expression cultures were prepared in M9 minimal medium, with glucose as the 
carbon source. At an OD600 value between 0.6-0.8, 0.5 mM isopropyl-β-D-1-
thiogalactopyranoside (IPTG), 0.5 mM aminolevulinic acid and 0.5 mM FeCl3 were 
added, to induce protein expression and as heme precursors, respectively. The 
cultures were then incubated on the orbital shaker (180 rpm) for 16-20 h at 16 °C. 
2.5.1.2 In A. tumefaciens 
Single colonies grown on the selection plates were inoculated in 10-20 ml of LB 
medium, containing the appropriate antibiotic. The cultures were left to grow 
overnight at 30 °C on the orbital shaker (180 rpm). 
2.5.2 Cell harvest & lysis 
At the end of the expression period, the cells were harvested via centrifugation at 
low speed (5,000 g) at 4 °C on a Sorvall centrifuge. The cells were then resuspended 
in lysis buffer, generally a sodium or potassium phosphate buffer at pH 7.4-8, 
supplemented with 200 M of phenylmethylsulfonyl fluoride (PMSF). The 
suspensions were stirred for 30 min in the cold room and then subjected to sonication 
bursts (using a Misonix S-4000 sonicator) at 70 % amplitude, 3 s on and 7 s off, for a 
total sonicating time of 4 min, to disrupt the cells and allow the release of the 
proteins. The soluble components were separated from the cell debris via 
centrifugation at 34,000 g at 4 °C for 15 min. 
Chapter 2: General Materials & Methods 
 
59 
 
2.5.3 Spectrophotometric evaluation of protein expression 
The presence of the target P450 proteins in the clarified lysates or at the end of the 
purification process could be verified using a UV-Vis spectrophotometer, by scanning 
within a wavelength window between 300 and 600 nm. If a cytochrome P450 is 
present in the mixture, an absorbance peak at 420 nm (related to the P450 enzyme 
in the oxidised resting state) should be clearly observed. To further verify the correct 
folding of the expressed protein, 5 mg of sodium dithionite were added in the sample 
cuvette to reduce the protein. The sample was then “bubbled” with carbon monoxide 
(1 bubble/s for 1 min, approximately). The final CO-bound state, indicative of a 
correctly folded protein, should present an absorption maximum at 450 nm (4, 133). 
2.5.4 SDS-PAGE verification 
Samples containing the protein of interest were mixed with Laemmli loading buffer 
(134), 3 parts protein: 1 part buffer, composed of 15 % (v/v) distilled water, 25 % (v/v) 
1M Tris-HCl, pH 6.8, 40 % (v/v) glycerol, 10 % (w/v) sodium dodecyl sulfate (SDS), 
0.05% (w/v) bromophenol blue and 20 % (v/v) -mercaptoethanol. After a 5-min 
incubation at 90 °C, the samples were loaded on a 12 % polyacrylamide gel.  The gels 
were casted right prior to loading; the separating section of the gel was composed of 
1.68 ml water, 1.25 ml 1.5 M Tris-HCl pH 8.8, 50 μl 10 % (w/v) SDS, 2 ml Protogel 
37.5:1 acrylamide to bisacrylamide stabilised solution (National Diagnostic), 37.5 μl 
10 % (w/v) ammonium persulphate (APS), 3.75 μl N-Tetramethylethylenediamine 
(TEMED). The stacking section of the gel, comprising the loading wells, was instead 
made of 1.22 ml water, 0.5 ml 0.5 M Tris-HCl pH 6.8, 20 μl 10 % w/v SDS, 0.26 ml 
Protogel solution, 15 μl APS, 3 μl TEMED. The electrophoresis was carried out at a 
voltage of 200 V in a BioRad miniprotean 3 cell, filled with running buffer, composed 
of 3 g/l Tris, 14.4 g/l glycine, 1 g/l SDS. At the end of the run, the separated analytes 
present in the sample were visualised by incubating the gel for 30 min on the rocker 
at room temperature with 20 ml of Expedeon Instant blue protein stain. The size of 
the analytes was compared with molecular markers, mainly NEB PageRuler plus, 
which covered the 10-250 kDa range of sizes. 
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2.5.5 Western blot verification 
At the end of the electrophoretic run, the SDS acrylamide gel was positioned on a 
nitrocellulose membrane (BioRad, 0.45 μm) and the two layers were encased in six 
total layers (three per side) of thick filter paper pre-soaked in Towbin transfer buffer 
(25 mM Tris, 192 mM glycine, 20% v/v methanol). The resulting “sandwich” was 
positioned within an electrified circuit (BioRad Transblot SD SemiDry Transfer cell) set 
up at 25 V, allowing the transfer of the analytes from the gel onto the membrane.  
The effective blotting on the membrane was verified via Ponceau staining, incubating 
the membrane briefly with a few ml of Ponceau S solution (0.1% w/v Ponceau S in 5% 
v/v acetic acid). The membrane was incubated for 1 h in PBS buffer (137 mM NaCl, 
2.5 mM KCl, 10 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) containing 5% w/v of skimmed 
milk powder. After this blocking step, the membrane was washed three times with 
PBS buffer containing 0.5% of Tween20 and incubated for at least 2 h with PBS buffer 
solution containing 1% BSA and an AntiHis polyclonal antibody conjugate from rabbit 
(1/2,000 dilution). At the end of the incubation period the membrane was rinsed 
three times with the 0.5 % Tween20 solution and finally developed, revealing the His-
tagged conjugated products, using a developing solution composed of 10 ml 
triethanolamine, 2 ml chloro-naphtol in methanol and 5 l of hydrogen peroxide. 
Authentic His-tagged proteins were also loaded on the SDS-PAGE gels, as positive 
controls.  
2.5.6 Protein purification 
The proteins present in the clarified cell lysates were purified via affinity 
chromatography, exploiting the affinity of the polyHistidine tags for the Nickel-
covered resin, either with a batch process or by employing automated pump systems 
(peristaltic pump or Akta purifier). 
Prior to the purification the clarified cell lysates were filtered through a 0.22 M 
Millex sterile filter unit (Millipore). 
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Batch process 
Small scale purification trials were performed in batch systems, consisting of pre-
equilibrated His-select Nickel affinity gel (0.5 ml / 10 ml of lysate) in a 50 ml Falcon 
tube. Briefly, the filtered lysate was incubated for more than 2 h (up to overnight) 
with the pre-equilibrated resin on the rocker. At the end of the incubation, the mix 
was centrifuged at 5,000 g for 10 min. The buffer was replaced (gently, using a 
pipette) with 15 resin volumes of fresh buffer, to remove the unbound proteins. After 
a brief mix and another centrifugation step (same conditions as above), the resin was 
washed again two more times. One resin volume of fresh buffer containing 5 mM 
imidazole was used to displace non-specifically bound proteins from the resin. After 
this fourth washing step, the proteins of interest were detached by incubation with 
one resin volume of buffer containing 500 mM imidazole. The mixture was incubated 
shaking gently for 1 h on the rocker and then centrifuged, in order to settle down the 
resin. The supernatant was collected and loaded onto a spin column (0.22 m in 
cellulose acetate, Agilent Tech), and centrifuged for 2 min at 16,000 g, to remove the 
remaining traces of resin. The protein solution was then dialysed twice against 5 l of 
potassium phosphate buffer pH 7 using Slide-A-Lyzer™ G2 Dialysis Cassettes 
(ThermoFisher Scientific). At the end of the process the protein solution was 
recovered, mixed 1:3 with 60 % (v/v) sterile glycerol, snap frozen in liquid nitrogen 
and stored at – 80 °C.    
Continuous process 
The filtered lysate was loaded at a rate of 0.5 ml / min onto a pre-equilibrated HisTrap 
FF crude (GE Healthcare Life Sciences) 1 ml / 5 ml chromatographic column, 
connected either to a peristaltic pump or to an ÄKTApurifier 10 system. Elution was 
carried out with a gradient of 30-300 mM imidazole, with a 1 ml/min flow. The eluted 
fractions were checked spectrophotometrically and those presenting the higher 420 
nm peaks (related to the CYP in the oxidised resting state) were pooled together, 
uploaded into Slide-A-Lyzer™ G2 Dialysis Cassettes and dialysed overnight in 
potassium phosphate buffer pH7, to minimize the imidazole concentration. The 
recovered protein was then concentrated using a centrifugal concentrator, generally 
a Vivaspin® 2 Centrifugal Concentrator. Purity and size of the protein in the collected 
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samples were determined using SDS polyacrylamide gel electrophoresis. The 
absorbance spectrum between 300 and 600 nm was measured to verify the presence 
of the characteristic peak at 420 nm. 
2.5.7 Protein quantification 
The quantity of protein present in solution was evaluated either directly, inputting 
the 280 nm absorbance read with a NanoDrop-1000 spectrophotometer in the 
Lambert Beer’s law, with the known extinction coefficient, or indirectly via Bradford 
assay. The latter was performed in a 96-wells format mixing 10 l of sample (diluted 
appropriately in order not to exceed the sensitivity of the assay) with 300 l of 
Coomassie dye. After a 10-s shaking, the absorbance at 595 nm, related to the dye-
protein complex, was read using a Tecan Sunrise™ microplate absorbance reader. 
The values were compared to those of bovine serum albumin (BSA) standards of 
known concentrations, ranging from 0 to 2 mg/ml, to calculate the final 
concentration of the protein present in solution. 
2.5.8 Activity assay 
CYP73A5 activity towards cinnamic acid 
After 24 h of growth at 16 °C the cells were harvested via centrifugation and 
resuspended in 50 mM potassium phosphate buffer pH 7 (100 mg cells / ml of buffer). 
The suspension of whole cells was used to assess the ability of the construct to 
catalyse the hydroxylation of cinnamic acid, the natural substrate of CYP73A5, to          
p-coumaric acid. The reaction, carried out at 28 °C with shaking (300 rpm) was 
initiated by the addition of 200M cinnamic acid and samples were collected over a 
period of 7 h. Reactions were terminated with methanol and the supernatant, after 
a centrifugation step to remove the cells, was analysed via HPLC with a Waters X-
Bridge C18 column (250 x 4.6 mm, 5 µM) heated to 30 °C, employing a gradient of 
water (A) and methanol with 0.1% acetic acid (B): 90 % A for the first 3 min, 90 to 55 
% A in 1 min, 55 % A for 5 min and 90 % A for 5 min. The HPLC system used consisted 
of a Waters Alliance 2695 separation module and a Waters 2996 photodiode array 
detector.
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Chapter 3: Soluble expression of Cytochromes 
P450 
3.1 Introduction: Bottlenecks in the heterologous expression 
of plant CYPs 
Eukaryotic cytochrome P450 enzymes, unlike their prokaryotic counterparts, are 
tightly bound to the membranes of the endoplasmic reticulum through an N-terminal 
hydrophobic domain. This means that when recombinantly expressed, eukaryotic 
cytochromes P450 are almost always insoluble. This insolubility issue has constituted 
a significant constraint in the process of discovering, and characterising, novel 
cytochrome P450 functionalities from eukaryotes. Generally, the native expression 
of plant CYP enzymes is very low, and tightly dependent on the developmental stage 
of the organism or on environmental inducers. Thus, many protein characterisation 
studies have been, and still continue to be, carried out by overexpressing genes of 
interest heterologously. Among the favourite hosts of expression are bacteria, such 
as E. coli, which are relatively simple and inexpensive systems.  
Several approaches have been used so far to tackle the problematic expression of 
eukaryotic enzymes in bacterial hosts. These include nucleotide sequence 
optimisation re-coding, to overcome codon usage bias, and protein sequence 
modification, to remove hydrophobic domains or amend the structural arrangement. 
Additionally, expression conditions and purification processes have to be optimised, 
depending on the characteristics of the target protein, such as the presence of tags, 
isoelectric point, stability. The first studies reporting the successful expression of 
eukaryotic CYPs in a bacterial system were published in 1991. Li and Chan succeeded 
in obtaining high levels (up to 75%) of soluble and active rat hepatic cholesterol 7 
alpha-hydroxylase cytochrome P450 (P450c7) in E. coli. This successuful expression 
was achieved by deleting the amino acids in positions 2 to 24 from the starting 
methionine; amino acids identified as forming the hydrophobic anchor from the N-
terminus (135). Barnes and co-workers (136) next obtained high levels of active 
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bovine CYP17-hydroxylase, a CYP that is involved in hormone biosynthetic 
pathways, using E. coli JM109 as the host for expression. Key to Barnes et al.’s success 
was the use of a strong, inducible promoter, as well as the modification of the N-
terminus of the protein. Specifically, a tryptophan was replaced with an alanine and 
four other codons were subjected to silent mutations. The authors explained that 
these mutations minimised the formation of secondary structures in the mRNA and 
adhered to the codon preference of the host organism, significantly improving the 
efficiency of the host ribosomal translation (136, 137). Subsequently, other groups 
demonstrated that simply replacing the N-terminal hydrophobic anchor with the 
eight amino acids derived from the modified bovine CYP17 (MALLLAVF) paved the 
way for expression and characterisation of many mammalian P450s such as human 
CYP1A2  (138), rabbit CYP2C3 (139) and human CYP2C10 (140). It is of note that in all 
these cases, the MALLLAVF peptide yielded high levels of CYPs, however, these 
products were all bound to the membranes in the host. Additional solubilisation steps 
with detergents were therefore needed to isolate the proteins. An alternative 
substitutive N-terminal peptide described in the literature was MAKKTSSKGKL, 
engineered for the first time by von Wachenfeldt et al. (141) and which allowed the 
expression, as well as functional and structural studies, of several eukaryotic CYPs 
such as rabbit CYP2C3 (141), human CYP2D6 (142), CYP2B6 (143), CYP2C8 (144), 
CYP2C9 (145), CYP2C5 (146, 147), CYP2R1 (148) and also Arabidopsis CYP74A1 (149), 
CYP98A3 (150) and burclover (Medicago truncatula) CYP93C20 (151). 
Dr. Julia Schuckel, a previous member of the Bruce group, attempted the expression 
of a set of plant CYPs – CYP81D11, CYP81D8 from Arabidopsis and CYP71A12 from 
peppermint (Mentha x piperita L.) - either by deleting the N-terminal anchor 
(CYP81D11tr and CYP81D8tr) or by replacing it with the bovine peptide mentioned 
above (CYP71A12 PM2-2). Additionally, she performed several expression screens, 
employing a broad range of different hosts (E. coli BL21(DE3), Rosetta 2, Rosetta gami 
2, DH5 strains and S. cerevisiae, WAT21 and WAT11 modified strains) and media 
(TB, M9 and LB), but the levels of expression were not sufficiently high to allow 
western blot verification of the purified products (152). Following the published 
procedure by Haudenschild et al. (153), CYP71A12 PM2-2 was transformed in E. coli 
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JM109 cells, but no expression could be observed on SDS-PAGE gels. Activity assays 
performed with whole cells showed no conversion of the substrate, limonene. 
Subsequently, Dr. Schuckel transformed each of the three constructs in all the above-
mentioned E. coli strains. No expression in any case could be observed for CYP71A12 
from peppermint. On the other hand, CYP81D11tr and CYP81D8tr (with the N-
terminal membrane-spanning domain cleaved off) were successfully expressed in 
Rosetta 2 E. coli cells grown in LB medium. The activity of CYP81D11tr and CYP81D8tr 
was tested, with the purified proteins as well as with whole cells and disrupted cells. 
The chosen substrates for the assays were methyltolyl-sulphide (expected to be 
hydroxylated to methyltolyl-sulphoxide) and limonene. No conversion at all could be 
observed for both substrates, not even when a redox partner, Arabidopsis ATR1 
reductase or spinach ferredoxin/ferredoxin reductase, was supplied. 
The protein targets selected for expression in this study were CYP73A5 and CYP81D11 
from Arabidopsis and CYP81A9 from maize (Zea mays). 
AtCYP73A5 is a well-characterised P450, responsible for the hydroxylation of 
cinnamic acid to p-coumaric acid (figure 3.1), one of the first steps of the 
phenylpropanoid pathway. For this reason, it was used to validate the constructs built 
in this chapter and in chapter 4. 
 
Figure 3.1: Reaction catalysed by CYP73A5: hydroxylation of cinnamic acid to p-coumaric acid. 
 
The first NADPH-dependent cinnamate hydroxylase from a plant microsomal fraction 
was originally described in 1967 by Russell et al. from pea (Pisum sativum) apical buds 
(154). Orthologues, classified as cytochrome P450s, were then isolated from sorghum 
(Sorghum bicolor x S. bicolor var. Sudanese hybrid) (155), Jerusalem artichoke 
(Helianthus tuberosus) (156), mung bean (Vigna radiata) (157) and Arabidopsis (158), 
and intensively studied since the early ‘90s.  
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To date, AtCYP81D11 is an uncharacterised enzyme, produced at medium basal levels 
throughout the different growth stages and in different tissues of the Arabidopsis 
plant (see GeneVestigator analysis in figures 3.2 and 3.3).  
 
 
Figure 3.2: Expression pattern of CYP81D11 in Arabidopsis at different developmental stages. 
 Source: https://www.genevestigator.com/gv/, 15/07/2014. 
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Figure 3.3: Expression pattern of AtCYP81D11 in different tissues. Source: 
https://www.genevestigator.com/gv/, 15/07/2014. 
 
Many studies have reported how CYP81D11 expression levels were upregulated in 
plants subjected to different types of stresses, such as bacterial infections, wounding, 
exposure to toxic compounds, extreme temperatures, drought (159). Interestingly, 
as highlighted by Ekman at al. (160), as well as in Gandia-Herrero et al. (161, 162), the 
gene encoding CYP81D11 is the most upregulated, up to 25 fold higher levels, upon 
treatment of Arabidopsis plants with the explosive 2,4,6-trinitrotoluene (TNT). Other 
upregulated genes identified in Gandia-Herrero et al.’s study (162), such as OPRs, 
GSTs and UGTs, were discovered to be directly active towards TNT or its derivatives 
(163, 164). Additionally, oxidative derivatives of this xenobiotic compound have been 
described in the literature (165). These observations might thus lead to the possible 
involvement of CYP81D11 in the detoxification of TNT.   
The ZmCYP81A9 shares a 79 % sequence identity with CYP81A21 and CYP81A12, two 
enzymes from Echinochloa phyllopogon, a pervasive weed of rice. Both EpCYPs are 
able to catalyse the demethylation of bensulfuron-methyl, an acetolactate synthase-
inhibiting herbicide (166). Another match (73% sequence identity) was found for rice 
(O. sativa) CYP81A6, which was reported as responsible for herbicide resistance in 
rice (167). An RNAseq study led by Liu et al. (168) showed that CYP81A9 is among the 
most upregulated genes upon treatment of maize plants with the herbicide 
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nicosulfuron, thus implying a potential role of this enzyme in the plants’ defence 
mechanisms against xenobiotics. For this reason, ZmCYP81A9 was chosen as an 
interesting target for potential agronomical purposes. 
The aim of this section is to optimise the production, via protein engineering and 
multiple expression screenings, of the selected set of plant CYPs. 
 
3.2 Materials and methods used for the soluble expression of 
plant CYPs 
3.2.1 Sequence analysis, PCR and cloning 
The native coding sequences for the target P450 enzymes were retrieved from the 
National Center for Biotechnology Information (NCBI) database (table 3.1). 
 
Table 3.1: Gene ID and locus tags of the proteins used in this chapter 
 
Protein Role Gene ID - locus tag 
AtCYP73A5 Hydroxylation of cinnamic acid 
(phenylpropanoid pathway) 
817599 - AT2G30490 
AtCYP81D11 Xenobiotic metabolism 
(hypothesised) 
822506 - AT3G28740 
ZmCYP81A9 Xenobiotic metabolism  
(hypothesised) 
103625869 - 
ZEAMMB73_713160 
AtCYP81D8 Xenobiotic metabolism  
(hypothesised) 
829891 - AT4G37370 
 
 
The native plant nucleotide sequences were codon-optimised for expression in E. coli 
using the ‘GeneOptimizer’ online tool 
(https://www.thermofisher.com/uk/en/home/life-science/cloning/gene-
synthesis/geneart-gene-synthesis/geneoptimizer.html) by ThermoScientific. The 
Expasy ‘protein translate’ online tool (web.expasy.org/translate/) was employed to 
convert the nucleotide sequences into amino acid sequences. The obtained 
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sequences were then analysed using the TMHMM 
(www.cbs.dtu.dk/services/TMHMM, Centre for Biological Sequence Analysis, 
Denmark Technical University) and the DAS (www.sbc.su.se/~miklos/DAS, a joint 
project by the Biological Research Center - Hungarian Academy of Sciences and the 
Stockholm University) online transmembrane domain prediction tools, in order to 
identify the possible N-terminal membrane-spanning regions. These tools employed 
two different algorithms to determine protein domains with affinity to the 
endoplasmic reticulum (ER). Removal of the DNA sequences encoding these domains 
could decrease the affinity of the resultant proteins to the ER membrane and thus 
increase their overall solubility.  The resulting optimised and truncated sequences of 
CYP81D11 (CYP81D11tr) and CYP81A9 (CYP81A9tr) were synthesised using the 
GeneArt™ gene synthesis service (Life Technologies). The CYP73A5tr sequence was 
already available in the Bruce group’s stock.  
A new expression construct, used in the work presented here, was designed 
specifically to express plant CYPs. This construct encoded the MAKKTSSKG peptide, 
hereafter named the S-tag, at the N-terminus of the target protein’s reading frame. 
In order to introduce this peptide “signal” (which would presumably decrease the 
protein’s affinity for the ER membrane), an intermediate cloning vector containing 
the peptide was synthesised by GeneArt™, called pMA-T. In addition to the N-
terminal tag, pMA-T also presented, within the cloning site, other strings of 
aminoacids, to subsequently use as a linker to connect the CYP and the redox partner 
in the fusion constructs (Chapter 4).  
The primers used to amplify the CYP sequences throughout the cloning process are 
summarised in table 3.2. 
  
Chapter 3: Soluble expression of CYPs 
 
70 
 
Table 3.2: Oligonucleotides used for the PCR amplification of the three CYP targets. 
 
 
Each reaction mix consisted of approximately 50 ng of plasmid DNA, 20 M of each 
primer, 10 mM DNTPs mix, 2 U of Pfu DNA polymerase in 10x Pfu buffer and water to 
a final volume of 50 l. The thermocycler was set to perform a first denaturation step 
at 95 °C, 30 cycles of 95 °C for 30 s (denaturation), Tm-5 °C for 30 s (annealing), 72 °C 
for 3 min (extension) followed by a final extension step at 72 °C for 5 min. 
The modified genes were then cloned via InFusion (Materials and Methods, Chapter 
2.4.6) into the destination expression vector. 
The vectors used in this chapter, pET28a and pMA-T are shown in figure 3.4. The NcoI 
and XhoI restriction sites flanking the multiple cloning site (MCS) in pET28a, were 
exploited to clone the S-tagged modified gene of interest, upstream of the C-terminal 
His-tag.  
 
 
Protein name Primers 
CYP73A5-1 Forward - 5' AGCAAAGGTGAGCTCGCCCTGCGTGGTAAAAAAC 3' 
Reverse - 5’ GCTGGTGCTACCGGATCCTGAGTTACGCGGTTTCAT 3’ 
CYP73A5-2 Forward - 5' AGGAGATATACCATGGATGGCCAAAAAAACCAGCAGCA 3' 
Reverse - 5’ GGTGGTGGTGCTCGAGTGAGTTACGCGGTTTCATCACA 3’ 
CYP81D11 Forward - 5' CCAGCAGCAAAGGTGAGCTCAGCAGCACCAAAACC 3' 
Reverse - 5’ TGGTGCTACCGGATCCCGGACAACTTGCATCCAG 3’ 
CYP81D11-int Forward - 5' TTTTTGTTGTTAGCAGCCAT 3' 
Reverse - 5’ TCAAAACACTGAACCAGACTAC 3’ 
CYP81D11-2 Forward - 5' AGGAGATATACCATGGATGGCCAAAAAAACCAGCAGCA  3' 
Reverse - 5’ GGTGGTGGTGCTCGAGCGGACAACTTGCATCCAGAAC 3’ 
CYP81A9 Forward - 5' AGGAGATATACCATGGATGGCCAAAAAAACCAGCAGCA  3' 
Reverse - 5’ GGTGGTGGTGCTCGAGCAGGCGTTTCAGAACACCAC 3’ 
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         S-CYP-L 
       sequence 
ccatggCCAAAAAAACCAGCAGCAAAGGTgagctcCCG AGC ACC GAA 
CAG AGC GCA AAA AAA GTT CGT AAA AAA GCC GAA AAC GCC CAT 
GGT CCT GGT CCA GGT CCT GGT CAT ATG CGT CTG GCG AGC ACC 
CAT ATGggatccGGTAGCACCAGCAGCGGTAGCGGTcctagg 
 
Figure 3.4: Plasmid maps for pET28a and for the synthetic pMA-T plasmid, carrying the solubility tag 
(S, highlighted in blue in the sequence reported) and the linkers (highlighted in yellow, purple, grey and 
green), used for the expression of the target genes. The yellow region corresponds to the B. 
megaterium BM3 natural linker between the heme and the reductase, the purple to a flexible glycine-
proline loop, the grey to the linker engineered for the P450cam-RhfRed fusion system. In small case 
are the restriction sites for the endonucleases: NcoI, SacI, BamHI, AvrII. The green region encodes for 
the ‘lam’ linker (152). 
 
 
 
pMA-T 
 S-CYP-L 
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3.2.2 Expression trials in E. coli: Rosetta 2, BL21(DE3), Arctic express 
For the complete expression procedure, see Materials and Methods, paragraph 
2.5.1.1. 
After sequencing verification, the constructs were transformed into BL21 (DE3), 
Rosetta2, A. express E. coli strains, using the conventional heat-shock protocol 
(Materials & Methods, Paragraph 2.4.7.1). Single colonies were picked and cultured 
in 5-ml batches of LB medium with appropriate antibiotics for selection, shaking at   
37 °C overnight. The following morning, the cultures were upscaled to 50-500 ml in 
Erlenmeyer flasks containing fresh M9 growth medium. At induction time, the 
cultures were supplemented with aminolevulinic acid, FeCl3 and, if needed, IPTG. The 
expression temperatures used differed, ranging from 16 °C to 28 °C. The cells were 
harvested after 16-48 h using gentle centrifugation and lysed mechanically 
(sonication or French press) to release the expressed proteins. Soluble and 
membrane cellular fractions were separated by centrifugation of the cell lysates at 
34,000 g for 15 min. 
3.2.3 Expression trials in yeast (Saccharomyces cerevisiae WAT11 
modified strain) 
The native sequences of CYP81D8 and CYP81D11, each already cloned into pYEDP60 
shuttle vectors (constructs retrieved from the Bruce’s group stock), were 
transformed with the LiAc/SS (lithium acetate salmon sperm-mediated) method by 
Gietz and Schiestl (169)  into the WAT11 S. cerevisiae yeast strain. This particular 
strain was chosen as it was engineered to express ATR1, one of the two natural 
Arabidopsis P450 reductases (170).  Single yeast colonies (from the glycerol stocks) 
were inoculated in 20 ml of YPGA medium and grown at 30 ˚C on the orbital shaker 
(200 rpm). The following day the optical density of the cultures was measured and 
adjusted to a final OD600 value of 0.15 with pre-warmed YPGA medium. The cells were 
incubated again at the same temperature and rotation speed as above, for 3-5 h, in 
order to allow at least two cell duplications. The cells were harvested by 
centrifugation at 3,000 g for 5 min, washed with cold sterile water and spun again at 
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3,000 g for 5 min at 4 °C. The cell pellet, resuspended in 1 ml of cold sterile water, 
was subdivided into 100 l aliquots. The fractions were centrifuged briefly and each 
pellet was incubated with the transformation mix (240 µl of PEG 3500 50% w/v, 36 µl 
of 1M lithium acetate, 50 µl of pre-boiled salmon sperm DNA, target DNA to a final 
volume of 360 µl) at 42°C for 30 min, with gentle inversions from time to time. The 
reaction mixtures were placed on ice for two min and centrifuged at high speed for 
30 s. The pellets were washed with 1 ml of sterile water, spun quickly and 
resuspended again in 1 ml of cold sterile water. A fraction of the transformed cells 
(1/20 of the volume) was spread onto selective SGI plates, which were then incubated 
at 30 °C for three to four days. 
Following the protocol by Pompon et al. (171), single transformants were cultured in 
rich liquid medium (SGI starter and YPGE main) in baffled flasks at 28 ˚C with 
agitation, on an orbital shaker set at 140 rpm. After 24 h of incubation, protein 
expression was induced by addition of galactose (stock: 200 g/l, volume added: 1/10 
of each culture). The cultures were then left shaking for further 16 h at 25 °C.  
Finally, the yeast cells were harvested via centrifugation, washed and disrupted 
mechanically with glass beads. Microsomes were then recovered via centrifugation 
and homogenised in a Tris-HCl buffer pH 7.5 with ethylenediaminetetraacetic acid 
(EDTA) and 30% glycerol. To check the effective expression of the target CYPs, 
microsome solutions were diluted and scanned using the spectrophotometer at 
wavelengths between 400 and 500 nm, to verify the presence of the 450 nm peak 
upon reduction with sodium dithionite and carbon-monoxide treatment. 
Media and buffers for yeast growth and harvest  
YPGA: 10 g/l bactopeptone, 10 g/l yeast extract, 20 g/l glucose, 200 mg/l adenine. 
SGI: 1 g/l bactocasamino acids, 7 g/l yeast nitrogen base, 20 g/l glucose, 20 mg/l 
tryptophane, 20 g/l agar. 
YPGE: 10 g/l bactopeptone, 10 g/l yeast extract, 5 g/l glucose. 30 mL ethanol was 
added after the autoclave sterilisation. 
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TEK: 50 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8, 100 mM KCl, pH 7.5. 
TES: 50 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8, 109 g/l sorbitol, pH 7.5. 
TEG: 50 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8, 30% vol/vol glycerol, pH 7.5. 
3.2.4 Purification 
The purification of the modified CYP constructs was accomplished through Ni-affinity 
chromatography, exploiting the C-terminal hexa-histidine tag. A phosphate buffer, 
either sodium or potassium-based, was used throughout the whole process 
(Materials and Methods, Paragraph 2.5.6), at pH values ranging from 7 to 8, according 
to the calculated pI for the protein products. The proteins, eluted with gradients of 
imidazole (0-500 mM) or histidine (0-50 mM), were dialysed overnight against 
phosphate buffer at the appropriate pH, then concentrated and stored in 20 % v/v 
glycerol in the freezer at -80 °C. 
3.2.5 Protein characterisation: UV-Vis spectrophotometry and activity 
Fractions collected throughout the purification process, as well as eluted proteins 
were subjected to UV-Vis spectrophotometric evaluation (Materials & Methods, 
Paragraph 2.5.3) and activity assays, in order to assess the correct folding and activity 
of the product of interest. The reaction mixture for the activity assays consisted of 
different amounts of purified protein (25 and 750 nM), an equimolar concentration 
of purified plant P450 reductase, 200 M of the substrate cinnamic acid, 300 M of 
NADPH and an NADPH regeneration system, made of 2 mM glucose 6-phosphate and 
3 U of glucose 6-phosphate dehydrogenase. Samples from the reactions were 
collected at the start of the assay, after 5 h, 10 h and 20 h, with the reaction from 
each time point quenched with an equivalent amount of cold methanol. After 
centrifugation, the samples were analysed via HPLC (see complete separation 
method in Materials and Methods, paragraph 2.5.8). 
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3.3 Results 
3.3.1 Sequence analysis and cloning 
The nucleotide sequences of the target proteins (AtCYP73A5, AtCYP81D11 and 
ZmCYP81A9) were retrieved from the NCBI gene database and translated into the 
corresponding amino acid sequences with the Expasy ‘Protein Translate’ online tool. 
The obtained sequences were double-checked with the corresponding FASTA files 
deposited on the UniProt database (172). The verified amino acid sequences were 
uploaded onto the Das and TMHMM servers for structure prediction (figure 3.5 A-C). 
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Figure 3.5A: Transmembrane domain predictions by DAS (panel A) and TMHMM (panel B) for 
AtCYP73A5. The Das analysis (panel A) predicted that an N-terminal membrane anchor might be 
formed by amino acids between position 10 and 22. The TMHMM analysis (panel B) did not yield a 
clear result. 
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Figure 3.5B: Transmembrane domain predictions by DAS (panel A) and TMHMM (panel B) for 
AtCYP81D11. The algorithms identified the region between amino acids 11-28 and 12-31 (as 
highlighted in blue on each result panel) as the one possibily forming the N-terminal transmembrane 
domain. 
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Figure 3.5C: Transmembrane domain predictions by DAS (panel A) and TMHMM (panel B) for 
ZmCYP81A9. The two algorithms indicated that the region between amino acids 9-19 and 5-22 might 
form the N-terminal transmembrane region, as highlighted in blue on each result panel. 
 
A 
Amino acids 
B 
Amino acids 
Chapter 3: Soluble expression of CYPs 
 
79 
 
As a result of these sequence analyses, the codon-optimised nucleotide sequences of 
CYP81D11, CYP81A9, were synthesised truncated of the first 30 and 19 codons, 
respectively (CYP81D11tr, CYP81A9tr). A truncated version of CYP73A5 (CYP73A5tr), 
lacking the sequence encoding the first 25 codons, was already available in the Bruce 
group’s stock. The nucleotide sequences were further analysed to make sure that 
there were no internal SacI, BamHI, NcoI or XhoI restriction sites within the 
sequences of the proteins, as these sites would be used for the following cloning 
steps. The CYP sequences were amplified using the primers and procedures described 
in Paragraph 3.2.1. The first cloning step was the PCR-amplification of CYP73A5tr and 
CYP81D11tr, with primers specifically designed with the flanking SacI and BamHI 
restriction sites, in order to introduce these products into the pMA-T construct, 
enabling the addition of the S-tag at the N-terminus of the protein (figure 3.6). The 
sequence for CYP81A9tr was directly excised from the synthetic vector pMK (from 
the manufacturer) using the SacI and BamHI flanking restriction sites.  
 
Figure 3.6: Electrophoretic analysis on 1.2 % agarose gel of the PCR amplification of CYP73A5tr (A) and 
CYP81D11tr (B), both performed in triplicate, with Pfu polymerase in order to introduce the InFusion-
compatible ends for the cloning in pMA-T. (C): Excision of CYP81A9tr from the original synthetic vector 
(1: double-digested plasmid, 2: SacI single cut, 3: BamHI single cut, 4: uncut plasmid). All three 
products of interest (amplicons for A and B and insert in C) were expected to have a final size of ~1,500 
bases.  
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In parallel, the pMA-T vector was double-digested with the SacI and BamHI restriction 
endonucleases (figure 3.7). 
 
 
Figure 3.7: Double digestion of the pMA-T vector with SacI and BamHI. (-) identifies the lane where 
the undigested plasmid (as negative control) was loaded.  
 
The PCR products were each cloned into the linearised vector via InFusion cloning (S-
CYP73A5tr and S-CYP81D11tr) and ligation (S-CYP81A9tr) (for the complete 
procedure see Materials and Methods, Paragraph 2.4.6). Subsequently, colonies 
were screened via colony PCR (Materials and Methods, Paragraph 2.4.1), to verify the 
presence of the desired CYP insert, employing as primers the same oligonucleotides 
used for the first PCR amplification for CYP73A5tr or internal primers for CYP81D11tr 
(figure 3.8). 
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Figure 3.8: Colony PCR verification of the presence of the insert in the transformed colonies. The PCR 
was performed with Pfu DNA polymerase using single colonies as templates and the CYP73A5-1 
primers (top panel) or the CYP81D11-Int primers (bottom panel). 
 
The positive colonies were cultured for subsequent isolation of the plasmid (see 
Materials and Methods, Paragraph 2.4.5) and sequencing.  
The pMA-T_CYP plasmids which had the correct sequence, comprising the upstream 
solubility tag, were again subjected to PCR amplification, (figure 3.9) this time 
employing primers carrying the adapters for the InFusion cloning of the construct into 
the final expression vector (primers in table 3.2, set 2).  
 
 
 
Figure 3.9: Electrophoretic analysis of the second set of PCR amplifications of S-CYP73A5tr (A), S-
CYP81D11tr (B) and S-CYP81A9tr (C), all performed in triplicate. The same DNA ladder was used for 
the three gels (NEB 1kb DNA ladder #N3232). 
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Concomitantly, pET28a was linearised with NcoI and XhoI (figure 3.10) 
 
 
 
 
 
Figure 3.10: Double digestion of pET28a with NcoI and XhoI. (-) identifies the lane where the 
undigested plasmid, as the negative control, was loaded. 
 
The CYP amplicons were cloned into pET28a and the InFusion reactions were then 
transformed into competent DH5 cells. The positive transformants were then 
inoculated for subsequent plasmid isolation and sequencing. 
3.3.2 Expression trials  
Preliminary expression trials were conducted on S-CYP73A5tr, to establish an 
expression method for all three CYPs. The presence of the S-tag on CYP73A5tr was 
predicted to increase the solubility of the CYP. To evaluate the effect of the S-tag, the 
N-terminally modified S-CYP73A5tr cloned into pET28a was expressed in a range of 
different bacterial hosts. The outcome of the expression trials can be observed in the 
SDS-PAGE gel analyses reported in figures 3.11-3.12. 
In the first expression screen, BL21(DE3) was chosen as host of expression. The 
transformed cells were grown in LB and subsequently in M9 medium, induced with    
1 mM of IPTG, incubated shaking at 16 °C and harvested after 20 h of incubation. 
Additionally, a colleague (Dr. Claudia Spandolf, personal communication) who 
worked on fungal P450s, observed higher yields of expression of P450 constructs 
when glycerol, instead of glucose, was used as carbon source for the cultures. For this 
reason, parallel cultures in M9 with 10 mM glucose and in M9 with glycerol (0.4 % 
v/v) were also carried out in the BL21(DE3) trials, in order to compare the yields.  
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Figure 3.11: SDS-PAGE analysis of the expression of S-CYP73A5tr in glucose or glycerol-fed BL21 
cultures, compared to cultures harboring the empty vector, in the soluble and membrane fractions of 
the sonicated cells. First 2 lanes: empty vector / 3rd-4th lane: glucose-fed batch / 5th-6th lanes: glycerol-
fed batch. The blue arrow pointer indicates the product bands at the correct expected size of 57 kDa. 
 
Bands at the correct size (~ 57 kDa) could be visualised on the gel (in the lanes related 
to both glycerol and glucose cultures) but no cross-reactivity with the antibody anti-
His in western blot assays could be detected. A 57 kDa band was sent for MALDI-TOF 
MS-MS analysis and identified as the Arabidopsis cinnamate hydroxylase. However, 
since the C-terminal His-tag could not be detected on the western blot, the protein 
could not be purified via His/Ni-affinity chromatography. 
The S-CYP73A5tr construct was subsequently transformed in other E. coli strains, in 
A. express and in Rosetta 2, in parallel with BL21(DE3). Samples before the induction 
with IPTG (0.5 mM) and at the end of the expression period were collected and 
analysed via SDS-PAGE (figure 3.12). 
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Figure 3.12: SDS-PAGE analysis of the expression of S-CYP73A5tr in three different expression hosts, E. 
coli A. express, Rosetta 2, BL21. For each culture three samples were collected and loaded on the gel: 
the total lysate pre-induction (pre or preIPTG TL) and the soluble (SOL) and membrane (M) fractions at 
the end of the expression period, after the cell lysis. The blue arrow pointer indicates the product 
bands at the correct expected size of 57 kDa. 
 
A western blot with antibodies directed towards the C-terminal His tag present in        
S-CYP73A5tr was performed, in order to verify if the bands with a size between the 
55 and 70 kDa markers were effectively given by the protein constructs of interest 
(figure 3.13).  
 
Figure 3.13: Western blot anti-His analysis of the samples collected in the expression trials of S-
CYP73A5tr in the three E.  coli strains (as for figure 3.12). preIPTG TL = total lysate prior to induction; 
SOL = soluble fraction; M = membrane fractions; pre = before induction; O/N = at the end of the 
expression period. Expected molecular weight of the products: ~57 kDa. 
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The western blot analysis (figure 3.13) clearly showed that all the chosen E. coli hosts 
were able to express the 57 kDa His-tagged product in the membrane fraction, but 
the Arctic express host also showed that the CYP product was present in the soluble 
cell fraction.  
Following the preliminary expression trials with S-CYP73A5tr, all the S-CYPtr 
constructs (S-CYP81A9tr and S-CYP81D11tr) were transformed into Arctic express 
competent cells for expression. The outcome of the expression trial was verified via 
SDS-PAGE and western blot (figure 3.14). 
 
Figure 3.14: Western blot analysis of the expression trials of the three S-CYPtr constructs in E. coli 
Arctic express. For each culture a sample of the soluble fraction prior to induction (pre-IPTG, negative 
control) and another sample of the soluble fraction at the end of the expression period (POST) were 
collected and loaded on the SDS-PAGE gel, which was then blotted on nitrocellulose and incubated 
with the antibody for detection. Expected molecular weight of the products: ~55-57 kDa. 
 
The western blot analysis clearly showed that all the S-CYPtr constructs were 
successfully expressed in the soluble fraction of the Arctic express cells. 
3.3.3 Expression in yeast 
Aiming at acquiring some experience in protein expression using a yeast system, two 
constructs, pYEDP60-CYP81D8 and pYEDP60-CYP81D11, were transformed into 
competent S. cerevisiae WAT11 yeast cells. Cell microsomes were then harvested and 
analysed using the UV-Vis spectrophotometer (see Materials and Methods, 
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Paragraph 2.5.3). Figure 3.15 shows the CO-binding spectra of the extracted 
microsomes, used to verify the presence of P450 products. 
 
Figure 3.15. CO-binding spectra of the microsomes collected from yeasts transformed with pYEDP60-
CYP81D11 (left panel) and pYEDP60-CYP81D8 (right panel). Microsomes were obtained via mechanical 
lysis of the yeast cells, separated from the residual debris via multiple centrifugations and 
homogenised in Tris-HCl buffer pH 7.5. 
 
No evidence of CYP expression could be observed, as the signature 420/450 nm peaks 
were both missing from the microsomes’ CO-binding spectra. 
3.3.4 Purification of the S-CYP73A5tr construct 
The soluble fractions containing the S-CYP73A5tr product from Arctic express cells 
were filtered and subjected to Ni-affinity chromatography (See complete procedure 
in Materials and Methods, Paragraph 2.5.6). The elution, carried out using a gradient 
of imidazole, from 10 to 300 mM, is shown in figure 3.16.  
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Figure 3.16: SDS-PAGE analysis of the samples collected during the purification of S-CYP73A5tr. Lane 
1: soluble fraction pre-loading, 2: wash, 3-8: elutions, 9: post-dialysis, 10: concentrated, MW: 
molecular weight marker. Expected molecular weight of the product: 57 kDa. 
 
The S-CYP73A5tr protein was successfully purified with a yield, calculated via 
Bradford assay (see Materials and Methods, paragraph 2.5.7), of 5 mg, from a 200 ml 
starting culture. 
When examined using the UV-Vis spectrophotometer, the product showed the 
characteristic absorbance peak at 420 nm related to the P450 enzyme in the resting 
state (figure 3.17).   
 
 
Figure 3.17: UV-Vis absorbance spectrum of the final purified S-CYP73A5tr. 
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An alternative purification procedure was trialed, employing a gradient of histidine, 
from 5 to 50 mM for the final elution, in place of imidazole, which has been reported 
as an inhibitor of CYP enzymes. As shown in the resulting SDS-PAGE gel (figure 3.18), 
the S-CYP73A5tr can be isolated from the cell extract in the absence of the commonly 
used imidazole (which could affect the activity of the protein), simply exploiting an 
excess of histidine to displace the protein-column interactions. 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: SDS-PAGE analysis of the samples collected during the purification of S-CYP73A5tr. 
Expected molecular weight of the product: 57 kDa (Lane 1: pre-loading, 2: unbound, 3-5: wash, 6: final 
elution, MW: molecular weight marker). 
 
Interestingly, the protein elution fractions showed a violet colouration (figure 3.19). 
 
 
 
Figure 3.19. Picture of the cuvettes containing only phosphate buffer (blank, left) and the eluted S-
CYP73A5tr (right).  
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The same purification procedure was employed for S-CYP81D11tr, but in this case, 
even modifying the composition of the lysis, binding and elution buffers, the 
purification was unsuccessful.   
Both purified S-CYP73A5tr batches were subjected to UV-Vis spectrophotometric 
characterisation, to assess the correct folding of the product. A purified sample of the 
microbial P450 XplA, kindly donated by Dr. Dana Sabir, was used as a positive control 
(figure 3.20). 
 
Figure 3.20: CO-binding spectrophotometric characterisation of the purified S-CYP73A5. A: batch 
purified with imidazole, B: batch purified with histidine, C: XplA control. 
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In the CO-binding assay there was no shift in the absorbance peak from 420 nm 
(related to the protein in the resting state) to 450 nm upon binding of the reduced 
product with carbon monoxide. The XplA positive control consisted of two protein 
populations: part showed a peak at 450 nm, but most retained the 420 nm peak. 
These results suggest that either most of the XplA control is made of non-correctly 
folded proteins or the CO-bubbling step was not sufficient to induce the desired 
structure reconfiguration homogeneously in the whole sample.  
3.3.5 Activity assay 
The CO-binding spectra are not always the only and unconfutable proof of active and 
correctly folded CYPs, as it has been demonstrated that some active plant CYP 
enzymes are able to catalyse reactions in absence of a “correct” CO-binding shifted 
spectrum (personal communication). For this reason, activity assays were performed 
with the purified S-CYP73A5tr towards the natural substrate, cinnamic acid, 
supplemented with a purified P450 reductase (ATR2 from Arabidopsis, cloned and 
expressed separately using the same system as for the CYP enzyme), NADPH as the 
electron donor and an NADPH regeneration system. 
Upon HPLC analysis of the samples collected from the two sets of reactions, with         
25 nM and 750 nM of S-CYP73A5tr, there was no significant decrease of the amount 
of substrate, cinnamic acid, nor formation of product, p-coumaric acid, within the 
chosen time frame (20 h) (Data not shown). 
 
3.4 Discussion 
The biochemical and structural characterisation of eukaryotic P450 enzymes has 
been significantly constrained by the challenge of producing these enzymes in 
conventionally exploited bacterial systems.  The situation is particularly problematic 
when plant CYPs are taken into consideration: almost 14,000 P450 genes have been 
annotated so far (according to the latest count, carried out on 6 April 2016 (173)), but 
most of the encoded proteins still remain uncharacterised. In this chapter, several 
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expression trials with three different plant P450 targets were carried out, with the 
goal of designing an optimal expression protocol to obtain soluble and active P450 
products.  
Gene expression in bacteria 
The process started with the optimisation of the original nucleotide sequence, in 
order to ease the translational process in the bacterial host of expression. The N-
terminus membrane-binding domains, determined via online sequence analysis 
tools, were cleaved and replaced with a short peptide, S- (MAKKTSSKG), which, as 
reported by many researchers in the cytochrome P450 field, helped in the expression 
of other human and plant P450 enzymes. The engineered constructs of S-CYP73A5tr, 
S-CYP81D11tr and S-CYP81A9tr were each cloned into His-tagged pET28a expression 
vectors and were transformed into multiple E. coli hosts. A successful soluble protein 
expression was obtained for all three protein targets when transformed E. coli Arctic 
express cultures were grown shaking in M9 medium at low temperatures (16 ˚C).          
S-CYP73A5tr was also successfully purified via Ni-affinity chromatography, using 
either a gradient of imidazole or histidine. When examined using the 
spectrophotometer, the purified proteins presented the signature absorbance peak 
at 420 nm (typical of P450 enzymes in the oxidised resting state), but they did not 
show the shift of the absorbance peak to 450 nm, which should be expected for 
correctly folded P450 proteins, when reduced and bound to carbon monoxide. This 
feature might be explained by the fact that the removal of the N-terminal domain 
and/or the addition of the ‘S’ peptide might have affected the overall folding of the 
protein product.  
In assays measuring the activity of S-CYP73A5tr, there was no significant 
hydroxylation of the provided substrate, cinnamic acid, to p-coumaric acid. This result 
might depend on the chosen set up: a different medium, different temperature or 
higher concentrations of the catalyst or different ratios of P450:P450 reductase might 
be required to carry out the reaction. The activity may be enhanced by the addition, 
in the reaction mix, of cytb5, as reported for assays with purified human CYP2A6 (174), 
human CYP17A1 (175), fungal CYP5136A1 (176). As Schenkman and Jansson 
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explained, cytb5 plays a direct role in the electron flux, by transporting one of the 
electrons or facilitating the interaction between the reductase and the CYP (177).  
Possible solutions, which have worked in the past for other eukaryotic P450 enzymes, 
is the co-expression of the redox partner or the creation of fusion polypeptides. In 
the latter case, the CYP and the reductase are encoded as a single macroprotein, 
mimicking the naturally-occurring and highly active P450 BM-3 (CYP102A1) from B. 
megaterium. 
Gene expression in yeast  
Yeasts constitute valuable alternatives to E. coli hosts for recombinant protein 
expression, given the relatively low costs for the cultures, and the presence of 
eukaryotic post-translational modification systems, which are particularly useful 
when the protein targets are of eukaryotic origin. WAT11 is a modified S. cerevisiae 
yeast strain, engineered to co-express the ATR1 P450 reductase from Arabidopsis. 
Several plant CYPs, cloned in the shuttle vector pYEDP60 (which contains a galactose-
inducible GAL10-CYC1 promoter) have been expressed using the yeast WAT11 and 
WAT21 strains, created by Pompon et al (171). Among these CYPs are wheat (Triticum 
aestivum) CYP51 (178),  soybean (Glycine max) CYP93A1 (179), Jerusalem artichoke 
(H. tuberosus) CYP76B1 (180) and CYP81B1 (181) and Arabidopsis CYP88A3 and 
CYP88A4 (182). The expression trials of the native sequences of AtCYP81D11 and 
AtCYP81D8 (cloned in the pYEDP60 vector) were not successful, as the 
spectrophotometric analysis of the extracted cell microsomes did not display the 
expected 420 nm and 450 nm signature absorbance peaks for CYP enzymes. This 
result might derive from the different codon usage between the source of the CYP 
sequences (Arabidopsis) and the host of expression, as the sequences were not 
optimised prior to cloning into the shuttle vector. Additional factors affecting the 
production of the target proteins could be the instability of the recombinant products 
or the presence of endogenous proteolytic systems. 
In the context of heterologous protein expression of P450 enzymes in yeast, Pichia 
pastoris (183-185) might be a valuable alternative species to Saccharomyces. Several 
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groups have already employed Pichia for the production of functional plant CYPs: 
among these are CYP79D1 and CYP79D2 from Cassava  (M. esculenta) (186) and 
Arabidopsis CYP85A2 (187). 
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Chapter 4: Expression screening and 
characterisation of P450- reductase fusion 
proteins 
4.1 Introduction: plant P450-reductase fusions 
CYP-mediated biotransformations are constrained by several drawbacks, such as the 
requirement of an electron donor, the necessity of flavin-based cofactors or iron-
sulfur clusters, and the need for a redox partner for an efficient electron shuttling and 
catalysis. Another aspect that has to be taken into account when working with CYPs 
is the high occurrence of undesired uncoupled reactions, which lead to the formation 
of reactive oxygen species and heavily affect the catalytic efficiency of these enzymes 
(43, 188).  
To overcome the problem of the low efficiency of electron transport from the electron 
donor to the P450 heme, fusion systems, mimicking the widely studied B. megaterium 
P450-BM3 (CYP102A1) (figure 4.1), have been developed. In these artificial fusions 
systems, the CYP is directly connected to the redox partner, sometimes using a 
synthetic linker as a spacer, creating a single polypeptidic chain in place of two 
different proteins. 
 
 
Figure 4.1: Structural configuration of B. megaterium P450-BM3. 
 
The resulting fusion system displays a more efficient electron transport, which thus 
results into improved enzyme activity. Murakami et al, in 1987, were among the 
pioneers in the production of P450-reductase fused proteins, generating a 130 kDa 
fusion of a rat CYP (P450c) with a rat reductase in yeasts. This particular product 
exhibited an activity four-fold higher than that of the native non-fused P450 (189). 
Heme domain Reductase domain N - - C 
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Alternatively, an increased electron transport could be achieved using reconstituted 
systems, whereby purified P450 reductases are incubated with the P450 enzyme of 
interest. An example is the use of purified rat liver microsomal NADPH P450 reductase 
incubated with bovine P45017α, heterologously expressed in E. coli cells (136).  
One of the first artificial plant fused systems, developed in 1995 by Hotze and 
coworkers, was the fusion of a Madagascar periwinkle (Catharanthus roseus) 
cinnamate hydroxylase (C4H) to a P450 reductase, from the same organism. The 
fusion system was built using traditional digestion/ligation cloning: the C4H sequence 
was truncated of its aminoterminal membrane-anchoring domain (at different 
lengths up to its total deletion, for comparison purposes) and introduced in the vector 
containing the N-terminally-truncated reductase, leading to six different final 
translational fusions. The linker was a short string of amino acids, with alternating 
serines and glycines (sequence: STSSGSG). Following expression in E. coli, the activity 
assays demonstrated that almost all the developed plant fusion chimeras were active 
towards the given substrate (190). Later, the same group generated another plant 
translational fusion, comprising CYP71D12 and a reductase, both from C. roseus, 
which allowed the verification of the involvement of this CYP in the biosynthesis of 
bisindole alkaloids (191). In 2002 Didierjean et al. created two chimeras of Jerusalem 
artichoke (H. tuberosus) CYP76B1 with the reductase from the same organism, HTR1; 
76B1-HTR1 contained the full-length reductase, whereas 76B1-HTR1Δ57 included an 
N-terminal truncated reductase. The aim of this study was to create an efficient 
system for the metabolism of phenylurea herbicides. In this case, it was demonstrated 
that the higher efficiency could be rather achieved with the CYP alone, not fused to 
the reductase (192). Leonard et al. developed a fusion between a G. max isoflavone 
synthase (CYP93C) and a C. roseus P450 reductase, connected via a polyGlySer linker 
(the same as for the C. roseus fusions mentioned above, with an additional upstream 
glycine). The CYP93C was N-terminally modified by trimming, or replacing, the 
membrane-spanning domain, generating different constructs for activity and 
solubility comparisons. The highest activity towards the given substrates, naringenin 
or liquiritigenin,  was achieved when the fusion contained the truncated CYP93C, with 
an N-terminal ‘MALLLAVF’ peptide, from bovine P45017α (see Chapter 3, 
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Introduction section) (193). An additional example of an effective amino terminal 
modification is the introduction of the hydrophilic sequence MAKKTSSKG, originating 
from the human CYP2C3 (141), which allowed the soluble expression of CYP73A5tr, 
CYP81D11tr and CYP81A9tr, as discussed in Chapter 3. 
Another aspect of particular importance in the development of such fusion systems 
is the linker between the P450 and the reductase partner. This spacer should be 
appropriately designed in order to gain the optimal distance and orientation of the 
two units for catalysis to occur (194). In bacteria, Robin et al. generated several 
fusions of the camphor-hydroxylating P450cam from P. putida with the Rhodococcus 
Rhf reductase (RhfRed), varying the length (2-16 amino acids) of the natural linker in 
the RhF fused system (195).  
Dr. Sabbadin, from Prof. Neil Bruce’s research group, exploited the same RhfRed 
domain to create a P450/reductase fusion platform, called LICRED. This platform was 
validated with the explosive-degrading XplA (CYP177A1) from Rhodococcus and 
P450cam (CYP101A) from P. putida: in both cases the LICRED construct led to the 
production of soluble and active P450 fusions. The LICRED fusion construct enabled 
the functional characterisation of additional bacterial CYPs: a set of N. farcinica P450 
enzymes (90, 91), as well as the identification of pharmacologically-interesting P450s 
from Rhodococcus jostii (196). 
The ACRyLIC and ACRyLAM constructs are two artificial chimeric systems developed 
previously, in a collaboration between Prof. Neil Bruce’s and Prof. Gideon Grogan’s 
research groups, by Dr. Schuckel: target P450s were fused to the Arabidopsis ATR2 
P450 reductase with two different linkers (RAFSS for the LIC system and GSTSSGSG for 
the LAM platform) and cloned into a pET28 vector (figure 4.2). 
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Figure 4.2: Map of the ACRyLAM/LIC fusion platform, designed by Dr. Schuckel. The his-tagged N-
terminally truncated P450 is connected through a LAM (sequence: GSTSSGSG) or LIC (sequence: 
RAFFSS) linker to the N-terminally truncated ATR2 reductase from Arabidopsis. 
 
The starting point of Dr. Schuckel’s project was the identification of an appropriate 
host for the expression of chosen plant P450 targets (Arabidopsis CYP81D11, 
CYP81D8 and CYP89A9, as well as the peppermint CYP71D15 PM2-2), by comparing 
different E. coli strains with WAT11/WAT21 modified S. cerevisiae (171). When yeasts 
were employed for expression, no CO-shift (420 - 450 nm) could be observed in the 
yeast microsomal preparations, indicating that none of the plant P450 targets was 
correctly folded. On the other hand, CYP81D11 and CYP81D8 were expressed in E. 
coli Rosetta 2, grown on LB medium, but despite the presence on the SDS-PAGE gel, 
the products could not be detected via western blot anti-histidine tags. Subsequent 
work focused on the choice of the reductase partner. Urban et al., in a function-
complementation study carried out in S. cerevisiae, identified two cDNAs from an 
Arabidopsis expression library, encoding for proteins that were able to compensate 
the disruption of an endogenous P450 reductase in the yeast host. It was 
hypothesised that these products were involved in the same type of reactions carried 
out by the original, disrupted, P450 reductase. Sequencing analysis of the isolated 
cDNA targets, alignments with other known P450 reductases, as well as activity 
assays with cytochrome c and CYP73A5 demonstrated that these two proteins, could 
LAM 
  LIC 
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be effectively classified as P450 reductases and therefore were named Arabidopsis 
thaliana Cytochrome P450 reductase (ATR) 1 and 2 (170). ATR1 (Locus tag: 
AT4G24520, gene ID: 828554) and ATR2 (Locus tag: AT4G30210, gene ID: Gene ID: 
829144) share a 66 % amino acid sequence identity, with conserved 
FAD/FMN/NADPH binding domains, with the N-terminus being the most diversified 
part of the amino acidic sequences, due to two different -in sequence and length- 
signal anchors. In addition, multiple studies demonstrated that if on the one side 
ATR1 is expressed at constant levels, the expression of ATR2 can be upregulated by 
wounding, as well as light and low temperature conditions, right before, or in parallel 
to, the induction of other effectors in the phenylpropanoid pathway (197-199). A 
third putative reductase has been also identified and named ATR3. Nevertheless, 
sequence alignments, localisation and functional comparisons to ATR1 and ATR2 
showed that ATR3 cannot be classified as a P450 reductase. It was instead proven 
that ATR3 is a cytosolic diflavin reductase involved in early plant embryogenesis 
(200).  
In Dr. Shuckel’s work the ATR1 and ATR2 reductases from Arabidopsis were truncated 
to remove the sequences encoding the amino-terminal membrane targeting domain. 
ATR1tr and ATR2tr were expressed in E. coli, purified and assayed for activity. ATR2tr 
was chosen due to its higher catalytic activity when compared to ATR1tr. The linker 
used by Leonard et al. (sequence: GSTSSGSG), here named LAM, and the short string 
of amino acids RAFSS, resulting from the intermediate steps for the ligation 
independent cloning procedure, named LIC, were then employed to create the 
artificial fusion constructs between the ATR2tr reductase and two P450 targets: G. 
max isoflavone synthase (IFS) and the Arabidopsis CYP73A5. In the CYP73A5-ATR2 
fusion, the first 25 amino acids from the CYP were also removed, to decrease the level 
of hydrophobicity of the final protein. These fusions were then compared in terms of 
activity and solubility to constructs where the same P450 enzymes were fused to the 
Rhodococcus reductase, RhfRed. The highest activities were observed for the IFS-
RhfRed fusion and for the CYP73A5tr-ATR2tr chimera, leading to the conversion of up 
to 50% of naringenin (IFS substrate) and 30% of cinnamic acid (CYP73A5 substrate). 
For the plant fusion, CYP73A5tr-ATR2tr, despite the solubility of the ATR2tr reductase 
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and the truncation of the N-terminal membrane-binding domain of CYP73A5, the 
activity was only detected in the cell membranes and not in the soluble fractions, 
indicating that the fusion protein was insoluble (152).  
The objective in this chapter is the development of a stable and active fusion 
construct, with the CYP directly connected, through an appropriate linker, to a redox 
partner. All the constructs here generated contained the Arabidopsis cinnamate 
hydroxylase (AtCYP73A5), employed as a model P450 also in Chapter 3, and the 
Arabidopsis ATR2 reductase (AtATR2tr). 
 
4.2 Materials and Methods used for the expression screening 
of the plant fusions 
4.2.1 Cloning steps 
The cloning procedure for the creation of the fusion platform, named pAtHlA2, was 
similar to the procedure exploited in Chapter 3, for the production of the S-CYPtr 
constructs. The first step consisted of the introduction of the chosen redox partner, 
AtATR2, in the final expression vector, pET28a, via InFusion cloning (for the complete 
procedure, see Materials and Methods, section 2.4.6), between the NcoI and XhoI 
restriction sites. The sequence of the ATR2 reductase (Gene ID: 829144, Locus tag: 
AT4G30210) was analysed using the Das (http://www.sbc.su.se/~miklos/DAS/) and 
TMHMM (http://www.cbs.dtu.dk/services/TMHMM/) online transmembrane 
structure prediction tools, to identify the N-terminal membrane-binding domain of 
the protein, which had to be cleaved (exactly as for the CYPtr in Chapter 3) to increase 
the chances of obtaining an overall soluble protein. The oligonucleotides for the PCR 
amplification of the ATR2 sequence were specifically designed to allow for the 
extension and amplification of the N-terminally truncated version of the reductase 
(ATR2tr). The S-CYP73A5tr sequence in pMA-T was PCR-amplified using primers 
specifically designed for the introduction of flanking NcoI, AvrII and XhoI restriction 
sites. Subsequently, the CYP was cloned via InFusion into the ATR2tr-pET28 construct. 
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The primers employed in the process are listed in Table 4.1. Plasmids containing the 
codon optimised ATR2 and CYP73A5 sequences were retrieved from the Bruce’s 
group stock.  
 
Table 4.1: Oligonucleotides used for the PCR amplification of the DNA sequences encoding the ATR2 
reductase and the S-CYP73A5tr. 
 
Protein Primer sequence 
ATR2 Forward - 5’ TGCGGCCGCACTCGAGAGCGGTCCTAGGGGTAGCGGTAATAGCAAAC 3’ 
Reverse - 5’ GGTGGTGGTGCTCGAGCCAAACATCACGCAGATAACGACCGCTGGT 3’ 
CYP Forward - 5’ AGGAGATATACCATGGATGGCCAAAAAAACCAGCAGCA 3’ 
Reverse - 5’ GCTGGTGCTACCGGATCCTGAGTTACGCGGTTTCAT 3’ 
 
The mix for the PCR amplification reactions consisted of 10 mM dNTPs mix, 20 M of 
each primer, 50 ng of template DNA and 1.25 U of Pfu DNA polymerase in 10x Pfu 
buffer and water to a final volume of 50 l. The cycles included a first denaturation 
step at 95 °C for 2 min, then 95 °C for 30 s, an annealing step at 50 °C for 30 s and 
extension at 74 °C for 2 min for a total of 30 cycles and a final extension step at 74 °C 
for 10 min. For the InFusion cloning procedure see Materials and Methods, paragraph 
2.4.6. The final construct consisted of the                   N-terminal ‘S’ solubility tag 
(sequence: MAKKTSSKG, for clarification see Chapter 3), followed by the truncated 
CYP enzyme, directly bound through a poly-glycine/serine linker to the truncated 
ATR2 reductase, with a C-terminal hexa-histidine tag (figure 4.3). The vector was 
transformed into competent E. coli cells (with the heat-shock procedure, see 
materials and methods paragraph 2.4.8), harvested from the cultures via plasmid 
prep (as described in materials and methods, paragraph 2.4.5), sent for sequence 
verification and used to initiate subsequent cultures for protein expression studies. 
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Figure 4.3: Map of the fusion platform. The cloning site is highlighted in blue. The fusion construct 
consists of an N-terminal S-CYPtr domain directly connected through a poly-serine/glycine linker to the 
C-terminal histidine-tagged ATR2tr redox partner (S-tag = MAKKTSSKG, linker: GSTSSGSG). 
 
4.2.2 First expression trials 
The first expression trial for the pAtHlA2 construct, containing CYP73A5tr, was 
performed using E. coli Arctic express as expression host, following the procedure 
which allowed the soluble expression of Arabidopsis P450s S-CYP73A5tr, S-
CYP81D11tr and S-CYP81A9tr (see details in Chapter 3, section 3.3.2). Briefly, the 
transformed cells were inoculated in LB medium and then subcultured in M9 medium. 
Protein expression was induced with 0.5 mM IPTG and cultures were harvested after 
20 h of incubation at 16 °C, shaking at 180 rpm.  
XhoI  BamHI  AvrII NcoI  SacI 
S-tag linker 
CYPtr ATR2tr 
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4.2.3 High-throughput automated expression screening 
A team, led by Dr. Jared Cartwright at the Protein Production Technology Facility of 
the University of York, developed an automated high-throughput expression 
screening platform, based on the system first described by Vincentelli et al. (201). Dr. 
Cartwright’s system involved the use of a Freedom EVO robot (Tecan), guided by a 
specifically-designed macro program, which allowed the setup and screening of 
different parallel expression conditions, on a 48-well plate.   
 
 
Figure 4.4: Overview of the automated process for protein expression screening designed by 
Vincentelli et al. (201). Cell cultures, in 2-ml format, are set up in multi-well microplates, allowing a 
quick spectrophotometric evaluation of cell density (OD600) using the microplate reader. Cells are 
harvested via centrifugation and disrupted chemically. A round of centrifugation allows the separation 
of the soluble fractions from the cell debris and collected samples (from the total lysate and from the 
soluble fraction) are blotted onto nitrocellulose for western blot analysis. All the steps are controlled 
through a computer and performed by a liquid-handling robot. 
 
The fusion construct of CYP73A5tr-ATR2tr (without the ‘S’ solubility tag) was re-
cloned via InFusion into five different expression vectors, named pETFPP 1 to 5. The 
oligonucleotides used for the PCR amplification of the whole CYP73A5tr-ATR2tr fused 
construct, as well as of the single CYP73A5tr and ATR2tr domain (each cloned and 
expressed alongside the fusion, as controls) are listed in Table 4.2. 
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Table 4.2: List of the oligonucleotides used as primers for the introduction of the S-CYPtr, ATR2tr and 
the CYP73A5tr-L-ATR2tr fusion (using the ‘F-CYP73A5tr’ and the ‘R-ATR2tr’ primers for the CYP/ATR 
fusion construct) in the expression vectors. 
 
The pETFPP_1-5 expression vectors used in this automated screening all presented a 
pET-YSBL3C backbone (reported in figure 4.5), with a cleavable N-terminal hexa-
histidine tag, for detection purposes, followed by one of four solubility tags (listed in 
Table 4.3). The tags included in the new open reading frame were the widely used 
maltose-binding protein (MBP (202-205)), glutathione transferase (GST (203, 206, 
207)), colicine immunity protein 9 (Im9, NCBI Reference Sequence: YP_002533538.1 
(208)), and green fluorescent protein (GFP (209, 210)). 
Figure 4.5: Map of the pET-YSBL3C vector, used as a backbone for the pETFPP_1-5 constructs. This 
expression vector is characterised by a T7 promoter, an N-terminal hexa-histidine tag, an HRV-3C 
cleavage site and the BseRI, AscI, NdeI restriction sites for insert cloning. In the pETFPP_1-5 expression 
vectors, an additional N-terminal tag is present, downstream of the his-tag. 
 
Oligo name Primer sequence 
F-CYP73A5tr 5’ – TCCAGGGACCAGCAATGGCCCTGCGTGGTAAAAAACTG – 3’ 
R-CYP73A5tr 5’ – TGAGGAGAAGGCGCGTTATGAGTTACGCGGTTTCATCAC – 3’ 
F-ATR2tr 5’ – TCCAGGGACCAGCAATGGGTAGCGGTAATAGCAAACG – 3’ 
R-ATR2tr 5’ – TGAGGAGAAGGCGCGTTACCAAACATCACGCAGATAACG – 3’ 
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Table 4.3: Structure of the pETFPP_1-5 expression vectors developed by Dr. Cartwright (HIS = hexa-
histidine tag, MBP = maltose-binding protein, GST = glutathione transferase, Im9 = colicine immunity 
peptide 9, GFP = green fluorescent protein). 
 
 
 
 
 
 
 
 
In the first screening, E. coli BL21(DE3) was chosen as host for expression and two 
different growth media, LB and AI (see composition in Materials and Methods, section 
2.3), were tested. After an overnight incubation of the BL21(DE3) transformants at   
37 °C, single colonies were picked from the selection plates and inoculated in each of 
the 2-ml wells of the screening platform, containing either LB or AI medium. The 
bacterial cultures were grown at 37 °C at a shaking speed of 660 rpm, until induction 
with 1 mM IPTG (only for the LB cultures), then the temperature was set to 16 °C for 
protein expression. After 24 h, the cell density (OD600) of all the cultures was 
measured and each adjusted to the minimum value recorded, for normalisation. The 
expression plate was subjected to centrifugation at 6,400 rpm to harvest the cultures. 
The cells were then disrupted chemically with a mixture of lysozyme and BugBuster 
Protein Extraction Reagent (both from Novagen) and the soluble fractions were 
separated from the cell debris via centrifugation. Following a treatment with 5 M 
guanidinium hydrochloride to denature the proteins, the fractions were blotted on a 
membrane and subsequently incubated with HRP conjugated antibodies (from 
Qiagen), raised against the his-tags. In this way, the result of the expression screening 
could be visualised as a dot plot, whereby the intensity of each spot (corresponding 
to each blotted culture/fraction) was proportional to the level of expression of the 
his-tagged protein. The detected product could be quantified by comparing the 
luminosity of each dot to the luminosity of his-tagged standards. 
Construct name N-terminus structure 
pETFPP_1 HIS-3CProtease-ORF 
pETFPP_2 HIS-MBP-3CProtease-ORF 
pETFPP_3 HIS-GST-3CProtease-ORF 
pETFPP_4 HIS-Im9-3CProtease-ORF 
pETFPP_5 HIS-GFP-3CProtease-ORF 
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4.2.4 Purification of the fused construct 
For the complete purification procedure see Materials and Methods, paragraph 2.5.6. 
Constructs yielding the highest levels of expression detected in the screen were 
identified for further study. The expression format was scaled-up from 2 ml to 500 ml 
cultures. The cells were harvested via centrifugation, resuspended in phosphate 
buffer supplemented with 200 M PMSF and 250-500 mM NaCl and lysed with the 
sonicator. The soluble fraction was separated from the cell debris via centrifugation 
and filtered prior to the loading on the Ni-affinity chromatographic column. The result 
of the purification was verified with an SDS-PAGE gel of the fractions collected 
throughout the process.  
4.2.5 Activity assay of the fused construct CYP73A5-ATR2 
The activity of the fusion protein was assayed using whole E. coli cells. After 24 h of 
growth at 16 °C the cells were harvested via centrifugation and resuspended in 50 
mM potassium phosphate buffer, pH 7 (100 mg cells / ml of buffer). The suspension 
of whole cells was used to assess the ability of the construct to catalyse the 
hydroxylation of cinnamic acid (Sigma-Aldrich), the natural substrate of AtCYP73A5, 
to p-coumaric acid (Sigma-Aldrich). The reaction, carried out at 28 °C and 200 rpm, 
was initiated by the addition of 200 M cinnamic acid to the cell suspensions (2 ml 
each, in 50 ml falcon tubes). Parallel reactions with cells transformed with the empty 
vector were carried out as negative controls. Samples were collected over a period of 
seven h. The reactions were terminated with an equivalent volume of methanol and 
35 l of the supernatant after centrifugation were analysed using an HPLC (Waters 
Alliance 2695 separation module equipped with a Waters 2996 photodiode array 
detector) with a Waters X-Bridge C18 column heated to 30 °C, employing a gradient 
of water (A) and methanol with 0.1% acetic acid (B): 90 % A for the first 3 min, 90 to 
55 % A in 1 min, 55 % B for A min and 90 % A for 5 min (separation method designed 
by Dr. Schückel (211) , modified from Chen and Morgan (212). With this separation 
method, cinnamic acid and p-coumaric acid eluted at 11.7 and 8.1 min, respectively. 
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4.3 Results 
4.3.1 Creation of the pAtHlA2 fusion platform 
The pAtHlA2 fusion platform was created starting from the production of the ATR2tr-
pET28 construct, followed by the introduction, upstream of the reductase, of the S-
CYPtr with Infusion-compatible ends. 
The sequence analysis of the ATR2 reductase, carried out using the Das and TMHMM 
online transmembrane structure prediction tools, revealed that the first 72 amino 
acids were likely to form the membrane-binding domain of the protein (figure 4.6).  
 
 
 
 
 
 
 
Chapter 4: Development of the CYP/CYPreductase fusion platform 
 
107 
 
 
 
Figure 4.6: Transmembrane domain predictions by DAS (panel A) and TMHMM (panel B) for AtATR2. 
As highlighted in blue on the results panels and with an arrow on the corresponding graphs, the 
algorithms identified the region between amino acids 55-71 and 52-72 as the one forming the N-
terminal transmembrane region. 
(A) 
(B) 
Amino acids 
Amino acids 
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For this reason, the oligonucleotides for the PCR amplification of the ATR2 sequence 
were specifically designed in order to allow the extension of a truncated version of 
the reductase (ATR2tr), while also introducing the NcoI, AvrII and XhoI flanking 
restriction sites. In parallel, the pET28 expression vector was double-digested with 
the corresponding NcoI and XhoI restriction endonucleases, following the instructions 
from the manufacturer. The outcome of the PCR amplification and of the digestion 
are reported in figure 4.7. 
 
Figure 4.7: Agarose gel analysis of the PCR amplification of ATR2tr (left panel, in triplicate; expected 
size of the amplicon: ~1.9 Kbases) and the double digestion of the pET28 vector with NcoI and XhoI 
(right panel). 1: undigested plasmid, 2: NcoI single cut, 3: XhoI single cut, 4: double cut. 
 
The ATR2tr amplicons were inserted using InFusion in the NcoI/XhoI-linearised pET28 
vector and the cloning reaction was transformed into competent E. coli cells, which 
were plated onto selective LB agar plates. The outcome of the PCR amplification 
(using primers specific to the T7 promoter and T7 terminator regions) performed on 
the colonies picked from the selective plates is shown in figure 4.8. 
 
 
Figure 4.8: Colony PCR for the verification of the presence of ATR2tr in the newly-built construct. The 
blue arrow indicates the positive colonies, presenting DNA bands with the correct size. Expected size 
of the amplicon: ~1.9 Kbases. 
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The S-CYP73A5tr encoding sequence was amplified via PCR, to introduce the NcoI and 
AvrII flanking restriction sites. In parallel, the pET28-ATR2tr plasmid was double-
digested with the corresponding endonucleases (figure 4.9). 
 
Figure 4.9: Agarose gel analysis of the amplification of the S-CYP73A5tr insert (left panel, in triplicate; 
expected size of the amplicon: ~1.5 Kbases) and of the double digestion of the pET28-ATR2tr plasmid 
with NcoI and AvrII (right panel). 1 = undigested plasmid, 2 = NcoI single cut, 3= AvrII single cut, 4 = 
double NcoI/AvrII cut). 
 
The S-CYP73A5tr amplicon and the linearised pET28-ATR2 plasmid were purified and 
mixed for the InFusion cloning reaction. The mix was directly transformed into 
competent E. coli cells for subsequent purification and sequence verification. 
4.3.2 First expression trial of the pAthlA2 (S-CYP73A5tr-ATR2tr) fusion 
in E. coli Arctic express 
The first expression trial of the newly-built pAthlA2 fusion was performed using the 
same conditions as for the expression of the S-CYPtr constructs in Chapter 3. 
The fusion construct was transformed into Arctic express E. coli cells and the M9 
cultures were harvested after 16 h from the IPTG induction. The result of the 
expression is reported in figure 4.10. 
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Figure 4.10: SDS-PAGE analysis of the outcome of the expression trial of pAtHlA2 (the fusion of S-
CYP73A5tr – ATR2tr), employing the A. express/M9 expression procedure developed in Chapter 3. PRE-
IPTG = before induction, O/N = overnight, MEMB = membrane fraction, SOL = soluble fraction. 
Expected size of the product: ~127 kDa. 
 
A band at the expected size of approximately 127 kDa was not observed on the SDS-
PAGE analysis of the samples collected after the expression induction for the Arctic 
express cultures (alongside the ones transformed with the empty vector, used as 
negative controls). In order to verify if this result was due to the presence of the 
reductase domain, an expression trial was performed with a construct consisting of 
the ATR2tr reductase cloned into a pET-YSBL3C vector, without the P450 domain. 
As shown in figure 4.11, the N-terminally truncated ATR2tr was expressed successfully 
using the Arctic express/M9 protocol. 
 
Figure 4.11: Western blot analysis of the expression of ATR2tr cloned in pETYSBL-3C in E. coli Arctic 
express. 1 = empty vector control, 2= ATR2tr in the soluble fraction. Expected molecular weight of the 
product: 71.5 kDa. 
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4.3.3 Re-cloning and automated protein expression screening 
The fusion of the Arabidopsis N-terminally truncated CYP73A5, connected with a 
polyGlySerThr linker (GSTSSGSG) to the truncated ATR2 reductase was cloned into five 
different pET-YSBL3C-based vectors (pETFPP_1-5), presenting five alternative N-
terminal tags. At the end of the expression trial, carried out using BL21(DE3) E. coli as 
host and AI and LB as growth media, the His-tagged products were detected through 
western blot (figure 4.12) and the molecular weight of the positive hits (MBP-AI/LB, 
GST-LB, GFP-LB, Im9-AI, within the red boxes) was estimated via SDS-PAGE (figure 
4.13). 
 
Figure 4.12: Western blot analysis of the membrane blotted with the fractions from the expression 
trial. Each dot corresponds to a specific construct. His-tagged products in the total lysate and in the 
soluble fraction of the cells grown in LB (left block) and AI (right block) media are detected by using 
antibodies anti his-tag. The scheme on the right illustrates the position of the constructs in each of the 
four panels. Highlighted in the red boxes are the fusion constructs. 
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Figure 4.13: SDS-PAGE analysis of the his-tagged products detected in the previous western blot of the 
BL21(DE3) cultures. GFP = construct with GFP tag; MBP = construct with MBP tag; GST: construct with 
GST tag; Im9 = construct with Im9 tag. For each culture, the total lysate (T) and the soluble fraction (S) 
were loaded in parallel. 
 
The SDS-PAGE gel (figure 4.13) showed a promising product band with the correct size 
for the Im9 construct, expressed in AI medium. 
Given the promising result, the expression of the Im9 fusion (Im9-CYP73A5tr-L-
ATR2tr) was scaled up from 2 ml to 500 ml. The production of the Im9 fusion was 
monitored spectrophotometrically, by recording the absorbance spectrum between 
300 nm and 600 nm, at different time points post induction (figure 4.14). 
 
Figure 4.14: Overlap of the spectra recorded for the soluble fractions of the cell lysates, over a period 
of 24 h after the induction. The spectrum for the negative control (e.v. ctrl = empty vector) was 
recorded at the final time point. 
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A clear peak at around 420 nm could be observed for the sample collected after 24 h 
from the induction time. Further evidence for expression was obtained by analysing 
the size of the proteins on an SDS-PAGE gel and via western blot (figure 4.15).  
 
Figure 4.15: SDS-PAGE and western blot analysis of the Im9-CYP73A5 fusion expression scale-up. 
Expected molecular weight of the product: 137 kDa. The (-)CTRL corresponds to the cells expressing 
the empty vector. 
 
The results in figure 4.15 show that the Im9-CYP73A5tr-ATR2tr fusion was expressed 
in the total lysate and the soluble fractions of the cells. 
4.3.4 Purification of the Im9-CYP73A5 fusion construct 
The separated soluble fractions of lysed BL21(DE3) cells expressing the construct 
were subjected to nickel-affinity chromatography for isolation. The samples collected 
throughout the process were loaded on an SDS-PAGE gel to verify the presence and 
purity of the desired product (figure 4.16). 
 
Figure 4.16: SDS-PAGE analysis of the fractions collected during the purification process of the Im9-
CYP73A5tr-ATR2tr fusion protein (1= total lysate, 2 = soluble fraction, 3= unbound, 4= wash 1, 5-7= 
elutions). 
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The 137 kDa fusion protein was not present in the eluates. A UV-Vis 
spectrophotometric analysis of the ‘unbound’ fraction (well 3, in figure 4.16) showed 
that the expected protein did not bind efficiently to the nickel resin. Further 
purification attempts were carried out, by diluting the cell suspensions (7.5 ml of lysis 
buffer / g of cells) or using different buffers (50 mM potassium phosphate pH 8 with 
500 mM NaCl, 50 mM sodium phosphate pH 8 with 300 mM NaCl, or 50 mM Tris-HCl 
pH 8 with 250 mM NaCl) or employing a batch purification process, where the protein 
extract was incubated for a long period (overnight) with HIS-Select Nickel Affinity Gel 
(Sigma Aldrich). In all cases, the full length fusion product was not obtained. 
4.3.5 Activity assay of the fused Im9-CYP73A5tr-ATR2tr construct 
As purified Im9-CYP73A5tr-ATR2tr protein could not be obtained, the activity assays 
to test the Im9 fusion protein were carried out on whole cells transformed with the 
construct. 
Cell suspensions in phosphate buffer at pH 7, supplemented with 100 M of cinnamic 
acid, the natural substrate of AtCYP73A5, were monitored over a period of 7 h. The 
resulting chromatograms at the end of the incubation and the conversion of cinnamic 
acid into p-coumaric acid are shown in figure 4.17. 
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Figure 4.17: HPLC analysis of the samples after 7 h of incubation of BL21(DE3) whole cells expressing 
the fusion Im9-CYP73A5tr-ATR2tr construct with 100 M cinnamic acid. Top panel: chromatogram 
showing the formation of the product, p-coumaric acid, in comparison to the negative control (empty 
vector) at the end of the incubation period. Bottom panel: conversion of cinnamic acid (blue diamonds) 
into p-coumaric acid (red squares) over time; for the empty vector (-) ctrl (green triangles) only the 
concentration of cinnamic acid is reported. Assay performed in triplicate ± SE. 
 
The assay showed that the expressed Im9-fusion was active in whole cells, with the 
conversion of more than 59 % of cinnamic acid to p-coumaric acid (final yield: 37.1 ± 
1.6 M) over a period of six h. 
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4.4 Discussion 
Cytochromes P450 enzymes are defined as NAD(P)H-dependent monooxygenases, 
strictly dependent on the presence of a co-expressed and co-localised redox partner. 
Exceptions to the general rule are some bacterial and fungal P450 macroproteins, 
characterised by a P450 heme domain structurally connected to the redox partner, 
forming a highly active ~110-120 kDa polypeptide. Important examples of these P450 
fusions are the widely studied B. megaterium P450 BM-3 (with multiple homologues 
found also in other Bacillus species (213, 214)), the Rhodococcus sp. strain NCIMB 
9784 P450Rhf (89), and the F. oxysporum P450foxy (215).  
Besides the STORR ((S)-to-(R) reticuline) protein discovered in 2015 by Winzer et al. 
in opium poppy (Papaver somniferum L.), no other natural plant P450 fusion has been 
described so far. The STORR multidomain macroprotein was identified during the 
discovery of the pathway of enzymes involved in the synthesis of morphinan alkaloids 
in opium poppy. Specifically, STORR consists of a P450 heme domain (CYP82Y2) 
connected at its carboxy terminus to an oxidoreductase domain. Comparing the 
phenotypes of different mutants at the specific storr locus, the researchers 
discovered that, interestingly, the P450 and the oxidoreductase catalyse two 
different sequential steps of the epimerisation of (S)-reticuline to (R)-reticuline, one 
of the intermediates in the synthesis of morphine and codeine. This meant that the 
C-terminal domain of the fusion was not a P450 redox partner, but instead, it was a 
protein with a specific catalytic function, with or without the P450-heme domain 
(216). 
With the final goal of creating a drop-in construct for the expression and functional 
characterisation of redox self-sufficient orphan plant CYPs, the main objective of this 
thesis chapter was the creation of an active plant P450-P450reductase fusion 
platform. With this purpose, a number of constructs were generated and screened. 
Starting from the results achieved by Dr. Schuckel, the AtATR2 reductase and the 
poly-glycine/serine linker were kept in the new artificial constructs; AtCYP73A5 was 
used to validate the activity of the chimera. Both the sequences of the reductase and 
the P450 were codon optimised for E. coli expression. Additionally, these two protein 
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sequences were truncated of the N-terminal membrane-binding domain, identified 
with the Das and TMHMM online prediction tools, to increase the chances of having 
an overall soluble product. The ‘S’ peptide (sequence: MAKKTSSKG, see Chapter 3) as 
well as the same expression host (E. coli Arctic express) and conditions that enabled 
the expression of three different plant P450s in Chapter 3, did not yield the expected 
127 kDa fusion polypeptide. It may be hypothesised that the bulky pAtHlA2 construct 
(S-CYP73A5tr-L-ATR2tr) could not be efficiently encoded by the translational 
machinery in the chosen expression host, which, alongside the exogenous proteins 
also co-expresses chaperones. Requiring a quicker and more efficient method to 
screen multiple conditions at once, an automated liquid-dispensing robot system was 
employed. The screen identified that the colicin immunity protein 9, Im9, effectively 
helped in the soluble expression of the whole P450/P450-reductase construct. The 
86-amino acid Im9 protein is encoded by E. coli cells as a self-defence system from 
the cytotoxic effects of colicins, which are compounds naturally produced against 
other competing bacteria. Specifically, Im9 binds tightly to the E9 colicin and 
dissociates from it once the complex reaches specific receptors on ‘rival’ cells (217). 
This solubilising effect on the CYP73A5tr-L-ATR2tr fusion could be due to the acidity 
of Im9 (pI: 4.2-4.5, calculated net charge at pH 7: - 8.8), as reported for other acid 
solubility peptides used in protein expression screenings by Su et al. (218). 
Alternatively, or perhaps additionally, Im9 could interact directly with the target 
proteins, minimising the chance of protein aggregation.  
Several attempts were made to purify the Im9-CYP73A5 fusion protein, using a range 
of conditions, but with no success. While more research is required to determine the 
optimal conditions for the purification of the soluble Im9-CYP chimera, a number of 
hypotheses could be drawn to explain why it was not successful this time. First of all, 
it could be possible that the N-terminal histidine tag was degraded or not readily 
accessible and, for this reason, the protein could not bind to the column. This was 
demonstrated by the fact that the product of the expected size of 137 kDa could be 
found, as shown in the SDS-PAGE gel verification, in the first washing fractions, during 
and right after the sample loading onto the chromatographic column. In addition, 
another factor to take into consideration is the status of the column. It might be 
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possible that the resin was not properly regenerated nor homogenously equilibrated, 
with resulting low binding capacity. Proposed approaches for new purification trials 
would be the re-positioning of the histidine tag at the C-terminus, the use of different 
binding buffers or the switch to a different column, such as for example the 2'5'-ADP 
Sepharose column. In this particular case, the resin, consists of sepharose beads 
coated with 2’,5’-ADP (adenosine 2′,5′-diphosphate, a structural analogue of NADP), 
which binds tightly to molecules that require NADP as cofactor (thus presenting NADP 
binding sites), without the need of an affinity tag. This approach has been successfully 
employed by Wadsäter et al. for the purification of the P450 reductase from S. bicolor 
(219). Given the lack of purified Im9-CYP73A5 fusion protein, to determine the 
integrity of the construct, activity assays with the natural substrate of CYP73A5 were 
carried out using whole cells expressing the construct. Cells incubated with cinnamic 
acid were able, as compared to cells transformed only with the empty vector 
(negative controls), to convert almost 60 % of the substrate, generating more than 30 
M of the hydroxylated product, p-coumaric acid, in a time frame of six h. Longer 
assays were also performed, but the chromatograms were not as clear as for the 
previous time points, possibly due to the formation of other unspecific compounds 
by the E. coli cells.  
 Considering these promising results, the Im9 construct, with a C-terminal AtATR2tr 
reductase could be used for the cloning, expression and characterisation of a plethora 
of plant P450s that are still uncharacterised to date. The cloning procedure, consisting 
of a single digestion and InFusion reaction is relatively easy and the coupling with an 
automated liquid sampling robot could significantly decrease the time and resource 
consumption related to the optimisation of the other expression parameters, such as 
expression host, growth media and temperatures. 
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Chapter 5: A role for CYP81D11 in the 
detoxification of the explosive TNT 
5.1 Introduction on the role of Cytochromes P450 in plant 
detoxification processes 
Plants exhibit an extensive collection of CYP genes, with more than 13,000 sequences 
currently annotated (220). These CYPs are key in numerous pathways related to 
structural development (lignins), defence mechanisms and signaling cascades 
(oxylipins, phytoalexins, glucosinolates, alkaloids, cyanogenic glucosides) and 
biosynthesis of hormones (gibberellins, brassinosteroids, abscisic acid, cytokinins) 
(15, 17, 221). Furthermore, CYPs are also involved in the synthesis of secondary 
metabolites of chemical/pharmaceutical value, such as artemisinic acid (used in 
antimalarial combination therapies (222, 223)), the anticancer compound taxol 
(paclitaxel, (112)), fragrances, flavours and nutraceuticals. Moreover, plant CYPs can 
also be responsible for the breakdown of endogenous molecules as well as of 
xenobiotics (221, 224).  
Similar to hepatic CYPs in mammalians, plant CYPs are able to detoxify - mainly via 
hydroxylation, dealkylation and oxidation - xenobiotic compounds. Among these are 
organic pollutants, such as herbicides and pesticides, taken up from the surrounding 
environment (224). The first evidence for P450-mediated xenobiotic detoxification 
was collected by Frear and coworkers almost 50 years ago: they observed that an 
oxidase from cotton microsomal fractions was able to dealkylate monuron (3-(4'-
chlorophenyl)-1,1-dimethylurea), a phenylurea herbicide. The connection to CYPs 
was easily made, considering the location of the active enzyme and the requirement 
of molecular oxygen as well as of NADPH (225, 226). Later, Mougin et al. confirmed 
that the herbicide chlortoluron (3-(3-Chloro-4-methylphenyl)-1,1-dimethylurea) was 
metabolised via dealkylation and hydroxylation by a set of microsomal CYPs in wheat 
(Triticum aestivum) (227). Following from Fonne-Pfister and colleagues’ studies on 
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xenobiotic metabolism in Jerusalem artichoke (H. tuberosus) (228), Robineau et al. 
determined that CYP76B1 was able to catalyse the dealkylation of further phenylurea 
herbicides, such as chlortoluron and isoproturon (180, 229). In all the examined 
cases, the result of CYP catalysis was the conversion of the compounds to more 
hydrophilic and less toxic derivatives, therefore contributing directly to the overall 
plant tolerance and resilience to such xenobiotics. All these early observations 
opened up the doors to the study and application of CYP enzymes to agronomics and 
bioremediation. Besides cytochromes P450, the metabolism of agrochemicals and 
pollutants in plants is also carried out by other classes of enzymes, including UGTs, 
GSTs and malonyl transferases, which are responsible for the conjugation of the 
compounds to molecules such as sugars, glutathione or malonate, respectively (230). 
These bio-converted compounds are then transferred to vacuoles or cell walls for 
storage (figure 5.1). 
 
Figure 5.1: Scheme illustrating the bio-conversion of xenobiotic compounds in plant cells. In Phase I, 
the xenobiotic (orange hexagon, X) in the cytosol is transformed into a generally more soluble 
derivative via hydrolysis, oxidation or reduction (blue circle). In phase II, the derivatised compound is 
conjugated with glutathione (yellow trapeze, G), with malonate (violet triangle, M) or with a molecule 
of sugar (gray hexagon, S) by GST (glutathione S-transferase), UGT (glucosyl transferase) or Mt (malonyl 
transferase), respectively. In phase III the conjugated molecules are trasported into the vacuole or in 
the cell wall. 
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Phytoremediation exploits the natural capability of plants to take up compounds that 
are present in their surroundings and then detoxify them. This ability, coupled by the 
presence of endogenous metabolic systems, can be further amplified by the 
introduction, via genetic engineering, of external genes, with known activity towards 
the target compounds, leading to a more efficient biotransformation and possibly 
less toxic derivatives. Successful examples of engineered P450-based systems for 
phytoremediation purposes are numerous. Kawahigashi et al. developed transgenic 
rice (O. sativa) crops (named pIKABCH, from rice cv. Nipponbare) with increased 
ability to extract numerous herbicides, from different media, due to the tandem 
expression of human CYP1A1, CYP2B6, and CYP2C19 (59). Mammalian CYP2E1, due 
to its demonstrated activity towards a broad array of environmental contaminants, 
such as trichloroethylene (TCE), benzene and chloroform (231), has attracted major 
attention over the years, leading to the development of multiple transgenic systems. 
Starting from assays with modified tobacco plants (232), Doty et al. created a CYP2E1-
expressing poplar hybrid (Populus tremula x P. alba, clone INRA 717-1B4), which was 
able to extract benzene and TCE from the air, and chloroform from a hydroponic 
solution (233). Subsequently, alfalfa plants (Medicago sativa L.) were modified by 
Zhang and coworkers to express human CYP2E1 and a GST. The resulting plants 
displayed enhanced cross-resistance to mixtures of xenobiotics (such as TCE, 
cadmium and mercury, if compared to wild type plants (234, 235).  
Besides volatile organic compounds and toxic metals, phytoremediation processes 
have been developed also for the removal and detoxification of explosives pollution, 
and, given the widespread nature of the contamination, a more effective alternative 
to the conventionally-used incineration, soil capping, soil removal or composting 
techniques (236). Prof. Neil Bruce’s group particularly focused extensive research 
efforts towards the development of viable phytoremediation strategies for the 
removal of nitroexplosives, such as the widely-used 2,4,6-trinitrotoluene (TNT) and 
hexahydro-1,3,5-trinitro-1,3,5-triazin (RDX). Both compounds, characterised by a ring 
with multiple nitro groups (figure 5.2), are toxic and recalcitrant to degradation in the 
environment. 
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Figure 5.2: Chemical structures of 2,4,6-trinitrotoluene (TNT) and hexahydro-1,3,5-trinitro-1,3,5-triazin 
(RDX). 
 
An important discovery, related to the application of CYPs to the phytoremediation 
of explosives, was made by Dr. Seth-Smith et al. in 2002. The team succeeded in the 
identification and characterisation of the enzyme responsible for the ability of a 
specific rhodococcal strain, R. rhodochrous 11Y, to use RDX as a source of nitrogen 
for growth (87). With preliminary evidences collected a few years earlier, the 
subsequently isolated ~70 kDa enzyme that was identified as a cytochrome P450 and 
named XplA (CYP177A1). This novel enzyme presented an unusual structure, with a 
fused N-terminal flavodoxin domain, expressed from the same gene cluster as a 12.4 
kDa flavodoxin reductase, named XplB (figure 5.3).  
 
Figure 5.3: Structure of the XplA-XplB system, as described by Jackson et al. (237). The XplA heme 
(CYP177A1) is fused at its N-terminus to a flavodoxin domain and is co-expressed with the reductase 
XplB. 
 
The full enzymatic mechanism for the degradation of RDX by XplA was described by 
other members of the Bruce’s group (figure 5.4). By measuring the production of 
nitrite and formaldehyde, in the presence and absence of oxygen, it was postulated 
that under anaerobic conditions, methylenedinitramine (MEDINA), nitrite and 
formaldehyde are the resulting derivatives. On the other side, when oxygen is 
present, 4-nitro-2,4, diazabutanal (NDAB), nitrite and formaldehyde are formed. 
NADPH + H+ 
NADP+ 
XplA-heme 
(CYP177A1) 
Flx XplB 
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Figure 5.4: Illustration of the XplA (CYP177A1) mechanism of action towards RDX, as proposed by 
Jackson et al. (237), on the basis of the measured nitrite and formaldehyde released in anaerobic and 
aerobic conditions. In anaerobic conditions, one mole of nitrite and two moles of formaldehyde are 
formed; under aerobic conditions, two moles of nitrite and one mole of formaldehyde are formed. In 
addition, in absence of oxygen MEDINA (methylenedinitramine) is formed, whereas when oxygen is 
present, NDAB (4-nitro-2,4, diazabutanal) is formed. The intermediates in brackets are hypothetical.  
 
Homologues of XplA (with more than 90 % amino acid sequence identity on a region 
covering > 60 % of the enzyme) were also found to be expressed by other bacterial 
isolates from RDX-contaminated soils in Australia, Israel and Belgium (88). Further 
activity and structural studies (figure 5.5) were conducted by Dr. Sabbadin. Assays 
performed with the purified XplA heme showed a Km for RDX of 10.23 ± 0.90 M (91, 
238). 
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Figure 5.5: Schematic representation of the elucidated structure of the XplA heme domain (figure from 
Sabbadin et al. (238)). 
 
The applicability of this enzymatic system for the phytoremediation of RDX was 
tested by introducing XplA into Arabidopsis (A. thaliana). Arabidopsis lines expressing 
the XplA heme were able to remove RDX from saturating solutions. Subsequent soil 
studies demonstrated that the transgenic lines were more resistant to RDX and were 
able to use it as a source of nitrogen to enhance biomass production. (88). These 
properties were further enhanced when XplB was also transformed into the plant 
(237). 
The explosive TNT is more recalcitrant to degradation than RDX. Studies over the 
years reported that biological activity towards TNT consists mainly of reductive 
reactions. One pathway sees the sequential conversion of TNT to the highly unstable 
4-nitroso-2,6-dinitrotoluene (NODT) which is reduced to 4-hydroxyl-2,6-
dinitrotoluene (HADNT), and then aminodinitrotoluenes (ADNT), by nitroreductases 
in bacteria (239). In plants, OPRs (163) are known to contribute to these reductive 
transformation steps, then both HADNTs and ADNTs can be conjugated, by UGTs to 
glucose molecules. Denitration with direct conjugation of GSH to the ring can also 
occur, catalysed by GSTs (164). The TNT conjugates are then thought to be 
sequestered into the cell wall or in the vacuoles (162). Another pathway consists of 
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the reduction of the TNT ring, yielding the hydride/dihydride-Meisenheimer 
complexes (figure 5.6). In bacteria, these complexes can condense, forming 
diarylamines (240).  
 
 
Figure 5.6: Steps in the biotransformation of TNT in plant roots and in bacteria, as described by Rylott 
et al. (241). Multiple consecutive reduction steps of the nitro groups can lead first to the formation of 
the unstable 2/4-nitroso-4/2,6-dinitrotoluene, then to the 2/4-hydroxylamino-derivative and finally to 
2/4-amino-4/2,6-dinitrotoluene. The latter two types of derivatives can be further glycosylated by UGT 
transferases. Alternatively, through reduction of the ring, TNT is converted into the hydride/dihydride-
Meisenheimer complexes. In bacteria, the condensation of these complexes with HADNT can occur, 
with formation of diarylamines. In addition, GST transferases can conjugate the TNT molecule to 
glutathione. NODT = 2/4-nitroso-4/2,6-dinitrotoluene; HADNT = 2/4-hydroxylamino-4,6-
dinitrotoluene; ADNT = 2/4-amino-4/6-dinitrotoluene; H-/2H- TNT = hydride/dihydride-Meisenheimer 
complex.   
 
At the end of all these reductive transformations steps, affecting specifically the 
functional groups of the molecule (nitro, -NO2) the aromatic ring remains intact. 
Besides some cases seen in fungi, studies on the mineralisation of TNT are quite 
limited, due to the high stability of the aromatic ring, whereby the carbon bonds are 
sterically 'protected' from attack (242).  
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Mineralisation levels observed in multiple bacterial strains exposed to TNT were 
minimal (< 1 %, if any) (243, 244). In the case of fungi, for example P. chrysosporium, 
Irpex lacteus and Clitocybula dusenii b12, TNT was firstly reduced to the amino 
derivatives and further metabolised, with release of water and CO2 (245-247). This 
kind of activity, absent in bacteria, was assigned to fungal endogenous enzymes, 
involved in the ligninolytic pathway, such as laccases, manganese peroxidases and 
lignin peroxidases (248, 249). 
In contrast to the previously described reductive mechanisms (seen in figure 5.6), 
Bhadra et al., investigated oxidative TNT metabolic pathways. These studies were 
conducted with the aquatic plant parrot feather (Myriophillum aquaticum), 
incubated in TNT-containing liquid medium. The HPLC-MS coupled with NMR 
analyses revealed the formation of a set of metabolites, all still presenting an intact 
aromatic ring, such as 2-amino-4,6-dinitrobenzoic acid (2-ADNBA), 2,4-dinitro-6-
hydroxy-benzyl alcohol, acetoxyamino-4,6-dinitrobenzaldehyde and 2,4-dinitro-6-
hydroxytoluene (165). The metabolite 2-ADNBA alongside 2,4,6-trinitrobenzoic acid 
(TNBA) were also observed in soil samples taken from a TNT-contaminated 
ammunition plant in Germany (250). 
A number of cytochrome P450 enzymes were among the hundreds of upregulated 
genes revealed in multiple gene expression studies performed on Arabidopsis plants 
exposed to TNT  (160-162). Among the overexpressed genes were also TNT-active 
GSTs, UGTs and OPRs. The most upregulated cytochrome P450 was CYP81D11, with 
expression levels exceeding the basal expression (without TNT) by more than 25 fold, 
and at comparable expression levels with many of the TNT-active genes. 
Furthermore, gene co-expression data regarding CYP81D11 on the CYPedia platform 
(251) demonstrated that, in multiple cases, CYP81D11 is expressed in the same 
tissues or overexpressed upon the same stimuli as glucosyl transferases, 
toxin/xenobiotic metabolisers and stress response agents (all co-expression data sets 
for CYP81D11 can be visualised at: http://www-ibmp.u-
strasbg.fr/~CYPedia/CYP81D11/CoExp_CYP81D11_Pathways.html).  
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The role of CYPs in the detoxification of TNT has not been investigated to date. Given 
the multiple evidences described above, including the discovery of oxidative 
derivatives of TNT in plant incubations, the overexpression of CYP enzymes upon 
treatment with TNT, as well as the gene co-expression data, it is hypothesised that 
the upregulated CYPs have a role in the detoxification of TNT.  
The aim of the work described in this chapter is to further our understanding of the 
function of CYP81D11, the most upregulated CYP upon TNT treatment, and to unravel 
new potential ways to detoxify this toxic environmental pollutant. 
 
5.2 Materials and Methods 
5.2.1. Plants and growth media 
Plants 
Tobacco (Nicotiana benthamiana) seeds were kindly donated by Luisa Elias, CNAP, 
University of York. 
Arabidopsis (Arabidopsis thaliana) CYP81D11-knockdown lines and CYP81D11-
overexpressing lines were kindly provided by Prof. J. Napier, Rothamsted Research. 
The wild type line, used as a control, was ecotype Columbia Col0.  
Growth media 
Soil: Levingtons F2 compost, treated with the Intercept insecticide (Imidacloprid), 
according to the manufacturer’s instructions, as a prophylaxis against sciarid fly 
larvae. 
½ MS (Murashige and Skoog) medium (132): 2.15 g/l of MS medium, 20 mM sucrose, 
dissolved in distilled ELGA-pure water. Plant agar (1% w/v) was added for the 
preparation of ½ MS agar plates. pH was adjusted to 5.7 with NaOH prior to autoclave 
sterilisation.  
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Tobacco plants were grown in soil for up to six weeks, prior to leaf disc harvest. 
Arabidopsis plants used for the incubation assays were grown on sterile ½ MS agar 
and subsequently transferred in ½ MS liquid medium. 
5.2.2. Sterilisation of Arabidopsis seeds 
The seeds were sterilised with the vapour-phase method. Briefly, small aliquots of 
seeds (~70) in open 1.5 ml Eppendorf tubes were exposed to the fumes from 100 ml 
of bleach mixed with 3 ml of hydrochloric acid, in an airtight container placed in a 
fume hood. After 4 h, the container was vented within the fume hood, and left for 
further 10 min to release the residual toxic gas. 
5.2.3 Verification of gene expression in the Arabidopsis CYP81D11-
modified lines via qPCR 
The RNA extraction was performed following the procedure used by Dr. Lorenz (161) 
and using an ISOLATE II RNA Plant Kit (Bioline). Plant tissues (harvested from whole, 
liquid-culture-grown two-week old plants, incubated for 6 h with 60 M TNT) were 
frozen in liquid nitrogen, then ground using a pestle and a mortar. The RLY lysis 
buffer, from the kit, mixed with 10 % (v/v) -mercaptoethanol, was added to the 
tissue powder (350 l/100 mg of tissue). After a brief vortex, the lysate was filtered 
through a spin column (provided in the kit). The flow-through was then mixed 1:1 
(v/v) with 70% (v/v) ethanol and loaded onto the RNA plant column. After a washing 
and a desalting step, the sample retained on the silica membrane was treated for 15 
min with DNaseI. The membrane was then subjected to three washing steps and the 
RNA eluted via centrifugation with RNase-free water. The purity of the resulting RNA 
was checked using a nanodrop spectrophotometer, as good quality samples have an 
Abs260/Abs280 ratio of approximately 2. The reverse transcription from the extracted 
RNA to cDNA was carried out employing a SuperScript II reverse transcriptase kit 
(Invitrogen). Following the instructions from the manufacturer, the reaction mixture 
consisting of 1 ng - 5 g of RNA, oligo(dT)12-18 and dNTPs was firstly incubated at 65 
°C for 5 min. The buffer (provided in the kit) and 0.1 M DTT were subsequently added 
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and the mix was cooled to 42 °C for 2 min. After the addition of the reverse 
transcriptase, the reaction was carried out at 42 °C for 50 min. At the end of the 
incubation, the enzyme was inactivated at 70 °C for 15 min. The resulting single-
strand cDNA was used as a template for the quantitative PCR amplification executed 
on a StepOne Plus Real Time PCR Systems machine (Applied Biosystems), using 
specifically designed oligonucleotide primers. Oligos complementary with the ACTIN2 
gene (At3g18780) were used for control amplification reactions (all primers are listed 
in table 5.1), to normalise the data collected. The measurements were performed 
with five biological replicates, each in technical triplicate. 
 
Table 5.1: List of oligonucleotides used for the measurement of the gene expression in the Arabidopsis 
modified plants. Actin was used as an endogenous control. 
 
Target gene Oligo sequence 
CYP81D11 Forward 5’ – TTATGATACTTGCCGGGACTG – 3’ 
Reverse 5’ – TCGATTTCGGTCTTTGCC – 3’  
Actin Forward 5’ – TACAGTGTCTGGATCGGTGGTT – 3’ 
Reverse 5’ – CGGCCTTGGAGATCCACAT – 3’ 
 
The use of SYBR® fluorescent dye (ThermoScientific) allowed the detection of the 
synthesis of double-stranded DNA products. The resulting melt curve data were 
collected and analysed with the StepOne™ Software. 
5.2.4. Hydroponic cultures of Arabidopsis transgenic plants & HPLC 
analysis of TNT uptake 
Surface-sterilised seeds were placed on ½ MS agar plates (in single rows of 20 seeds 
for the root-length experiments), subsequently wrapped in aluminum foil. The plated 
seeds were stratified at 4 °C for 72 h, then placed in a growth chamber with a 16-h 
photoperiod, 21 °C day and 18 °C night temperatures and 100 mol/m2 s of light. 
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After one week, germinated seedlings, in batches of 8 seedlings, were transferred 
from the plates into 100 mL Erlenmeyer flasks containing 20 ml ½ MS medium, 
supplemented with 20 mM sucrose, pH 5.7.  The flasks were placed on a rotating 
shaker at 125 rpm, under 20 mol/m2 s of light. After two weeks of growth, the 
medium was replaced with an aqueous solution of 200 M TNT. Samples from the 
liquid medium were collected at regular time points for HPLC analysis. After a 
centrifugation step for 15 min at 34,000 g, the samples were subjected to HPLC 
analysis (Waters X-Bridge C18 column, column temperature: 30 °C, mobile phase: 48 
% methanol / 52 %water). 
5.2.5. Root length on-plate comparison for differential TNT-resistance 
Germinated seeds were transferred onto ½ MS plates (20 seedlings per plate), 
supplemented with 20 mM sucrose and different concentrations of TNT, ranging from 
0 to 30 M and grown vertically in the same chamber described in section 5.2.4. 
Pictures of the plates were taken after 20 days and the length of the roots were 
measured with the ImageJ processing program (252).  
5.2.6. Transient expression of CYP81D11 in Nicotiana benthamiana 
Cloning 
The cDNA extracted from Arabidopsis whole seedlings was used as template for the 
amplification of the genes of interest, employing gene-specific primers. A second PCR 
amplification was performed in order to add the adapter ends for the “LR” 
recombination step of the Gateway cloning process (253). The two sets of primers 
used for the sequential PCR reactions are listed in table 5.2. The original Gateway 
cloning protocol was slightly modified, as 100 ng of purified PCR amplicons were 
added to 150 ng of the pK2GW7 destination vector (figure 5.7) in TE buffer, pH 8.0.  
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Table 5.2: Oligonucleotides used for the 3-step amplification of the target gene for cloning in the 
pK2GW7 plasmid. PCRext: 5’-3’ gene-specific primers, with start codon and stop codon in bold / 
PCRHis: primers for the introduction of the His tag / PCRAttL: primers for the introduction of the LR 
recombination sites.  
 
Name Oligo sequence 
PCRext Forward 5’ - CCAACTTTGTACAAAAAAGCAGGCTATGTCATCAACAAAGACAATAATG – 3’ 
Reverse 5’ - TTA GTG GTG GTG GTG GTG GTG TGG ACA AGA AGC ATC TAA AAC – 3’ 
PCRHis Forward 5’ - CCAACTTTGTACAAAAAAGCAGGCTATGTCATCAACAAAGACAATAATG – 3’ 
Reverse 5’ - CCA ACT TTG TAC AAG AAA GCT GGG TTT AGT GGT GGT GGT GGT 
PCRAttL Forward 5’ - CAAATAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAA 
                    TTGATAAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGCA – 3’ 
Reverse 5’ - CAAATAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAA 
                    TTGATAAGCAATGCTTTCTTATAATGCCAACTTTGTACAAGAAAGCT – 3’ 
 
 
Figure 5.7: Map of the pK2GW7 vector employed for the expression of CYP81D11 in the tobacco plants. 
 
The reaction mixture, after the addition of 2 l of LR Clonase II enzyme mix 
(ThermoFisher Scientific), was incubated for 1 h at 25 °C. The reaction was terminated 
by adding 1 l of proteinase K solution and further incubated at 37 °C for 10 min. 
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Competent DH5 E. coli cells were transformed with the reaction mixture. Colonies 
were picked and inoculated in LB medium for overnight incubation at 37 °C and 
subsequent plasmid isolation and sequencing. 
Agrobacteria electroporation and cultures 
The purified plasmids carrying the CYP81D11 gene, along with the empty pK2GW7 
vector and the P19 construct (viral suppressor of gene silencing) (254), were 
transformed via electroporation into A. tumefaciens competent cells (for complete 
protocol see Materials and Methods, paragraph 2.4.7.2). After 48-72 h of incubation 
at 30 ˚C on LB agar plates (supplemented with 50 g/ml spectinomycin and 50 g/ml 
gentamycin for selection), single colonies were picked and inoculated into 100 mL of 
LB medium with antibiotics and incubated again at 30 ˚C with shaking.  
Infiltration and harvesting of leaf discs 
The Agrobacterium cultures were harvested 48 h later via centrifugation, at 5,000 g 
for 15 min and washed twice with a ½ volume of double distilled water. The density 
of the cultures was checked spectrophotometrically and adjusted to a final 0D600 
value of 0.4. CYP cultures were mixed 1:1 with P19 cultures for co-expression and 
infiltrated using a 1-ml syringe into the abaxial side of the leaf of 5-6 week-old 
tobacco plants. Cell cultures harboring the empty vector were also mixed with P19 
cultures and infiltrated into tobacco leaves, as negative controls. Three leaves per 
plant were infiltrated, in a total of 8 plants for the CYP81D11 cultures and 8 for the 
empty vector cultures. After 5 days, 20 discs (approximately 0.5 cm diameter) from 
each plant were excised from the treated leaves. Half of the harvested discs (10) were 
subjected to treatment with TNT whereas the remaining 10 were collected for 
subsequent verification of protein expression through SDS-PAGE and western blot 
analysis.  
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Verification of protein expression: protein extraction, SDS-PAGE verification and 
western blot analysis 
Approximately 53 mg of tissue were obtained from each infiltrated leaf and ground 
in liquid nitrogen. The resulting powder was resuspended in Lysis buffer (50 mM Tris-
HCl pH 7.8, 10 mM EDTA, 300 mM sucrose, 100 mM NaCl, 1 mM DTT and 200 M 
PMSF). The samples were then subjected to sequential centrifugations, 10 min at 
1,000 g, 7 min at 2,000 g and 5 min at 1,000 g to remove tissue residues. For the 
complete SDS-PAGE and western blot procedures see Materials and Methods, 
paragraphs 2.5.4 and 2.5.5. 
Leaf discs incubations 
Ten leaf discs from the treated plants (CYP81D11 cultures or empty vector cultures), 
along with discs from non-infiltrated plants (second negative control set) were 
incubated in 20 mL of ½ MS medium containing 100M TNT. The discs were soaked 
by vacuum application. The 100 ml glass Erlenmeyer flask containers were wrapped 
in aluminum foil, to minimise the photodegradation of TNT. Samples of the liquid 
medium as well as of the tissues were collected over a period of 48 h. In order to 
detect the levels of TNT uptake and TNT-derivatives in the CYP-expressing samples 
and the controls, the medium samples were centrifuged for 10 min at 13,000 rpm 
and the supernatants analysed by HPLC (Waters X-Bridge C18 column, column 
temperature: 30 °C, isocratic mobile phase: 50% water / 50% acetonitrile). With this 
method, TNT eluted at ~ 8.2 min and peak areas were integrated at 230 nm. 
Metabolite extraction from the leaf discs 
Following the procedure used by Hannink et al. (239), the TNT metabolites retained 
in the tissues were extracted by grinding the discs in liquid nitrogen. The resulting 
powder was re-suspended in acetonitrile (10 ml / g of tissue). After two vortex spins 
(10 s each), the tissue debris was pelleted via centrifugation at 14,000 rpm and the 
acetonitrile evaporated with a GeneVac EZ2 evaporator (SP scientific), for 45 min at 
60 °C. Subsequently, the pellets were re-suspended in 400 l acetonitrile and 
analysed via HPLC (Waters X-Bridge C18 column, column temperature: 30 °C, mobile 
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phase: 50% acetonitrile / 50 % 20 mM tetrabutylammonium dihydrogen phosphate 
(TBAP), pH 7).  
5.3 Results 
5.3.1 Verification of CYP81D11 expression in Arabidopsis 
The modified levels of CYP81D11 transcripts in the Arabidopsis lines received from 
Rothamsted Research were quantified via qPCR expression analysis. The results of 
the quantitative Ct comparative analysis, reported in figure 5.8, confirmed that 
upon treatment with TNT the CYP81D11-modified plants produced higher levels (for 
the CYP81D11-overexpressors) or lower levels (CYP81D11-knockdown) of the 
transcript, when compared to the wild type plants. 
 
Figure 5.8: qPCR results from the cDNA obtained from the two-week-old Arabidopsis plants grown on 
½ MS medium supplemented with 60 M TNT. WT = wild type, OE = CYP81D11-overexpressor, KD = 
CYP81D1- knockdown. The results shown are the average of 5 biological replicates ± S. E. 
 
The qPCR data collected for the untreated plants were not clear, as no significant 
difference in expression levels could be observed between the wild type and 
CYP81D11-knockdown plants (Log10(fold expression) values: wild type = -1.89 ± 0.12 
/ CYP81D11-overexpressor = 3.27 ± 0.13 / knockdown = 0.56 ± 0.24). 
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5.3.2 TNT uptake by hydroponic Arabidopsis cultures 
The result of the HPLC analysis of the samples collected from the plant growth 
medium supplemented with TNT is shown in figure 5.9.  
 
Figure 5.9: TNT concentration in the plants’ growth medium. The 3-week-old seedlings were incubated 
with 200 M TNT in ½ MS for 1 week. NPC = no plant control, WT = wild type control, OE = CYP81D11-
overexpressor, KD = CYP81D11-knockdown. Results shown are means of 8 biological replicas ± SE. 
Statistical analysis carried out with SPSS OneWay Anova, p < 0.05. 
 
The HPLC analysis revealed differences in TNT uptake of the liquid-culture grown wild 
type and CYP81D11-modified plants. The knockdown plants showed a significantly 
faster uptake (for all the recorded values up to the 48 h time point, verified with SPSS 
OneWay Anova, P < 0.05) of the xenobiotic, than the wild type or overexpressing line. 
For the knockdown line, more than 90 % of the TNT was removed from the medium 
in the first 48 h; whereas, for the overexpressing and wild type lines, 7 days were 
needed to remove the same amount of TNT. As expected, in the no plant control 
samples the concentration of TNT remained stable throughout the time frame.  
5.3.3 Comparison of CYP81D11-modified plants’ root length 
To test for a possible correlation between the expression of CYP81D11 and resistance 
to TNT, a comparative assay was carried out, by growing the wild type, 81D11-
knockdown and 81D11-overexpressing Arabidopsis plant lines on TNT-containing 
plates. Pictures of the plates were taken after 20 days (figure 5.10 a-e).  
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(Figure 5.10 a-e, continues on following page) 
(a) 
No TNT 
(b) 
+ 2M TNT 
(c) 
+ 7 M TNT 
(d) 
+ 15 M TNT 
         KD                                Wild Type                                 OE 
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Figure 5.10 a-e: Pictures of 20-day-old Arabidopsis plants grown on 1/2MS + sucrose plates. Each row 
(a-e) represents one TNT concentration set, in the range 0 - 30 M. Left column: KD (CYP81D11-
knockdown) / middle column: Wild type / right column: OE (CYP81D11-overexpressor).  
 
The root measurements are shown in figure 5.11. A specific trend could be observed 
across the lower concentrations of TNT (0, 2, 7 M): both overexpressing and 
knockdown lines displayed longer roots, compared to wild type. When a higher 
concentration of TNT was present (15, 30 M) in the plate, the trend was reversed, 
with the knockdown plants displaying significantly shorter roots, in comparison to the 
wild type and overexpressing lines. 
 
Figure 5.11:  Root lengths of 20-day old Arabidopsis seedlings grown on plates with different 
concentrations of TNT. Three replicates for each concentration and line, 20 seeds per plate.  WT = wild 
type, OE = CYP81D11-overexpressor, KD = CYP81D11-knockdown. Statistical analysis performed with 
OneWay Anova and Tukey test. One asterisk (*) denotes data sets significantly different from the wild 
type, with p < 0.05; two asterisks (**) denote data sets significantly different from WT, with p < 0.01. 
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5.3.4 Transient expression of CYP81D11 in tobacco leaves 
Expression of CYP81D11 
Following the established protocol used by colleagues at the Institut de Biologie 
Moléculaire des Plantes (IBMP, CNRS), the construct containing the histidine-tagged 
CYP81D11 native sequence was transformed into Agrobacterium. Transformed 
cultures, mixed with cultures expressing the viral P19 inhibitor, were infiltrated into 
tobacco leaves. Half of the discs excised from the leaves were used for the verification 
of protein expression (figure 5.12) and the other half for TNT incubations. 
 
Figure 5.12: Western blot analysis of CYP81D11 expression in the infiltrated tobacco leaves (samples 
1-4: empty vector control / samples 5-9: CYP81D11 samples). 
 
Three of the samples examined via western blot clearly gave a band at the expected 
size (lanes 6, 7 and 9); for the other two samples (lanes 5 and 8), the concentration 
of the his-tagged protein might have been too low for detection. 
Analysis of TNT uptake and conversion 
Time point samples from the tobacco leaf discs incubations dosed with TNT were 
analysed via HPLC. All the resulting chromatograms (except the no plant controls) 
presented two peaks, one eluting at 6.2 min and the other at approximately 8.3 min. 
Analysis of the standards demonstrated that the 6.2’ peak corresponded to a mixture 
of 2/4-ADNTs, while the 8.3’ peak corresponded to the TNT standard. The collected 
data are shown in figures 5.13 and 5.14. 
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Figure 5.13: TNT uptake observed during the incubation of tobacco leaf discs expressing CYP81D11 on 
½ MS + 20 mM sucrose containing 100 M TNT.  The samples were analysed at the HPLC (Waters C18 
XBridge column, 5 µm, 4.6 x 250 mm) using an isocratic method, with the mobile phase consisting of 
50:50 water:acetonitrile. NPC = no plant control, EV = empty vector. Mean of eight biological replicates 
± s.e. 
 
 
 
Figure 5.14: Levels of ADNT derivatives observed during the incubation of tobacco leaf discs expressing 
CYP81D11 on ½ MS + 20 mM sucrose containing 100 M TNT.  The samples were analysed at the HPLC 
(same method as above) NPC = no plant control, EV = empty vector. Mean of eight biological replicates 
± s.e.  
 
The analysis of the samples of the liquid medium showed that there was no significant 
difference (verified with a statistical T-test) in the rate of TNT removal nor in the 
formation of TNT derivatives by the discs expressing CYP81D11, when compared to 
those transformed with the empty vector alone.  
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At the end of the incubation period, the leaf discs were collected. Upon visual 
inspection no significant difference could be noticed, in terms of chlorosis (figure 
5.15). 
 
Figure 5.15: Pictures of the tobacco leaf discs after 48 h of incubation on ½ MS + 20 mM sucrose, in 
presence of 100 M TNT. Left panel: empty vector control/ right panel: CYP81D11-expressor. Each dish 
contains the ten discs harvested from each biological replicate.  
 
Levels of TNT metabolites found in the tissues of the wild type, knockdown and 
overexpressing lines are shown in figures 5.16 and 5.17. 
 
Figure 5.16: Chromatographic profiles of the samples collected from the tobacco leaf tissues. The 
metabolites were extracted with acetonitrile and analysed via HPLC, employing an isocratic method 
50:50 20 mM TBAP pH 7:acetonitrile. EV = empty vector control. 
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The TNT standards (25, 50, 100 M) were subjected to the same treatment as the 
ground tissues (mixed with acetonitrile, GeneVac evaporation and resuspension), in 
order to verify whether TNT decomposes under these specific conditions. Single 
peaks eluting at 8.2 min were obtained for all the tested TNT concentrations. None 
of the samples from the tissue extracts (CYP81D11 nor empty vector) presented any 
peak eluting at that retention time nor with the same UV trace. However, peaks 
eluting after 6.5 min and at ~9.1 min were observed. This meant that in the tissue 
samples the TNT taken up from the liquid medium was totally converted into two 
derivatives. On the average of the replicates, the CYP81D11-containing samples 
produced an amount of the 9.1’ product approximately 1.9-times higher than the 
empty vector controls (figure 5.17). Nevertheless, the statistical analysis (T-test) of 
the data demonstrated that the observed difference is not convincing enough to 
consider the two data sets from the CYP81D11-expressors and the negative control 
significantly different. 
 
Figure 5.17: Comparison of the peak areas of the tobacco tissue extracts. Represented are the means 
of 8 biological replicates ± S.E. 
 
In order to verify the identity of the resulting compounds, the samples were 
subjected to electro-spray ionisation mass spectrometry (ESI-MS), in negative mode. 
This analysis showed that the 6.5’ peak yielded a correspondent fragment with an 
m/z ratio of 196, exactly as the commonly found amino-dinitrotoluene derivatives. 
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For the peak eluting at 9.1 min, a fragment was generated, with an m/z value of 405 
(figure 5.18). This metabolite was observed only in the plant tissues and was not 
detected in the medium. 
 
 
 
 
 
 
Figure 5.18: ESI spectra resulting from the MS analysis, in negative mode, of the metabolites extracted 
from the tobacco leaf discs. Prior to the MS analysis, the analytes in the extracts were separated via 
HPLC, using an isocratic analytical method of 50:50 water:acetonitrile. The fragments of interest, 
corresponding to the 6.5’ (top panel) and the 9.1’ (bottom panel) peaks, are circled in blue, with 
relative structures represented on the side.  
 
In order to verify this outcome, a similar incubation experiment, following the same 
procedure as for the tobacco samples (see section 5.3.9), was carried out using the 
D151015_sample1 #551 RT: 14.03 AV: 1 NL: 2.98E5
T: - c ESI Full ms [ 100.00-1500.00]
200 400 600 800 1000 1200 1400
m/z
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
220000
240000
260000
280000
In
te
ns
ity
405.1
121.3 1253.0464.7
1101.8
1446.6196.2 849.2328.3 872.6 1126.2
643.1 845.9315.2 1180.2 1294.91073.6552.8 943.3
790.2
D151015_sample1 #273 RT: 7.01 AV: 1 NL: 1.49E5
T: - c ESI Full ms [ 100.00-1500.00]
200 400 600 800 1000 1200 1400
m/z
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
In
te
ns
ity
196.2
913.6
405.1
1227.2887.2
1392.9
1188.6
732.3
1478.81289.7
197.6 762.3
1085.3
1000.9692.4241.7
870.7343.1
476.2
255.9143.0
690.2543.6
Chapter 5: Investigating the role of CYP81D11 in TNT detoxification 
 
143 
 
Arabidopsis CYP81D11-modified lines (overexpressing and knockdown). The result of 
the HPLC analysis of the tissue extracts is reported in figure 5.19. 
 
Figure 5.19: Comparison of the peak areas deriving from the chromatographic separation of TNT 
derivatives from Arabidopsis incubations, performed following the same procedure as for the tobacco 
transformed lines. Assay performed with eight biological replicates ± SE. 
 
As shown in figure 5.19, two compounds were formed during the incubation period: 
one eluted at 6.4 min and displayed the same UV trace as the 6.5’ compound formed 
in the tobacco incubations. Additionally, a second peak was visualised, eluting 
approximately one min after the first peak, at 7.4 min. No significant difference in the 
formation of both the derivatives could be deduced by comparing the data sets for 
the three plant lines - CYP81D11-overexpressor, CYP81D11-knockdown versus wild 
type – used in this study. 
 
5.4 Discussion 
Thousands of cytochrome P450 gene sequences have been annotated to date and 
the most numerous group is constituted by plant CYPs. As an example, Arabidopsis 
alone encodes for more than 240 P450 sequences (in comparison, humans present 
only 57 CYPs), as revealed by genome sequencing (17).  
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Of the set of plant P450 enzymes studied to date, many have been attributed roles in 
essential mechanisms in planta, such as structural development, signaling and stress 
responses (17). Additionally, plant CYPs have also been described as key to a 
multitude of synthetic pathways, leading to high-value compounds for human 
consumption (nutraceuticals, aromas and flavours, dyes, pharmaceuticals) (109, 
255). Mirroring the detoxification function of human hepatic P450s towards drugs, 
plant CYPs can also be active towards herbicides and pesticides found in the 
environment, with promising agronomical and phytoremediation applications. An 
area which has not been explored so far is the use of plant CYPs to help in the 
remediation of explosive-contaminated environments. Previous investigations 
carried out in our group demonstrated the potential of an array of plant enzymes, 
such as OPRs (163), UGTs (162) and GSTs (164, 256) for this purpose. These groups of 
enzymes were firstly highlighted in analyses of gene expression in Arabidopsis plants 
exposed to TNT and other xenobiotics (160, 162, 257). Hypothesising a direct 
correlation between the enhanced expression of these particular classes of enzymes 
with a detoxifying activity towards the target toxic compounds, previous members of 
Prof. Bruce’s group performed direct assays with heterologously expressed and 
purified OPRs, UGTs and GST enzymes, as well as with transgenic plants exposed to 
TNT (162-164, 258).  
Cytochromes P450 were also among the upregulated genes in the TNT-treated plants 
and their involvement in TNT detoxification has not been investigated until now. An 
explanation for this could be the vastness of literature describing the reductive 
catabolism of TNT (241), not only by plant but also by microbial enzymes; 
mechanisms which do not fall within the standard P450 oxidative catalysis. In 
addition to the expression data gathered by Dr. Lorenz’s microarray study (161) and 
the serial analysis of gene expression by Ekman et al. (160), a further hint on the 
potential role of CYPs in TNT detoxification can be deduced by analysing the co-
expression patterns of the most TNT-upregulated CYP, CYP81D11, on the CYPedia 
platform (159, 251). In this database, CYP81D11 is expressed in the same tissues or 
organs, stress situations and upon the same hormonal stimuli as the TNT-detoxifying 
GSTs and UGTs, thus drawing the supposition that CYP81D11 might be involved in 
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reactions upstream or downstream to those catalysed by the co-expressed enzymes. 
Furthermore, Bhadra et al. (1999) reported the production of a set of oxidative 
derivatives of TNT in liquid incubations of parrot's-feather plants with the explosive, 
therefore providing evidence that TNT can also undergo oxidative attack. Similar TNT 
derivatives have been found also by Bruns-Nagel in TNT-contaminated soils (250).  
Encouraged by these preliminary observations, multiple assays were carried out, 
employing CYP81D11-overexpressing and knockdown lines of Arabidopsis plants as 
well as tobacco leaf discs transiently expressing CYP81D11. Both overexpressing and 
knockdown lines of CYP81D11 were kindly donated by Prof. J. Napier from 
Rothamsted Research, where CYP81D11 was the subject of studies on plant-insect 
multitrophic interactions and biotic stress responses.  
In order to verify the respective levels of CYP81D11 expression in each line (wild type, 
versus overexpressing and knockdown) a qPCR analysis was performed on tissues 
harvested from two-week old Arabidopsis plants of all three lines. In the absence of 
TNT overexpressing lines displayed, as expected, elevated levels of CYP81D11 
transcripts. Wild type and knockdown lines exhibited similar levels of expression, 
suggesting that the expression of CYP81D11 is regulated and depends on external 
stimuli, in this case TNT. When TNT was added in the medium, the plants showed 
significantly different CYP81D11 transcript levels.  
In general, when the CYP81D11-modified plants were grown on TNT-containing agar 
plates and liquid media, no significant difference between wild type and 
overexpressing plants was observed in terms of root length and TNT uptake 
respectively. On the other side, interesting outcomes could be noted for the 
knockdown plants. A deduction that can be made, upon examination of the results 
obtained for the wild type and overexpressing lines, is that the overexpression of a 
CYP reductase partner might also be required concomitantly, to efficiently support 
the augmented activity, i.e. boosted electron flux, related to the overexpression of 
the P450 heme. 
A comparison of the root length of plants grown on agar plates with a range of TNT 
concentrations was used as an indicator of the plants’ health and resilience to the 
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xenobiotic. The observed outcome (at TNT concentrations of 15 M and 30 M 
knockdown lines displayed significantly shorter roots than wild type and 
overexpressing lines) could signify that, by producing lower amounts of CYP81D11, 
the overall defence mechanism of the plant to high concentrations of TNT was 
weakened, rendering the seedlings not able to grow further under such conditions. 
This result contradicts the results of the liquid media experiments (where knockdown 
plants displayed faster uptake of TNT and no visible sign of higher toxicity, if 
compared to the wild type and knockdown lines) and is hard to explain. Furthermore, 
a lot of variation was noted across the TNT concentrations and different replicates, 
to be able to draw a safe conclusion. Clearly this experiment needs to be repeated, 
possibly with lower amounts of seeds in each plate and using fresh seeds batches.  
For further investigations on the function of CYP81D11 in planta, N. benthamiana 
leaves were Agrobacterium-infiltrated to transiently express the target CYP. A BlastP 
sequence analysis could not find matches exceeding 42% sequence identity over 28 
% of the CYP81D11 sequence, which was the result found for a tobacco endogenous 
N-demethylase (sequence ID: ANF07088.1). This proves that the tobacco system does 
not present a CYP81D11 orthologue and therefore no overlapping endogenous 
activity should be observed. The HPLC analysis of the samples collected showed that 
all the supplied TNT (100 M) was removed from the medium within 48 h. In the 
tobacco tissue extracts, two types of TNT derivatives were found, with retention 
times of 6.5’ and 9’. The first compound (eluting at 6.5 min) presented the same UV 
trace and MS fragmentation pattern of the aminodinitrotoluene derivatives, typical 
derivatives resulting from the reduction of TNT, and probably the result of 
endogenous nitroreductases present in the tissues. Nitroreductases might also be 
responsible for the production of the second metabolite observed (eluting at 9 min), 
which, upon electrospray ionisation, generated an ion with an m/z ratio equal to that 
observed for azoxy-tetranitrotoluenes (m/z = 405). The formation of a 
macromolecule with such m/z ratio, resulting from the condensation of two reduced 
molecules of TNT, has been also described in the past after incubations with TNT of 
a purified rat liver reductase (259), of fungal mycelia (260, 261) and of batches of 
contaminated soil (with related indigenous bacteria (262)).  
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When extracts from CYP81D11-overexpressing and wild type Arabidopsis plant, from 
plants incubated with 100 M TNT (as for the tobacco experiment) for 48 h, were 
analysed by HPLC, two derivative molecules could be observed again, with retention 
times of 6.4 and 7.5 min. While the 6.4’ peak corresponded to the already identified 
ADNTs, MS analysis is still required to identify the second product (eluting at 7.5 min). 
In both cases, there was no significant difference in the amount produced, between 
the wild type and the CYP81D11-overexpressing plants, suggesting that in the 
examined Arabidopsis lines CYP81D11 does not perform any direct action towards 
the given substrate (nor subsequent derivatives) in the 48 h-time frame.   
Overall, the results obtained in this chapter evidenced that CYP81D11 is indeed 
implicated in the stress response by the plant towards TNT. This role could be further 
proved by carrying out metabolite profiling in the CYP81D11-knockdown Arabidopsis 
plant extracts and compare these result to the profiles for the wild type and 
overexpressing plants. This approach could also be useful to determine whether 
other parallel pathways intervene when CYP81D11 is downregulated. A direct activity 
of CYP81D11 towards TNT could be proven by performing activity assays with the 
purified enzyme. Moreover, it has to be taken into account that the Arabidopsis 
CYP81D11 transgenic plants (knockdown and overexpressing) used here are single 
lines donated by Prof. Napier. For this reason, such studies, for accuracy and 
reliability of the results, should be repeated after the generation of multiple 
independent CYP81D11-modified lines. It could also be argued that the levels of 
CYP81D11 transcripts in the modified lines are not sufficiently different from the wild 
type levels, thus the lines used in this chapter might not be optimal to be able to 
observe specific, measurable, phenotypes upon TNT exposure. In addition, clearer 
results on the effective physiological role of CYP81D11 could be obtained by 
depleting completely the expression of the enzyme, generating CYP81D11-knockout 
lines. 
Previous studies on Arabidopsis plants’ response to chemicals conducted by Baerson 
et al., highlighted that CYP81D11 is the most upregulated CYP upon exposure to 
benzoxazolin-2(3H)-one (BOA), a benzoxazinoid derivative belonging to the family of 
allelochemicals and antimicrobial/antiherbivore defence compounds produced by 
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plants. In Baerson’s study, numerous other chemicals induced the expression of 
CYP81D11, such as drugs, herbicide safeners and 2,4,5-trichlorophenol (20 mM 
phenobarbital, 100 M Fenclorim, 0.1-1 mM Benoxacor, 100 M TCP, respectively) 
(263). Additionally, members of Prof. Napier’s laboratory, demonstrated that 
CYP81D11 in Arabidopsis is involved in the cis-jasmone-dependent plant defence to 
herbivore attacks. In particular, upon stimulation, CYP81D11-overexpressing plants 
mediated the production of volatile signaling compounds, affecting the interactions 
between insects (and their pests) and plants (264-266). Recently, Walper et al. 
reported that CYP81D11 expression is triggered in response to oxylipins (specifically 
to 9-hydroxy-10,12,15-octadecatrienoic acid, 9-HOX). In the test carried out in 
Walper’s study, CYP81D11 overexpressor and wild type plants were grown on 
medium containing 9-HOX. The plants overexpressing the CYP displayed longer roots, 
i.e. higher tolerance to the chemical (267, 268). 
All these findings lead us to the consensus view that CYP81D11 might not be directly 
active towards TNT specifically, but instead it could be part of a general defence 
response mechanism, induced by external biotic and abiotic stresses. 
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Chapter 6: Final discussion 
Cytochromes P450 are heme-thiolate monooxygenases that can be found in almost 
all organisms, from microbes and mammalians to insects and plants. CYPs catalyse 
important activities, from the synthesis of essential endobiotics (such as vitamins, 
sterols, hormones, fatty acids) to the metabolism of xenobiotic compounds (such as 
drugs and environmental pollutants). Since their discovery, in 1958, and the first 
characterisation studies by Omura and Sato a few years later, cytochromes P450 have 
attracted the attention of numerous research groups around the world. One of the 
reasons for the significant interest in CYPs is the potential use of these enzymes as 
biocatalysts for biotechnological applications, such as engineered processes for the 
production of high-value chemicals. 
The pharmaceutical industry has particularly benefited from P450-related research: 
a wide array of bacterial, plant and fungal CYPs have been discovered in the synthetic 
pathways leading to chemotherapeutics, antimicrobial, antioxidant, antimalarial 
compounds (15, 106, 114, 221, 223, 255, 269-271). Additionally, the mammalian 
hepatic CYPs have contributed extensive data in the context of drug metabolism; data 
of particular importance for pharmacokinetics and toxicity studies during drug 
development. 
In plants, given the role of cytochromes P450 not only in the metabolism of 
exogenous compounds, but also in endogenous signalling and structural 
development pathways, CYPs can be engineered to enhance tolerance to biotic and 
abiotic stresses (180, 192, 272), to extract pollutants from the environment (23, 235) 
or to enhance the nutritional value of crops (125). 
Of the 35,000+ CYP sequences (173), most have been found in plants, subdivided in 
127 families and, on the basis of phylogeny, eleven clans (101). Besides the high 
sequence divergence found between the CYPs, another constraint in the functional 
and structural characterisation of plant cytochromes P450, is the natural insolubility 
of these enzymes, due to the hydrophobic N-terminal domain and internal 
hydrophobic patches. Whilst in contrast, microbial CYPs are generally soluble 
enzymes, therefore, easier to isolate, reconstitute and characterise. 
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In this project a genetic fusion construct was developed, to ease the heterologous 
expression and functional characterisation of plant CYPs with unknown functions. In 
addition, a variety of in vitro and in vivo assays were carried out in order to evaluate 
the potential role of Arabidopsis CYP81D11 in the detoxification of the explosive TNT. 
Chapter 3 focused on the screening for optimal conditions for the soluble expression 
of plant CYPs in E. coli. The target cytochromes P450 were the well-described 
cinnamate hydroxylase (CYP73A5) from Arabidopsis, CYP81D11 from Arabidopsis as 
well, and maize CYP81A9. The first target, CYP73A5, was chosen for the availability of 
the standards for activity assays, whereas the other two were selected due to their 
potential application in the detoxification of xenobiotics (in particular explosives for 
CYP81D11 (160, 162) and herbicides for CYP81A9 (168), on the basis of their 
expression patterns). The replacement of the N-terminal membrane anchor with a 
short string of amino acids (sequence: MAKKTSSKG, named in chapter 3 ‘S’-peptide), 
the codon-optimisation of the sequences for expression in E. coli and the use of the 
Arctic express strain as host for expression, enabled the production of all three CYP 
targets, as soluble products. This successful outcome was demonstrated with the 
visualisation of bands with the correct size on SDS-PAGE gels and by western blot 
analysis. No CO-differential spectrum could be recorded for any of the purified CYP 
targets, showing that the replacement of the natural N-terminal hydrophobic 
domain, and possibly also the chosen purification conditions, have affected the 
structural configuration of the proteins. Activity assays performed with the purified 
S-CYP73A5tr did not yield the expected product, indicating that the protein was not 
active, probably due to unfolding. Additionally, the assay conditions (such as 
temperature and proportion of CYP and supplied reductase) might not have been 
optimal to be able to observe catalysis. As an alternative, plasmids carrying the native 
sequences of AtCYP81D11 and AtCYP81D8, were transformed into yeast WAT11 cells 
(co-expressing the AtATR1) for expression, with no success. 
In Chapter 4, a fusion construct for the co-expression of CYPs with a suitable redox 
partner was built. The first component of the platform was a cytochrome P450 
reductase from Arabidopsis, ATR2, which had been previously characterised and 
compared in terms of catalytic efficiency to ATR1, the other CYP reductase found in 
Chapter 6: Final discussion 
 
151 
 
Arabidopsis, by Dr. Schuckel (152). The chosen reductase was truncated to remove 
the N-terminal hydrophobic membrane-binding domain and codon-optimised for 
expression in E. coli. Subsequently, a short linker (sequence: GSTSSGSG, from Dr. 
Schuckel’s ACRyLAM construct (211) and from Koffas’ fusion of isoflavone synthase 
with a plant reductase (193)) was introduced upstream of the reductase, as a spacer 
region to enable the appropriate spatial arrangement of the heme and reductase 
domains. The well-characterised Arabidopsis CYP73A5 was chosen as a reference to 
validate the fusion construct. The CYP was modified in the same way as the reductase 
partner and cloned via Infusion upstream of the poly-GlySer linker. In addition, 
multiple N-terminal tags were introduced, in order to increase the solubility of the 
product and to ease the subsequent purification process: the ‘S’ peptide (from 
chapter 3), the conventional His, MBP, GST, GFP tags and the Im9 colicin immunity 
protein. Although it had been effective for the soluble expression of CYP73A5, 
CYP81D11 and CYP81A9, the ‘S’ tag did not have a beneficial effect in the expression 
of the CYP-reductase fusion. Among the other tags, Im9 allowed the production of 
the chimera. Purification trials were unsuccessful, but activity assays performed with 
whole E. coli cells expressing the Im9-CYP73A5tr-ATR2tr construct showed that the 
catalyst was active towards the given substrate, cinnamic acid, converting 60 % of the 
compound into the hydroxylated derivative, p-coumaric acid, in six h. This assay was 
performed with exactly the same conditions used in the past by Dr. Schuckel for the 
evaluation of the ACRyLAM and ACRyLIC fusion constructs, with CYP73A5; in that case 
the maximum conversion (40 %) was achieved with the ACRyLAM construct, in 48 h 
(211). 
In Chapter 5, assays with modified Arabidopsis and tobacco plants were carried out, 
using a set of established protocols from Prof. Bruce’s and Prof. Werck’s groups. 
With the aim of identifying novel TNT-detoxifying enzymes for phytoremediation 
purposes, Dr. Lorenz (a past member of Prof. Bruce’s group), conducted microarray 
gene expression analyses in Arabidopsis tissues following exposure to the explosive 
TNT (161, 162). The results obtained confirmed the outcomes of another genetic 
analysis published by Ekman et al.  (160). In both studies, among the most highly 
induced transcripts by the TNT treatment were GSTs, UGTs, CYPs, transporters, 
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signalling proteins and transcription factors. Therefore, research has focused on the 
characterisation of those highly induced groups of enzymes. CYPedia co-expression 
analyses data (co-localising P450s with known xenobiotic metabolisers (159)) as well 
as the identification of oxidative derivatives of TNT (165, 250), motivated the study 
of the potential role of the upregulated CYPs in the detoxification of TNT, upstream 
of the GST and UGT activities. 
In Dr. Lorenz’s study, CYP81D11 was revealed as the most upregulated CYP (24 times, 
compared to the untreated) in Arabidopsis, in response to TNT exposure. 
Transgenic CYP81D11-overexpressing and CYP81D11-knockdown Arabidopsis plants, 
kindly donated by Prof. Napier (Rothamsted Research), were employed to verify 
whether CYP81D11 confers tolerance to TNT. 
Three-week old Arabidopsis seedlings were grown on TNT-containing liquid medium 
and TNT removal in a time frame of 168 h (one week) was analysed via HPLC. The 
knockdown lines were able to take up the compound present in the medium 
significantly faster (p > 0.05) than the wild type and the overexpressing lines. 
Specifically, more than 90 % of TNT (from an initial amount of 200 M) was removed 
in the first 48 h, whereas the other two lines were able to reach the same level only 
after one week. No difference could be observed in terms of toxicity signs (chlorosis, 
reduced shoots/roots size) across the three lines. 
When the three Arabidopsis lines were germinated and grown on TNT-containing 
agar plates, the CYP81D11-knockdown plants displayed lower tolerance towards TNT 
than the wild type and overexpressing lines, showing significantly shorter roots (-38.1 
% in plates with 15 M TNT and -40.7 % in plates with 30 M TNT) after 20 days of 
growth.  
The liquid incubation study showed that lower levels of CYP81D11 (in the CYP81D11-
knockdown line) lead to an increase of the removal rate of TNT from the medium, 
with no signs of increased toxicity. In the root length experiment, knockdown plants 
exhibited lower tolerance to TNT. The contrasting results between the liquid and agar 
incubations might have been influenced by the different developmental stage in 
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which the plants have been assayed. The plants were germinated on the TNT-
containing agar, whereas in the liquid medium experiment three-week old plants 
were incubated with TNT. In addition, there only one independently-transformed 
plant line for the CYP81D11-overexpressor and CYP81D11-knockdown Arabidopsis 
plants was available for the assays. Other independent lines need to be generated, 
and the assays have to be repeated with a suitable number of replicates, in order to 
minimise the experimental variation and errors, as well as to validate the outcomes.   
To investigate the possible TNT derivatives coming from CYP81D11 activity, tobacco 
leaves were infiltrated with Agrobacteria expressing CYP81D11. The HPLC analysis of 
the TNT-containing medium, from the leaf discs incubations, showed that all the TNT 
(initial concentration: 100 M) was removed in 48 h. The HPLC-MS analysis of the 
tissue extracts demonstrated that mainly ADNTs and tetranitroazoxy-derivatives 
were formed, possibly deriving from endogenous nitroreductases and from the 
condensation of the reduced aromatic rings, as described in the literature (262).  
 
Future perspectives 
Fusion platform 
Given the success with AtCYP73A5, the Im9 fusion platform here developed could be 
useful for the expression of other unknown plant cytochromes P450. The C-terminal 
Arabidopsis ATR2 should enable an efficient electron flux from NADPH to the heme. 
The strategically-designed flanking restriction sites could be exploited for the 
relatively easy InFusion cloning of different CYP targets in the platform, as well as, 
(eventually, for comparative purposes) for the introduction of other reductase 
partners. In addition, the 48-well screening platform used in this study could be of 
great help for the parallel screening of multiple expression conditions, to tailor the 
process to the specific CYP/CYPreductase targets, reducing operational time and 
costs. 
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Elucidation of the role of CYP81D11 in TNT detoxification 
The experimental work carried out in this project did not demonstrate activity of 
CYP81D11 towards TNT. This outcome requires further investigation and additional 
experiments, which could not be carried out due to time constraints. The work that 
needs to be performed consists in the repetition of the TNT uptake liquid medium 
experiments and root length comparisons with a larger pool of independent 
transgenic lines, including CYP81D11-knockout plants in place of the knockdown 
lines. In addition, heterologously expressed and purified CYP81D11, should be 
assayed directly towards TNT or its derivatives. 
 
 
 
 
 
 
 
  
Abbreviations 
 
1/2 MS Murashige and Skoog medium, half strength 
ADNT Aminodinitrotoluene 
ADP Adenosine diphosphate 
ADR Adrenodoxin Reductase 
ADX Adrenodoxin 
AI  Autoinduction medium 
ATR1 Arabidopsis thaliana P450 reductase 1 
ATR2 Arabidopsis thaliana P450 reductase 2 
BSA Bovine serum albumin 
cDNA Complementary DNA 
CO Carbon monoxide 
CPR Cytochrome P450 oxidoreductase 
CYP Cytochrome P450 
Cytb5 Cytochrome b5 
DNA Deoxyribonucleic acid 
DNTP Deoxyribonucleotide triphosphate 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
EV Empty vector 
FAD Flavin adenine dinucleotide 
FMN Flavin mononucleotide 
GFP Green Fluorescent Protein 
GST Glutathione S-transferase 
h Hour(s) 
HADNT 4-Hydroxyl-2,6-dinitrotoluene 
His Histidine 
 
HPLC High-performance liquid chromatography 
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IM9 Colicin E9 immunity protein 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
KD Knockdown 
LB Luria-Bertani medium 
MBP Maltose-binding protein 
min Minutes 
MS Mass spectrometry 
NADH Reduced nicotinamide adenine dinucleotide  
NADP Nicotinamide adenine dinucleotide phosphate 
NADPH Reduced nicotinamide adenine dinucleotide phosphate 
NODT 4-Nitroso-2,6-dinitrotoluene  
NPC No plant control 
OD Optical density 
OE Overexpressing 
OPR Oxo-phytodienoate reductase 
P450 Cytochrome P450 enzyme 
PCR Polymerase chain reaction 
RDX Hexahydro-1,3,5-trinitro-1,3,5-triazine 
RNA Ribonucleic acid 
rpm Revolutions per minute 
s Seconds 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SE Standard error of the mean 
TB Terrific broth 
TBAP Tetrabutylammonium dihydrogen phosphate 
TCE Trichloroethylene 
TEMED Tetramethylethylenediamine 
TNT 2,4,6-trinitrotoluene 
UGT Uridine diphosphate glycosyltransferase 
v/v Volume to volume ratio 
w/v Weight to volume ratio 
WT Wild type 
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